INDEX TO VOLUME 51—1983

INDEX TO AUTHORS

Original articles are indicated by (O), editorials (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

ABALOS, R. M., (B) 606
ABE, M., (A) 657
ABOU-ZEID, C., (A) 139, 140, 622
ACEDO, J. R., (A) 658
ACHARYA, B. P., (A) 612
ACHENBACH, R. E., (A) 614
ADU, H. O., (A) 143, 441, 449, 625
AGGARWAL, S. S., (A) 440
AGUERO, H., (A) 451
AHMED, H. A., (O) 22
AIZER, F., (C) 254
ALEMAYEHU, A., (A) 295
ALEXANDER, G. J. M., (A) 156
ALFIERI, N., (A) 613
ALLEN, B. W., (A) 631
ALLEN, W. G. L., (A) 631
ALMEIDA, J. G., (O) 366, 374, 378, 382, 385
ALMEIDA NETO, E., (A) 273
ALVARADO, J., (O) 531
AMERIO, N., (A) 133
ANDERSEN, J. G., (A) 130, (O) 203, (A) 298
ANDERSON, O., (A) 445
ANDERSON, R., (A) 609
ANGULO, M. H., (A) 630
ANTHONY, J., (A) 442
ANTIA, N. H., (A) 440, 615, 616, 620
APPA RAO, A. V. N., (A) 275
ARAGON, M. E., (A) 670
ARANZAZU, N., (O) 169, 531, (A) 670
ARES, B. R., (O) 321
ARIAS, D. A., (A) 283
ARIMOCHI, Y., (A) 437
ARNOLD, J., (A) 135
ARORA, N. K., (A) 301
ARPINI, R., (A) 451, 451, 451
ARRICK, B. A., (A) 288
ARRUDA, M. S. P., (A) 287
ARRUDA, O. S., (A) 287
ASHTON, R., (A) 619
ASSEIS, E. A., (A) 145, 297
ATLAW, T., (A) 656
AVGOUSTAKIS, D. G., (O) 331
AYALA, J. L., (A) 633
AYASAMY, A., (A) 614
AZULAY, D. R., (A) 281
AZULAY, R. D., (A) 281, (C) 418

BACH, J. F., (A) 444
BACH, M.-A., (A) 292, 442, 442, 616
BACHMANN, A. E., (O) 321
BAHR, G. M., (A) 133
BAILLIE, E. E., (A) 271
BAILLIE, R. A., (A) 271
BAJI, P. S., (A) 441
BAKER, C. J., (E) 397
BAKKE, A. C., (A) 647
BAKOS, L., (A) 275
BALAKRISHNAN, S., (A) 134, 274, 274, 285, 295, 436, 439, 439
BALE, U. M., (A) 146
BALINA, L. M., (O) 321, (B) 606
BALYBIN, E. S., (O) 18
BANERJEE, B., (A) 627
BANKS, P. M., (A) 298, 632
BAPAT, C. V., (O) 466, 540
BAQUERO, G. F., (A) 630
BAQUILLON, G., (A) 273, 611, 611
BARAS, M., (A) 146
BARBA-GOMEZ, J. F., (A) 137
BARBA-RUBIO, J., (A) 289
BARBOSA, I. S., (A) 281
BARET, A., (A) 294
BARG, L. L., (A) 662
BARKSDALE, L., (C) 107, (A) 290, 633
BARNETSON, R. ST.C., (O) 7
BARREYO, D. A., (A) 146
BARRIERE, H., (A) 632
BARTH, Y. L., (A) 145, 297
BASKIN, G. B., (A) 664, 665
BDOVINA, N. A., (A) 278
BECHELLI, L. M., (N) 118, (A) 435, 435
BEDWAL, R. S., (A) 443
BEECHING, N. J., (A) 129
BELAUBE, P., (A) 129, (O) 328
BELDA, W., (A) 275, (C) 418
BELEHU, A., (O) 22, 33, (A) 286, 286, (O) 305, 312, (A) 618
BENETSANOS, P., (A) 618
BERNARDI, C., (A) 146, 275
BERND, L. A. G., (A) 443
BERWALD, L. G., (A) 448
BETHLEM, N. M., (A) 301
BHALERAO, V., (O) 540
BHARADWAJ, V. P., (A) 291
BHARDWAJ, O. P., (A) 154
BHAT, K. R., (A) 292, 449
BHATIA, H. M., (A) 146
BHATIA, V. N., (A) 134, 285, 295, 436, 439, 439
BHATKI, W. S., (O) 466, 540

Bhutani, L. K., (A) 287, 669
Binford, C. H., (N) 429, (Ob) 587, (A) 664, 665, 666, 668
Binkhuysen, F., (A) 282
Birdi, T. J., (A) 616
Bloom, B. R., (A) 136, (O) 505
Bocquet, B., (A) 613
Boerrigter, G., (A) 613
Boja, M. D., (A) 451, 451
Bonini, S., (C) 417
Bonvoisin, B., (A) 613
Bottasso, O. A., (A) 133, 282
Boucher, P., (A) 611, 611, 630
Boulliat, J., (A) 613
Bourrel, P., (A) 630
Boutboul, R., (A) 129, (O) 328
Bouvier, M., (A) 613
Boyle, A., (A) 151
Brandsma, J. W., (A) 298, 630
Brandt, F., (A) 440, 613
Brazin, S. A., (A) 276
Brennan, P. J., (E) 387, (A) 616, 623, 659
Brown, H. L., (A) 664, 665
Brown, I. N., (A) 143
Brown, K. E., (C) 592
Browne, S. G., (C) 256, (N) 596
Bryceson, A. D. M., (A) 133
Buchanan, T. M., (A) 443, (O) 524, (A) 622, 655, 658, 660, 662
Buechner, S. A., (A) 298, 632
Bulakh, P. M., (A) 441
Bullock, W. E., (A) 649
Bumb, R. A., (C) 410

Cacciatore, R., (A) 156
Capece, A. C., (A) 614
Carayon, A., (A) 130, 610
Cardama, J. E., (A) 278, (E) 576, (B) 606
Carney, W. P., (A) 156
Carrara, R. C., (A) 283
Cartel, J.-L., (O) 461
Casabianca, N., (A) 153, 453
Casagrande, N. A., (A) 145, 297
Casim, G., (A) 451, 451, 451
Cassels, A., (A) 154
Castel, T., (A) 284
Castellazzi, Z., (A) 670
Castro, J., (A) 284
Caver, C. V., (A) 613
Cavicchi, G., (A) 143
Cellona, R. V., (B) 606
Chacko, C. J. G., (O) 366, 374, 378, 382, 385
Chakrabarty, A. K., (A) 134, 288, 442
Chakraborty, A. K., (A) 138
Chakravarti, R. N., (A) 450
Chan, Y. C., (A) 631
Chaparas, S. D., (A) 154, 299, 652
Chapo, R., (A) 451, 451, 451
Charosky, C. B., (A) 151, (E) 576
Chaturvedi, R. M., (O) 540
Chaudhuri, S., (A) 131, (O) 159
Chaudhury, D. S., (B) 126, (N) 267
Chaudhury, R. R., (A) 277
Chauhan, N. S., (A) 152
Chawhan, R. N., (A) 614
Chehl, S. K., (C) 256, (A) 649
Cho, S.-N., (A) 616, 659
Choong Rim Haw, (A) 302
Chopra, J. S., (A) 631
Christian, M., (A) 149, (N) 264, 265, 265, (O) 366, 374, 378, 382, 385, (A) 437
Christiansen, J. V., (A) 276
Christie, J. D., (A) 629
Chulawala, R. G., (A) 129, (O) 466, 540
Clangelo, G., (A) 614
Clark-Curtiss, J. E., (A) 667
Clavel, S., (A) 140
Clement, F., (A) 140
Clezy, J. K. A., (C) 413
Closs, O., (A) 285, 445, 618, 625
Cocito, C., (A) 139, 140, 140, 290, 622, 623
Cohn, Z. A., (A) 288, 650
Collier, P. J., (A) 627
Collins, F. M., (O) 481
Cologlu, A. S., (A) 628
Colston, M. J., (A) 293, (O) 336
Comesana, G., (A) 283
Constant-Desportes, M., (A) 610
Contractor, N. M., (A) 146
Convit, J., (A) 136, (O) 169, 531, (A) 670
Cook, A., (A) 152
Cook, G. C., (A) 276
Corachan, M., (A) 276
Corona, C. J., (A) 133, 282
Costa, M. H. L., (A) 291
Cottenot, F., (A) 442, 442, 616, 617
Crouch, H. E., (N) 124
Crouse, D. T., (A) 629
Cubria, J. L., (A) 284
Curtis, J., (A) 143, 441, 449, 625
Curtiss, R., III, (A) 667
Cussell, D., (A) 619

D'Amaro, J., (A) 150
Daftary, D. K., (A) 280
Dahle, J. S., (O) 312
Dang Duc Trach, (O) 174
Danhaive, P., (A) 140
Das, M. L., (A) 295
Das, P. K., (A) 282, 289
Das, R., (A) 276
Dasgupta, A., (A) 442
Dastazini, I., (A) 287
David, C. S., (A) 632
David, H. L., (A) 140, 142, 291, 445, 447
Dawber, R. P. R., (O) 205
Dawson, P. J., (Ob) 105, (O) 336
de Almeida-Filho, J., (A) 273
de Aragon, M. E., (O) 531
de Campos, I., (A) 613

DE LA CRUZ, F., (A) 283
DE MAAR, E. W. J., (A) 277
DE MUYNCK, A., (A) 295
DE OVANDO, F., (A) 633
DE SLOOVERE, T., (A) 140
DE SOLDENHOFF, R., (N) 125
DE SORRENTINO, A. H., (A) 284
DE SOUZA, J. M., (A) 273
DE VRIES, R. R. P., (A) 150, 444
DECAZES, J. M., (A) 438
DEL PINO, G., (A) 275
DELVILLE, J., (A) 140, 140, 290, 623
DEMICCO, C., (A) 129
DENNIS, D. T., (A) 156
DEO, M. G., (O) 466, 540, (A) 617
DESHPANDE, J. M., (A) 155
DESHPANDE, S. S., (A) 128
DESIKAN, K. V., (O) 1, (A) 280, (C) 409, (O) 473
DEVAUX, J., (A) 129, (O) 328
DEYOUNG, D. R., (A) 157
DHAR, U., (A) 152
DHARMALINGAM, R., (A) 627
DHOLE, T. N., (A) 441
DHOPLE, A. M., (A) 140, 446, 653
DIAZ, G. A., (A) 290, 624
DIAZ, J. W., (A) 283
DISSANAYAKE, S., (A) 443, 658
DOBSON, G., (A) 446, 446
DONDE, S. V., (A) 440
DONGRE, V. V., (A) 128
DRAPER, P., (A) 446, 446, 448, (O) 563
DUIVON, J. P., (A) 613
DUNCAN, M. E., (O) 7, (C) 112, (A) 130, 136
DUTTA, A. K., (A) 132
DUTTA, S., (A) 295

EDDLESTON, A. L. W. F., (A) 156
EDWARDS, M. L., (A) 453
EHRHARDT, R. L., (A) 629
EKDESMAN, R., (A) 451
EL-GOTHAMY, Z., (A) 440
ELFERINK, D., (C) 110, (A) 444
ELLIS, B. P. B., (A) 296
ELLIS, C. J., (A) 129
ENNA, C. D., (A) 152
ESBERGENOV, B., (A) 278
ESCALONA, M., (A) 451, 451
ESPANA, A., (A) 283
ESTEVEZ, M. E., (A) 283
ESTRADA-PARRA, S., (A) 658

FAJARDO, T. T., (B) 606
FEKETE, E., (A) 295
FENG BI, (A) 130
FERRACCI, C., (A) 273, 611, 611
FERREIRA, J., (A) 146, 275
FIELDSTEEL, A. H., (O) 336
FILE, S. K., (A) 629
FINE, P. E. M., (A) 147, (O) 553
FINIASZ, M. R., (A) 283
FINKELSTEIN, S., (A) 277
FISCHER, M., (A) 150
FLAGEUL, B., (A) 442, 442
FLEMING, B., (A) 283
FLEURY, R. N., (A) 277, 287, 613
FLIESS, E. L., (A) 277, 283
FODSTAD, F., (A) 445
FOLSE, D. S., (A) 629, 663
FOLTZ, R. L., (A) 275
FONTAINE, F., (A) 140, 140, 623
FOTEDAR, A., (O) 159, 550
FRAGUELA RANGEL, J. V., (A) 630
FRANCKEN, A., (A) 141, 142
FRANCO-GAMBOA, E., (A) 287
FREERKSEN, E., (C) 261, 407
FREHEL, C., (A) 445, 447
FREILICH, A. R., (A) 609
FRITSCHI, E. P., (A) 298, 298, (O) 366
FUKUDA, M., (A) 281
FUKUNISHI, Y., (A) 666, 668
FUMOUX, F., (A) 294, 444
FURNESS, M. A., (A) 271
FURUKAWA, F., (A) 617
FUSARO, R. M., (A) 302, 443

GAILLY, C., (A) 140
GALANTI, M. R., (O) 495
GALLETTI, G., (A) 143
GAMBOA-MARQUEZ, A., (A) 137
GANAPATI, R., (A) 128, 438
GANERIWAL, S. K., (A) 441
GANGULY, N. K., (A) 450
GARCIA, R. R., (A) 277
GARDNER, I. D., (A) 292
GARG, B. R., (A) 278, 296
GARRIDO NEVES, R., (C) 418, (A) 435, 435
GATSON, A. M., (A) 629
GATTAS, C. R., (A) 288
GATTI, C. F., (A) 632
GATTI, J. C., (A) 278, (E) 576, (B) 606
GAULIER, A., (A) 617
GEBHARD, J. F., (A) 619
GELBER, R. H., (A) 134, 616, 649, 659
GENESSI, J., (A) 295
GENTILI, F., (A) 277
GERBASE, A. C., (A) 275
GERONE, P. J., (A) 664, 665, 666
GERSHON, W., (N) 121
GERVINI, R. L., (A) 275
GHEI, S. K., (A) 285
GHEORGHIU, M., (A) 445
GHORPADE, A., (O) 354
GHOSH, S., (A) 131, 441
GILBERT, E., (A) 284
GILLIS, T. P., (A) 655
GIMENEZ, M. F., (A) 278
GIMENEZ, M. M., (A) 150, 284
GIRDHAR, B. K., (O) 1
GIRLING, D. J., (A) 631
GIROIR, A. M., (A) 610

Glynn, A. A., (A) 143
Godal, T., (A) 443, (O) 510, (A) 618
Goihman-Yahr, M., (A) 437
Golyshevskaya, V. I., (A) 633
Gomez-Estrada, H., (A) 289
Goncalves, H., (A) 291
Goncharonko, I., (A) 283
Gonzalez-Mendoza, A., (A) 137, 287, 289
Goode, D., (A) 299
Goodrich, J. M., (A) 453
Goracci, G., (A) 614
Gordon, G. R., (O) 45, 54
Gormus, B. J., (A) 664, 665, 666
Gorzynski, T. J., (A) 632
Goswami, A., (A) 276
Goyal, B. M., (A) 131
Granata, F., (A) 277
Grange, J. M., (A) 300, 300
Gratacos, R., (A) 284
Greco, D., (O) 495
Gregory, D., (A) 291
Groothuis, D. G., (A) 448
Grosset, J. H., (A) 450, (O) 461, (A) 610
Gu Shenggui, (A) 130
Guelpa-Lauras, C.-C., (O) 461, (A) 610
Gueur, M. C., (A) 140, 140, 623
Guha, P. K., (A) 149
Guinto, R. S., (B) 606
Guld, J., (O) 559
Gummer, C. L., (O) 205
Gupta, S., (O) 354
Gurfinkel, A. C. M., (A) 128
Gurung, P. K., (A) 154
Gutierres, M., (A) 275
Guzman, C. S., (A) 630

Ha, D. K. K., (A) 292
Habib, M. A., (A) 440
Haddad, N., (A) 435, 435
Hadfield, T. L., (A) 665
Hahn, M. D., (A) 435, 435
Hair, L. S., (A) 288
Hall, R. M., (O) 490
Hallmans, G., (A) 153
Hamashima, Y., (A) 617
Hameedullah, A., (A) 278
Handoyo, I., (A) 300
Harboe, M., (O) 33, (A) 136, 286, 299, (O) 305, 312, (A) 445, 618, 623
Haregewoin, A., (A) 286, (Ob) 404, (O) 510, (A) 618
Hargrave, J. C., (B) 433
Harikrishnan, S., (A) 134, 295, 436, 439, 439
Harnish, J. P., (A) 658
Harper, J. M., (A) 301
Hartwig, C., (A) 156
Hastings, R. C., (E) 89, (N) 124, (C) 256, (A) 649
Haverkamp, J., (A) 448
Hazra, J., (A) 627
Hazra, S. K., (A) 131
Hegarty, J. E., (A) 156
Heineman, E., (A) 154
Hendrick, S. S., (A) 436
Hibino, T., (A) 293
Higashi, G. I., (A) 440
Hilbers, H. W., (O) 191, 359
Hilson, G. R. F., (A) 293
Hirata, T., (O) 84
Hirooka, Y., (A) 450
Hoang Thuy Long, (O) 174
Hoffbrand, B. I., (A) 633
Hoffeld, J. T., (A) 652
Hoffenbach, A., (A) 292, 616
Hoffman, S. L., (A) 156
Hofman, F. M., (A) 274, 285
Holla, V. V., (O) 29
Horwitz, D. A., (A) 647
Horwitz, M. A., (A) 288
Hudson, T., (A) 295
Hue, P. T., (A) 282
Hughes, R. A. C., (O) 33
Humber, D. P., (A) 286
Humphres, R. C., (A) 134
Hunter, S. W., (A) 616, 623, 659
Hurtel, B., (A) 450
Husser, J.-A., (A) 135

Ibrahim, A. A., (A) 282
Iliadi-Alexandrou, M. E., (A) 618
Ilyina, I. N., (A) 633
Imaeda, T., (A) 290, 663
Imamura, S., (A) 617
Ingle, P., (A) 297
Ishaque, M., (O) 64, (A) 293
Isozaki, Y., (A) 293
Ito, T., (A) 437
Ivanyi, J., (A) 619
Izaki, M., (A) 293
Izaki, S., (A) 293
Izumi, S., (A) 624

Jacobs, W. R., (A) 667
Jacobson, R. R., (A) 649
Jain, V. K., (A) 440
Jaled, M. M., (B) 606
Janczura, E., (A) 140
Jantzen, E., (A) 445
Jaswaney, V. L., (A) 284
Jensen, J. R., (A) 276
Jha, S. S., (A) 128
Ji Bao-Hong, (A) 273
Jiang Jun, (A) 130
Jin Liang-Jian, (A) 273
Job, C. K., (C) 256, (O) 347, (A) 649
Jogaikar, D. G., (A) 439
Johl, J. S., (A) 645
John, J. K., (A) 437
Johnson, F. B., (A) 666, 668
Jones, R. O., (A) 453
Jonguieres, E. D. L., (A) 131
Jopling, W. H., (C) 420

JOSEPH, B., (A) 298
JOSHUA, S., (A) 298
JUWATKAR, P. S., (A) 129

KADLUBOWSKI, M., (O) 33
KALTHOFF, P. C., (A) 613
KAMAT, R. S., (A) 155
KAMPIK, A., (A) 440
KANO, K., (A) 619
KAPLAN, G., (A) 288, 650
KARDJITO, T., (A) 300, 300
KASHIWABARA, Y., (A) 653
KATARIA, S., (A) 279
KATHIPARI, K., (A) 301
KATO, L., (O) 77
KATOCH, K., (A) 132, 437
KATOCH, V. M., (A) 290, 624
KAUFMANN, A., (B) 270
KAUR, S., (A) 149, 279, 450, 631
KAWAGUCHI, Y., (A) 144, 144, 145, 294, 625
KAWATSU, K., (A) 281, 625
KEARNEY, G. P., (A) 668
KEEN, M., (A) 619
KELKAR, S. S., (O) 41
KELLY, M. T., (A) 629
KENETKAR, M. V., (O) 29
KENZHEBAEV, A. Y., (A) 278
KEYSTONE, J. S., (A) 277
KHANOLKAR, S. R., (O) 524, (A) 655, 658, 662
KHARATIYAN, A. M., (A) 278
KHER, J. R., (A) 441
KHOMENKO, A. G., (A) 633
KIKUCHI, I., (A) 655
KIM, D. I., (A) 443
KIM, Y. W., (A) 443
KIMANUKA, T., (A) 634
KIRAN, U., (A) 155
KIRCHHEIMER, W. F., (A) 290, (O) 347
KLOKKE, A. H., (C) 256, (A) 278
KOBAYASHI, S., (A) 281
KODJOVI, M., (A) 135
KOFI EKUE, J. M., (A) 277
KOHSAKA, K., (A) 437
KOIMAN, I., (A) 156
KOLHATKAR, M. K., (O) 29
KON, S., (A) 293
KOROLEV, M. B., (A) 633
KOSEKI, M., (A) 655
KOTICHA, K. K., (A) 129, 146
KRAHENBUHL, J. L., (Ob) 105, (A) 134, 645
KRISHNA, D. R., (A) 275
KRISHNAMOORTHY, K. V., (A) 131, 296
KRUYT, J. A., (A) 278
KUKREJA, N., (A) 301, 301
KULKARIN, C. N., (O) 29
KULKARNI, V. M., (A) 274
KUMAR, A., (A) 274
KUMAR, B., (A) 149, 279, 450, 631
KUMAR, K. S. A., (A) 296
KUMAR, R. P., (A) 153
KUNDU, S. K., (A) 131
KURUP, I. G., (A) 135
KUSAKA, T., (A) 624
KYRIAKIDIS, M. K., (O) 331

LAD, S. J., (A) 284
LAGRANGE, P. H., (A) 292, 450, 616
LAHA, N. N., (A) 279
LAI VAN GIOI, (O) 174
LAL, S., (A) 278, 296
LAMBERT, P. H., (A) 134, 442
LANCASTER, R. D., (A) 293
LAPA E SILVA, J. R., (A) 301
LAVALLE, P., (A) 633
LAWTON, J. W. M., (A) 292
LECHAT, M. F., (A) 284, (N) 422, (B) 434
LECLERQ, S., (A) 154
LEDERMANN, J. A., (A) 633
LEFFORD, M. J., (A) 651
LEIKER, D. L., (B) 126, (A) 150, (B) 606
LESEC, G., (A) 617
LEVIS, W. R., (A) 288
LEVY, L., (A) 146, (C) 254
LEWIS, S., (A) 279
LI WENZHONG, (A) 130
LIFTOGT, T., (A) 630
LIGESTI, D. J., (A) 155
LIM, S. D., (A) 443
LIN DE-PAO, *et al.*, (A) 298
LITVINOV, V. I., (A) 633
LIU ZIJUN, *et al.*, (A) 135, 135
LIU, K. M., (A) 651
LIVSHIN, Y., (A) 132
LOBO, D., (A) 153
LOMBARDI, C., (A) 275
LONG, E. G., (A) 629, 663
LONGO, I. M., (A) 443
LOPEZ, M. L., (A) 278
LOPEZ, R. I., (O) 169
LOUGHEED, W. M., (A) 277
LØVIK, M., (A) 625
LOWNEY, E. D., (A) 155
LUTSKY, I., (C) 254
LYBERG, T., (A) 285
LYDYARD, P. M., (A) 133
LYNCH, N. R., (O) 169
LYONS, N. F., (A) 296

MA BUKUAN, (A) 130
MA LIN, (A) 130
MACEDO, P. M., (O) 219, 225, (A) 291, 448
MACKAY, I. G., (A) 285
MAGALHAES, L. B., (A) 145, 297
MAHADEVAN, P. R., (A) 135, 284, 616, 620
MAHALINGAM, C., (A) 296
MAIRE, M. A., (A) 134, 442
MAKINO, M., (A) 437
MALLA, O. K., (A) 440
MALVIYA, G. N., (O) 1
MANDERS, W. W., (A) 668

MANGAL, H. N., (A) 443
MANI, K., (O) 197
MANIMAKALAI, (A) 285
MANO, D. B., (A) 301
MANUNGO, J., (A) 130, 131
MANZUR, J., (A) 279
MARGARINOS, R. A., (A) 278
MARIAM, SISTER S. G., (B) 270
MARIANAYAGAM, Y., (A) 620, 621
MARIAT, F., (A) 287
MARKS, S. C., (A) 615
MAROOF, S., (A) 153
MARTIN, J. M., (A) 613
MARTIN, L. N., (A) 664, 665, 666
MARTINEZ, A. R., (A) 144
MAS, A. C., (A) 271
MASSONI, F., (A) 135
MATHAI, R., (C) 416
MATHUR, D., (A) 443
MATHUR, N. K., (C) 410, (A) 443
MATHUR, R. S., (A) 443
MATSUO, Y., (O) 72
MATSUOKA, M., (A) 144, 144, 145, 294, 625
MCDOUGALL, A. C., (A) 293, (C) 592, (B) 606, (A) 628
MCTIGHE, A. H., (A) 279
MEHRA, V., (A) 136
MEHTA, J. M., (A) 439
MEHTA, M. M., (A) 146
MEHTA, R. S., (A) 279
MEIER, J. L., (A) 663
MELCHIOR, E., (A) 435
MELCHIOR, E., JR., (A) 435
MELSOM, R., (O) 7, (A) 136, (E) 235
MENDELSOHN, D., (A) 444
MENDES, N. F., (A) 443
MENZEL, S., (O) 7
MERKUS, F. W. H. M., (O) 191, 359
MESTER DE PARAJD, L., (A) 274
MESTER DE PARAJD, M., (A) 274
METAH, D., (A) 280
MEYER, P. R., (A) 285
MEYERS, W. M., (A) 664, 665, 666, 668
MICHAUD, R. M., (A) 150
MICHEL, G., (A) 139, 622
MICHELSON, M., (A) 294
MIDDLETON, D. M., (A) 626
MILGROM, F., (A) 619
MILLAN, J., (O) 461, (A) 610
MILLAN, S. G., (A) 144
MILLER, R. A., (A) 443, (O) 524, (A) 655, 658
MINAGAWA, F., (A) 657
MINNIKIN, D. E., (A) 446, 446
MINNIKIN, S. M., (A) 446
MISHNER, H. S., (A) 279
MISTRY, N. F., (A) 616
MITCHISON, D. A., (A) 631
MITRA, A. K., (A) 276
MITTAL, A., (A) 142, 446
MIURA, M., (A) 281
MIYAJI, I., (A) 657
MODDERMAN, E. S. M., (O) 191, 359
MODLIN, R. L., (A) 274, 285, 619, 647
MONFORT, J., (A) 284
MORI, T., (A) 141, 437
MORINI, J. C., (A) 133, 282
MORITO, T., (A) 619
MORRISON, N. E., (O) 481
MOULSDALE, M. T., (A) 301
MOURA, N. C., (A) 443
MSHANA, R. N., (O) 33, (A) 286, 286
MUKHERJEE, A., (O) 1, 473
MULLER, D., (A) 453
MURRAY, J. F., JR., (O) 45, 54
MURTHY, J. M. K., (A) 631
MURZY DE SOUZA, G. R., (A) 301
MUSTAFA, A. S., (A) 443, (O) 510, (A) 618

NAAFS, B., (A) 295, 298
NACK IN KIM, (A) 302
NADKARNI, J. S., (A) 284
NAGAR, K. S., (A) 279
NAIK, S. S., (N) 431, (A) 438
NAIR, N. G. K., (A) 149
NAKAGAWA, H., (A) 653
NAKAMURA, M., (A) 141, 141, 290, 290, 654
NARAVANAN, R. B., (A) 287
NASH, D. R., (A) 155
NATH, I., (A) 137, 142, 287, 446, 669
NAZAROV, K. I., (O) 18
NEDUGAYIL, K., (A) 615
NEELAN, P. N., (A) 436
NEFF, J. C., (A) 155
NELSON, K. E., (C) 413, (A) 649
NEVILLE, J., (B) 270
NGUYEN HUU HUAN, (O) 174
NGUYEN, N., (A) 132
NIELSEN, D. R., (A) 615
NIGAM, P., (A) 131
NOGUEIRA, N., (A) 288, 650
NOORDEEN, S. K., (O) 556
NOURI-ARAI, K. T., (A) 156
NOUTSIS, C. G., (O) 331
NOVALES, J., (A) 633
NUGTEREN, W. A. H., (A) 298
NUTI, M., (C) 417
NYE, P. M., (A) 287
NYEIN, M.-M., (A) 141

OAKEY, R. E., (C) 112, (A) 130
OCAMPO, J. C., (A) 278
OLCEN, P., (Ob) 404
OPPENHEIM, J. J., (A) 652
OPROMOLLA, D. V. A., (A) 277, 287, 613
ORTEGA-ARAIZA, M. E., (A) 137
OSBORN, T. W., (A) 301
OZAKI, M., (A) 617
OZAWA, T., (A) 655, 657

PACIN, A., (A) 277
PADE, S. S., (A) 129

Pagnano, P. M. G., (A) 435, 435
Pal, B., (A) 441
Pal, R., (A) 441
Palagie, A., (A) 617
Palmieri, J. R., (A) 156
Pannikar, V. K., (A) 437
Parissis, N., (A) 618
Parissis, N. G., (O) 331
Partono, F., (A) 156
Patramani, I., (A) 618
Pattyn, S. R., (A) 141, 142, 142, 273, 436, 446, 447, 610, 624
Pavlatou, M., (A) 618
Payne, S. N., (A) 446
Pearson, J. M. H., (O) 7, 205, (A) 611
Perani, E., (A) 610
Pereira, A. C., Jr., (A) 128, (C) 418
Pernambuco, J. C. A., (A) 287
Peters, J. H., (O) 45, 54
Petri, V., (A) 132
Pettit, J. H. S., (C) 258, 420
Pham Man Hung, (O) 174
Piessens, P. W., (A) 156
Piessens, W. F., (A) 156
Pinrat, A., (A) 617
Pinto, J., (A) 153
Pio, A., (A) 139
Pizzi, M., (A) 129, (O) 328
Plant, J., (A) 143
Pokharel, R. P., (A) 440
Pollack, A., (A) 453
Portaels, F., (A) 141, 142, 142, 446, 447, 634
Prabhakar, M. C., (A) 275
Prabhu, R., (A) 634
Prabhu, S. R., (A) 280
Prabhune, P. V., (A) 280
Prasad, H. K., (A) 137, 142
Prasad, S. B., (A) 280
Prat, J. J., (A) 617
Price, J. E., (A) 287, 631
Pring, D. J., (A) 153, 453
Priscinotti, T., (A) 145, 297
Privat, Y., (A) 129, (O) 328
Prydz, H., (A) 285
Puig, N., (A) 133

Quadra, A. A., (A) 281
Qui, T. H., (A) 282

Rabello, F. E., (C) 418
Rabson, A. R., (A) 444, 445
Racanelli, A., (A) 615
Radhakrishna, S., (A) 149, 302
Radhakrishnan, K., (A) 631
Rahut, C. B., (A) 154
Rajjan, W., (A) 140, 290
Ramanakar, T. V., (A) 275
Ramanathan, U., (A) 132, 271, 437
Ramanathan, V. D., (C) 409
Ramesh, A., (O) 354
Ramos-Caro, F. A., (A) 280
Ramos-Zepeda, R., (A) 137, 287
Ramu, G., (O) 1, (A) 132, 151, 152, 271, 280, 285, (C) 409, (A) 437, 438, (O) 473
Rangarajan, R., (A) 282
Rao, K. S., (A) 153
Rao, S. S., (A) 284
Rao, S. S. L., (A) 132
Rao, T., (A) 132
Rao, T. D., (A) 132
Rasi, G., (C) 417
Rastogi, N., (A) 142, 445, 447
Ratiwayanto, S., (A) 156
Ratledge, C., (B) 127, (O) 490
Raval, S. N., (A) 280
Ravettini, B. A., (A) 614
Ravi, N. T., (A) 275
Ravisse, P., (A) 450
Rea, T. H., (A) 274, 285, 288, 619, 647
Recarte, M., (A) 451, 451, 451
Reddy, B. V., (A) 441
Reddy, M. V., (A) 634
Ree, G. H., (A) 438
Rees, R. J. W., (A) 271, (O) 515
Reich, C. V., (Ob) 587
Reichart, P. E., (A) 280
Resoagli, E. H., (A) 144
Resoagli, J. P., (A) 144
Revankar, C. R., (A) 128, 287, (N) 430, 431, (A) 438
Reves, O., (O) 531
Ridel, P.-R., (A) 611, 611, 645
Ridell, M., (O) 179, 185, (A) 291
Ridley, D. S., (A) 137, 620
Ridley, M. J., (A) 137, (O) 211, (A) 620, 620, 621
Risso, H. I., (A) 150, 296
Ritchie, L. R., (A) 667
Roberts, G. D., (A) 157
Robinson-Kyriakidis, C. A., (O) 331
Roder, J. C., (A) 656
Roenhorst, H. W., (A) 278
Rohatgi, M., (A) 155
Rollins, D. E., (A) 275
Romanova, R. Y., (A) 633
Romero, A., (A) 628
Rook, G. A. W., (A) 133, 137, 283, 287, 302
Rosa, C., (C) 417
Rotberg, A., (A) 142, (C) 411
Roy, I. S., (A) 276
Roy, S. N., (A) 149, 279
Ruan Xi-Yuan, *et al.*, (A) 280
Rubenstein, A., (A) 136
Rubio, J. B., (A) 287
Ruby, J. R., (C) 256
Ruitenberg, E. J., (A) 282
Ryter, A., (A) 447

Sabato, S., (A) 631
Saha, K., (A) 138, 138, 288, 442
Saikawa, K., (A) 296
Saint-André, P., (A) 274, 611, 611

SAITO, H., (A) 626
SAITO, N., (A) 450
SAITO, T., (A) 657
SAKAMOTO, Y., (A) 657
SALGAME, P. R., (A) 620
SAMPAIO, A. P., (A) 632
SAMPOONACHOT, P., (A) 657
SANABRIA NEGRIN, J., (A) 630
SANADA, K., (A) 655
SANCHEZ CABALLERO, H., (A) 131
SANCHEZ, R. M., (O) 347
SANDERS, C. R., (A) 634
SANDERS, S. W., (A) 275
SANDERS, W. E., JR., (A) 156
SANKARAN, K., (A) 652
SANSARRICQ, H., (A) 128, (N) 263, (A) 272, 628
SANT'ANNA, C. C., (A) 301
SANTOS, M. F. G., JR., (A) 275
SAOJI, A. M., (O) 41
SARNO, E. N., (A) 281, 288
SASAKI, N., (A) 281
SASAZUKI, T., (A) 655
SASIAIN, M. DEL C., (O) 321
SATHISH, M., (A) 142, 446, 669
SATOH, M., (A) 293
SAXEGAARD, F., (A) 445
SAXENA, H. N., (A) 131
SCHAUF, V., (C) 413, (A) 649
SCHIEFER, H. B., (A) 626
SCHLAGEL, C. J., (A) 665
SCHNEIDER, N., (A) 156
SCHREUDER, I., (A) 150
SEAL, K. S., (Ob) 405
SEANG HOO NAH, (A) 615
SEHGAL, V. N., (A) 138, 138, 288, (O) 354
SELLIAH, K., (A) 614
SELVAPANDIAN, A. J., (O) 197
SEN, L., (A) 283
SENGUPTA, S. R., (A) 441, 614
SENGUPTA, U., (A) 280, 285, (C) 409, (A) 438, 619
SERJEANTSON, S. W., (A) 451
SESHADRI, P. S., (A) 275, 436, 446
SETH, S. D., (A) 301
SETH, V., (A) 301, 301
SETHI, N. C., (A) 279
SEYDEL, J. K., (A) 274
SHAH, A., (A) 440
SHANGHAI ZHUNYI HOSPITAL, *et al.*, (A) 611
SHANMUGAM, N., (A) 153
SHANMUGAN, P., (A) 627
SHANMUGHAM, N., (A) 285
SHANNON, E. J., (A) 649
SHARMA, A. K., (A) 287, 669
SHARMA, K. D., (A) 155
SHARMA, O. P., (A) 285
SHARMA, V., (A) 138, 138, 288
SHARMA, V. D., (A) 132
SHEPARD, C. C., (A) 138, 272, (O) 519, (A) 612, 626, 646
SHESKIN, J., (A) 132, 281, 631
SHIELD, M. J., (A) 302
SHILO, S., (A) 132
SHRINIWAS, (A) 154, 155
SHULMAN, D. G., (A) 132
SHUNZHANG YE, (A) 138, 626
SILVA, M. T., (O) 219, 225, (A) 291, 448
SIMA, A. A. F., (A) 277
SIMKIN, A., (A) 631
SIMMON, V. C., (O) 45
SIMONE, C., (A) 615
SINCLAIR, S., (A) 301
SINGH, R., (A) 137
SINHA, S., (A) 285, (C) 409, (A) 619
SIRDESHPANDE, S. H., (A) 614
SISK, J. E., (A) 634
SIVARAMAN, S., (A) 635
SKINSNES, O. K., (A) 139
SKOFF, A. M., (A) 651
SKOFF, R. P., (A) 651
SMITH, D. W., (A) 453
SMITH, J. H., (A) 629, 663
SODERBERG, T., (A) 153
SOGARD, H., (A) 276
SONI, S., (A) 297
SOO DUK LIM, (A) 302
SORRENTINO, A. P., (A) 284
SPECTOR, W. G., (A) 620, 621
SPEISER, F., (A) 157
SPINA, A., (A) 140, 290
SPITZ, I. M., (A) 132
SQUIRES, P., (A) 146
SRINIVASAN, G. R., (N) 121
SRINIVASAN, H., (A) 153, 153, 297
SRISUWAN, S., (A) 280
STACH, J.-L., (A) 135, 294, 444
STANFORD, J., (B) 127, (A) 133, 287, 302
STARLEY, J. N. A., (O) 205
STEINGRUBE, V. A., (A) 155
STEINMAN, R. M., (A) 288
STENSTROM, S., (A) 153
STEVENS, M. H., (A) 615
STINGL, P., (A) 436
STONER, G. L., (O) 22, 33, (A) 645
STROBEL, M., (A) 294, 444
SUBRAMANIAM, K., (A) 615
SULA, L., (A) 448
SUNDAR RAO, P. S. S., (C) 416
SUNDARAM, K. R., (A) 301
SUNDARARAJ, G. D., (O) 197
SUPPLISSON, C., (A) 438
SUSHIDA, K., (A) 144, 144, 145
SUTHERLAND, I., (A) 302
SVANDOVA, E., (A) 302

TAKIZAWA, H., (A) 281
TALWAR, G. P., (O) 159, 550
TANEMURA, M., (A) 144, 144, 145, 145
TAYLOR, C. R., (A) 274, 285, 619, 647
TAYLOR, P. M., (O) 366
TEDLA, T., (A) 295

ten Dam, H. G., (A) 139
Terencio de las Aguas, J., (A) 133, 612
Tewes, M. E., (A) 629
Thatcher, G. N., (A) 301
The, T. H., (A) 278
Thestrup-Pedersen, K., (A) 276
Thomas, J. E. P., (A) 130, 131
Tiwari, V. D., (O) 473
Tolentino, M. M., (A) 287
Tolman, K. G., (A) 275
Tomioka, H., (A) 626
Tonelli, H. B., (A) 278
Tonello, C. J. S., (A) 287
Tonello, C. S., (A) 277
Torgal, J., (A) 291
Tornero, N., (A) 145, (A) 297
Toutouzas, P. C., (O) 331
Touw, J., (O) 22
Touw Langendijk, E. J. M., (O) 305, 312
Tran Huu-Ngoan, (C) 262
Tripathy, S. R., (A) 295
Tulp, A., (A) 289
Turk, J. L., (A) 143, 288, 441, 449, 625

Ulrich, M., (O) 169, 531, (A) 670
Ura, S., (A) 287, 613
Ussia, G., (A) 143

Vaidya, M. C., (A) 292, 442, 449
Vaishnavi, C., (A) 450
Valdez, H., (A) 156
Valdez, R., (A) 283, (O) 321
van de Meeberg, M., (B) 127
Van den Breen, L., (A) 142
Van der Veid, D., (A) 438
Van Droogenbroeck, J., (A) 610
van Eden, W., (C) 110, (A) 150, 444
Van Landingham, R. M., (A) 138, 612, 626
Van Loo, G., (A) 273
van Rood, J. J., (A) 150
Van Voorhis, W. C., (A) 288
Vanderveken, M., (B) 434
Vaquer, R. R., (A) 271
Vazquez-Escobosa, C., (A) 289
Veeraraghavan, N., (A) 291
Vellut, C., (A) 153, 438
Venetsianos, P. J., (O) 331
Venkataramaniah, H. N., (A) 295, 436
Venkatesam, B., (A) 296
Verghese, A., (A) 437
Verma, K. C., (A) 440
Vieira, L. M. M., (A) 281
Voiland, A., (A) 139, 622
Vyssoulis, G. P., (O) 331

Wadee, A. A., (A) 444, 445
Walerstein, M., (A) 146
Walker, A. N., (A) 277
Walker, L. L., (A) 138, 612, 626
Wallach, D., (A) 442, 442, 616, 617
Walsh, G. P., (A) 664, 665, 666, 668
Warndorff, J., (O) 203
Warndorff, T., (O) 191, 359
Warndorff-van Diepen, T., (O) 305, 312
Watson, S. R., (O) 481, (A) 649
Wayne, L. G., (A) 290, 624
Wemambu, S. N. C., (C) 259
Wheeler, P. R., (A) 143, 291, (O) 490, (A) 624
Whiting, J., Jr., (A) 668
Wieten, G., (A) 448
Wilkin, J. K., (A) 436
Wilkinson, R. D., (A) 132
Williams, G. T., (A) 621, 622
Williams, R., (A) 156
Winkelmann, R. K., (A) 298, 632
Winsley, B. E., (C) 592
Wolf, R. H., (A) 664, 665, 666
Woo, C. S., (A) 443
Wos, J., (A) 440
Wu Qin-xue, (N) 119

Xu Keyu, *et al.*, (A) 150, 629

Yagnik, C. S., (A) 439
Yanagihara, D. L., (A) 616, 659
Ye Gan-yun, (A) 130, (N) 266, 430
Yemaneberham, T., (A) 618
Yemul, V. L., (A) 441, 614
Yew, W. W., (A) 631
Yodfat, Y., (A) 146
Yoneda, K., (A) 437
Yoshida, H., (A) 617
Yoshida, T., (A) 288
Yoshino, Y., (A) 657
Yosipovitch, Z., (A) 631
Youn, J. I., (A) 443
Young, D. B., (A) 292, (O) 524, (A) 622, 655, 658, 660, 662
Younger, B., (A) 150

Zaffora, S., (A) 451, 451, 451
Zawar, P. B., (A) 614
Zhang Yongfa, (A) 130
Zhang Jun-Tan, *et al.*, (A) 133
Ziegler, J. E., (A) 453
Zimmer, B. L., (A) 157
Zone, J. J., (A) 275
Zuidema, J., (O) 191, 359
Zuniga, M., (O) 531, (A) 670
Zylber-Haran, E., (A) 132

INDEX TO SUBJECTS

Names of authors of original articles (O), editorials (E), and correspondence (C) are distinguished by large and small capital letters. Authors of abstracted articles (A), obituaries (Ob), news and notes (N), and books (B) are shown in ordinary type.

Acid-fast characteristics,
Infection by *Mycobacterium haemorphilum*, a metabolically fastidious acid-fast bacillus. Moulsdale, M. T., *et al.* ..... (A) 301
Ultrastructure of *Mycobacterium leprae* and other acid-fast bacteria as influenced by fixation conditions. Silva, M. T. and Macedo, P. M. ..... (A) 448

Acid, fatty,
Fatty acid and polar lipid analysis as tools in the identification of *Mycobacterium leprae* and some related slow-growing mycobacterial species. Anderson, O., *et al.* ..... (A) 445
Gas chromatography of constitutive fatty acids in *Mycobacterium leprae*. Kusaka, T. and Izumi, S. ..... (A) 624

Actinomycete(s),
Crossreactivity between *Mycobacterium leprae* and various actinomycetes and related organisms. RIDELL, M. ..... (O) 185
Growth of actinomycetals in relation to the pH of the medium. Portaels, F. and Kimanuka, T. ..... (A) 634

Adenosine triphosphatase (ATP),
Application of ATP assays to patient care in leprosy. Dhople, A. M. ..... (A) 653
Reduction of potassium tellurite and ATP content in *Mycobacterium leprae*. David, H. L., *et al.* ..... (A) 445

Africa,
Experimental transmission of leprosy in African green monkeys (*Cercopithecus aethiops*) and the rhesus monkey (*Macaca mulatta*). Wolf, R. H., *et al.* ..... (A) 664
Leprosy in Zimbabwe. Lyons, N. F. and Ellis, B. P. B. ..... (A) 296
Leprosy under control in Togo with work done increasingly by Togolese. ..... (N) 595
Remarks on the orofacial symptoms of leprosy observed in Somalia. Goracci, G. and Clangelo, G. ..... (A) 614
Southern Sudan to receive DM1.8 million for leprosy work from the German Leprosy Relief Association. ..... (N) 595
Zimbabwe Leprosy Symposium. Browne, S. G. ..... (N) 596

Allergy,
Dissociation between allergy and immunity in mycobacterial infections. Turk, J. L. ... (A) 288

Alpha-1-antitrypsin,
Alpha-1-antitrypsin in lepra reaction. Chawhan, R. N., *et al.* ..... (A) 614

American Leprosy Missions (ALM),
Dr. Roy F. Pfaltzgraff joins American Leprosy Missions. ..... (N) 124

Amikacin,
Activity of amikacin against mycobacteria *in vitro* and in murine tuberculosis. Sanders, W. E., Jr., *et al.* ..... (A) 156
Amikacin in the treatment of pulmonary tuberculosis. Allen, B. W., *et al.* ..... (A) 63

Anemia,
Hemolytic anemia induced by dapsone transmitted through breast milk. Sanders, S. W., *et al.* ..... (A) 275

Antibody(ies),
Definition of species-specific and cross-reactive antigenic determinants of *Mycobacterium leprae* using monoclonal antibodies. Ivanyi, J., *et al.* ..... (A) 619
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B. and Buchanan, T. M. ..... (A) 660

Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* ..... (A) 300
Effect of treatment on antibody activity against *Mycobacterium leprae* antigen 7 in tuberculoid leprosy. DAHLE, J. S., *et al.* ..... (O) 312
Evaluation of the significance of antibodies to phenolic glycolipid of *Mycobacterium leprae* in leprosy patients and their contacts. Buchanan, T. M., *et al.* ..... (A) 658
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *Mycobacterium leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 655
Generation and characterization of monoclonal antibodies to the *Mycobacterium leprae* phenolic glycolipid. Khanolkar, S. R., *et al.* ..... (A) 662
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., *et al.* ..... (A) 138
IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* ..... (A) 136
Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., *et al.* ..... (O) 33
Laboratory diagnosis of tuberculous lymphadenitis using soluble antigen fluorescent antibody test. Kiran, U., *et al.* ..... (A) 155
Monoclonal antibody-defined T-cell subsets in lepromatous leprosy. Bach, M.-A., *et al.* ..... (A) 442
Relation between anti-*Mycobacterium leprae* antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., *et al.* ..... (O) 305
Salivary immunoglobulin and antibody activities in leprosy. Abe, M., *et al.* ..... (A) 657
SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* ..... (A) 134
Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shriniwas. ..... (A) 154
Studies on the Paul-Bunnell antigen-antibody system. III. Detection of a Paul-Bunnell-related antigen in syphilis and leprosy. Morito, T., *et al.* ..... (A) 619
T cell subsets in leprosy lesions: *in situ* characterization using monoclonal antibodies. Narayanan, R. B., *et al.* ..... (A) 287
The production of human monoclonal antibodies against *Mycobacterium leprae*. Atlaw, T. and Roder, J. C. ..... (A) 656
The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* ..... (A) 621

Antigen(s),
Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. Piessens, W. F., *et al.* ..... (A) 156
Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. ..... (A) 299
Comparison of the cytoplasmic antigens of leprosy-derived corynebacteria and some mycobacteria. Gueur, M. C., *et al.* ..... (A) 623
Definition of species-specific and cross-reactive antigenic determinants of *Mycobacterium leprae* using monoclonal antibodies. Ivanyi, J., *et al.* ..... (A) 619
Delayed hypersensitivity eliciting lipoprotein antigen of *Mycobacterium tuberculosis* H37Rv. Deshpande, J. M., *et al.* ..... (A) 155
Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* ..... (A) 443
Effect of treatment on antibody activity against *Mycobacterium leprae* antigen in tuberculoid leprosy. DAHLE, J. S., *et al.* ..... (O) 312
Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* ..... (O) 481
Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from *Mycobacterium leprae*. Hunter, S. W. and Brennan, P. J. ..... (A) 623
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *Mycobacterium leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 655
Hepatitis-B-surface antigen (HBsAg) in leprosy patients. Balakrishnan, S., *et al.* ..... (A) 439

HLA and leprosy. I. Frequency incidence of HLA-A, B antigens among leprosy patients of Han nationality. Xu Keyu, *et al.* ..... (A) 150
HLA antigens in leprosy patients. Bale, U. M., *et al.* ..... (A) 146
Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., *et al.* ..... (A) 442
Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., *et al.* ..... (O) 33
Immune-response gene-associated antigens (Ia/DR). Structure and function in immunologically related diseases. Gorzynski, T. J. and David, C. S. ..... (A) 632
In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T. ..... (A) 443
Laboratory diagnosis of tuberculous lymphadenitis using soluble antigen fluorescent antibody test. Kiran, U., *et al.* ..... (A) 155
Prevalence of Australia antigen (HBsAg) in hanseniasis patients. Sarno, E. N., *et al.* ..... (A) 281
Ribosomal antigens of *Mycobacterium leprae.* Ridell, M. ..... (A) 291
SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* ..... (A) 134
Sensitization or tolerance to *Mycobacterium leprae* antigen by route of injection. Shepard, C. C., *et al.* ..... (A) 138
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. ..... (A) 157
Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shriniwas ..... (A) 154
Studies on the Paul-Bunnell antigen-antibody system. III. Detection of a Paul-Bunnell-related antigen in syphilis and leprosy. Morito, T., *et al.* ..... (A) 619
Study of the association between the antigens of the HLA system and Hansen's disease. de la Cruz, F., *et al.* ..... (A) 283
The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* ..... (A) 133
Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. ..... (A) 137

Argentina,
1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. Charosky, C. B. ..... (A) 151
Infantile leprosy in the registry of patients of the Service of Leprology of the Policlinico Intendente Carrasco de Rosario. Arpini, R., *et al.* ..... (A) 451
Registry of patients of the Service of Dermatoleprology of the Policlinico Intendente Carrasco de Rosario. Arpini, R. H., *et al.* ..... (A) 451
Sociedad Argentina de Dermatologia (Asociacion Medica Argentina). ..... (N) 596

Armadillo(s),
A new communication on natural mycobacteriosis in armadillos (*Dasypus novemcinctus* Linn.). Martinez, A. R., *et al.* ..... (A) 144
A single subcutaneous inoculation of 10^7 armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* ..... (A) 450
Bacteriological studies of armadillo livers infected with *Mycobacterium leprae.* Portaels, F., *et al.* ..... (A) 141
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. ..... (A) 624
Disposition of prothionamide in rats and armadillos. PETERS, J. H., *et al.* ..... (O) 54
Leprosy in wild armadillos (*Dasypus novemcinctus*) of the Texas Gulf Coast: Epidemiology and mycobacteriology. Smith, J. H., *et al.* ..... (A) 629
Progress in the preparation of an antileprosy vaccine from armadillo-derived *Mycobacterium leprae.* REES, R. J. W. ..... (O) 515
SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* ..... (A) 134

Sylvatic leprosy in wild armadillos of the Texas Gulf Coast. Smith, J. H., *et al.* ..... (A) 663
The mycolic acids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Draper, P., *et al.* ..... (A) 446
Variable lepromin response to *Mycobacterium leprae* in resistant armadillos. JOB, C. K., *et al.* ..... (O) 347

Arthropod(s),
Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. ..... (A) 628

Asia,
A study of case-holding in leprosy patients in Asia, based on duration of treatment. Collier, P. J. ..... (A) 627
Leprosy; our Southeast Asian refugee experience. Younger, B., *et al.* ..... (A) 150
Proceedings of the 3rd International Workshop in Training of Leprosy Workers in Asia, Bangkok, Thailand, 18–28 January 1982. ..... (B) 607
Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7–11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. ..... (B) 608

Assay(s) (*see also* ELISA),
Application of ATP assays to patient care in leprosy. Dhople, A. M. ..... (A) 653
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B. and Buchanan, T. M. ..... (A) 660
Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* ..... (A) 443
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. ..... (A) 157

Australia,
Leprosy in the Northern Territory of Australia with Particular Reference to the Aborigines of Arnhem Land and the Arid Regions of the Northern Territory. Hargrave, J. C. .... (B) 433

Baby(ies),
A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. DUNCAN, M. E., *et al.* ..... (O) 7
IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* ..... (A) 136

Bacilli,
A study of continuous bacillaemia in borderline and lepromatous type of leprosy. Raval, S. N., *et al.* ..... (A) 280
Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., *et al.* ..... (A) 288
Electron microscopic observations of intracytoplasmic inclusions in human and murine leprosy bacilli. HIRATA, T. ..... (O) 84
Induction of delayed type hypersensitivity against ultrasonicated *Mycobacterium lepraemurium* bacilli without simultaneous local reactivity against live bacilli. Løvik, M. and Closs, O. ..... (A) 625
Infection by *Mycobacterium haemorphilum*, a metabolically fastidious acid-fast bacillus. Moulsdale, M. T., *et al.* ..... (A) 301
Infection with *Mycobacterium avium-intracellulare* and the protective effects of bacille Calmette-Guerin. Edwards, M. L., *et al.* ..... (A) 453
Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. ..... (A) 628
Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* ..... (O) 466
The development of clinical tuberculosis following infection with tubercule bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection,

linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., *et al.* ..... (A) 302
The *in vitro* culture of the leprosy bacillus. BAKER, C. J. ..... (E) 397

Bacteriology,
Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L. and Sanchez Caballero, H. ..... (A) 131
Bacteriological studies of armadillo livers infected with *Mycobacterium leprae*. Portaels, F., *et al.* ..... (A) 141
Bacteriology of *Mycobacterium leprae*. Pattyn, S. R. ..... (A) 624
Bacteriophage typing of strains of *Mycobacterium tuberculosis* from Nepal. Goode, D. ..... (A) 299
Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., *et al.* ..... (A) 279
Leprosy review: The bacteriology of *Mycobacterium leprae*. DRAPER, P. ..... (O) 563
Morphology of bacteriophages from *Mycobacterium lepraemurium*. Rastogi, N. and David, H. L. ..... (A) 142
Mycobacterium leprae infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., *et al.* ..... (A) 293
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. ..... (A) 438

BCG (bacille Calmette-Guérin),
An investigation of a range of new tuberculins. I. The effects of ageing, place of domicile, BCG immunisation and tuberculosis. Stanford, J. L., *et al.* ..... (A) 302
Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. ..... (A) 299
Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., *et al.* ..... (A) 301
Changes in BCG strains. Osborn, T. W. ..... (A) 301
Comparative immunogenicity of BCG and *Mycobacterium leprae* in normal and in *M. leprae*-tolerant mice. Shepard, C. C. ..... (A) 646
Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae,* and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* ..... (A) 626
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* ..... (A) 300
Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* ..... (A) 285
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and *Mycobacterium lepraemurium*. Stach, J.-L., *et al.* ..... (A) 294
IgE in leprosy; effect of a *Mycobacterium leprae*-BCG vaccine. LYNCH, N. R., *et al.* ..... (O) 169
In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T. ..... (A) 443
Infection with *Mycobacterium avium-intracellulare* and the protective effects of bacille Calmette-Guérin. Edwards, M. L., *et al.* ..... (A) 453
Intradermal BCG vaccination complications—analysis of 51 cases. Murzy de Souza, G. R., *et al.* ..... (A) 301
Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. ..... (A) 621
Isolated epithelioid cells from disaggregated BCG granulomas—some functional studies. Williams, G. T. ..... (A) 622
Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. ..... (A) 139
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. ..... (A) 296

The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* ..... (A) 621
The use of subcellular components of BCG for studying host-mycobacterium interaction in relation to leprosy. Das, P. K., *et al.* ..... (A) 282
Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., *et al.* ..... (A) 301

Behçet's Syndrome,
Abnormalities of T-cell subsets in Behçet's syndrome. Soo Duk Lim, *et al.* ..... (A) 302

Belehu, Ayele,
Obituary. Haregewoin, A. and Olcen, P. ..... (Ob) 404

Belgium,
Prix des Concours Ordinaires awarded Madame Françoise Antoine-Portaels. ..... (N) 596

Biochemistry,
Biochemical studies of leprosy-derived corynebacteria. Cocito, C., *et al.* ..... (A) 140
Biochemical investigation of the peribacillary substance of *Mycobacterium leprae*. Fukunishi, Y., *et al.* ..... (A) 668
Biochemical properties of *Mycobacterium lepraemurium* cultivated in cell-free liquid medium. Nakamura, M. ..... (A) 654

Blood,
Studies in interleukin 1 production by peripheral blood mononuclear cells from leprosy patients. Watson, S. R., *et al.* ..... (A) 649
T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors. Fleming, B. and Rook, G. A. W. ..... (A) 283
The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* ..... (A) 133
Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* ..... (A) 647

Bolivia,
Epidemiologic patterns of leprosy in Vallegrande, Bolivia. De Muynck, A. ..... (A) 295

Bone,
An unusual location of leproma of bone; a case report. ANDERSEN, J. G. and WARNDORFF, J. ..... (O) 203
Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., *et al.* ..... (A) 630
The rate of loss of maxillary anterior alveolar bone height in patients with leprosy. Subramaniam, K., *et al.* ..... (A) 615
The resistance of C57BL/6 mice to subcutaneous infection with *Mycobacterium lepraemurium* is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., *et al.* ..... (A) 625

Borderline leprosy,
A study of continuous bacillaemia in borderline and lepromatous type of leprosy. Raval, S. N., *et al.* ..... (A) 280
Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L. and Sanchez Caballero, H. ..... (A) 131
Immune status of subsided cases of tuberculoid (TT) and borderline tuberculoid (BT) leprosy. Mackay, I. G., *et al.* ..... (A) 285
Leprosy, borderline-lepromatous, and cytomegalovirus infection. Kruyt, J. A., *et al.* ..... (A) 278
Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., *et al.* ..... (A) 613
Orchiepididymitis in dimorphous leprosy. Gimenez, M. F. and Tonelli, H. B. ..... (A) 278
Positioning of borderline and indetermined groups in the hanseniasis classification. Pereira, A. C., Jr. and Gurfinkel, A. C. M. ..... (A) 128
Relation between anti-*Mycobacterium leprae* antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., *et al.* ..... (O) 305

Bowel,
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene®) in the treatment of prurigo nodularis. BELAUBE, P., *et al.* ..... (O) 328

Brazil,
Epidemiology of hanseniasis in the state of Rio Grande do Sul. Bernardi, C. and Ferreira, J. ..... (A) 146
II International Congress of the College of Hansenology of the Endemic Countries. ..... (N) 263
IV Brazilian Congress of Hansenology. Bechelli, L. M. ..... (N) 118
Some aspects of hanseniasis in the region of Londrina, Parana, 1968–1978. 1. General characteristics. Asseis, E. A., *et al.* ..... (A) 145
Some aspects of hanseniasis in the region of Londrina, Parana, 1968–1978. 2. Specific characteristics. Tornero, N., *et al.* ..... (A) 297
The epidemiology of leprosy in Chaco. Risso, H. I. ..... (A) 296

Burma,
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18-19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. ..... (O) 500

C3,
A single subcutaneous inoculation of 10^7 armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* ..... (A) 450
An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., *et al.* ..... (A) 138
CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., *et al.* ..... (A) 618
Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Harikrishnan, S., *et al.* ..... (A) 134
Serum levels of C3-activator (antifactor B) in leprosy. WEMAMBU, S. N. C. ..... (C) 259
Susceptibility to *M. lepraemurium* of CBA, DBA and C3H mice. Kawaguchi, Y., *et al.* ..... (A) 625
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. V. Host resistance of *M. avium* of hybrids of C3H origin. Kawaguchi, Y., *et al.* ..... (A) 144

C3d,
An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., *et al.* ..... (A) 138

Cancer,
Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia, and lepromatous leprosy. Moura, N. C., *et al.* ..... (A) 443

Candida albicans,
Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* ..... (A) 283
Phagocytosis of *Candida albicans* by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* ..... (A) 287

Candida pseudotropicalis,
Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* ..... (A) 283

Carbon,
Metabolism of carbon sources of *Mycobacterium leprae*: a preliminary report. Wheeler, P. R. ..... (A) 143

Caribbean,
III Meeting of the Standing Committee of Leprosy Control in the Caribbean (SLCC III). ..... (N) 120

Cat(s),
Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schiefer, H. B. and Middleton, D. M. ..... (A) 626

Catalase,
Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of *Mycobacterium lepraemurium* TMC 1701. Katoch, V. M., *et al.* ..... (A) 290
Serological approaches for the characterization of catalase in tissue-derived mycobacteria. Katoch, V. M., *et al.* ..... (A) 624

Cell(s),
Abnormalities of T-cell subsets in Behçet's syndrome. Soo Duk Lim, *et al.* ..... (A) 302
Activated suppressor T cells in leprosy. Mehra, V., *et al.* ..... (A) 136
Binding of phosphatidylethanolamine and phosphatidylinositol to OKT8+ lymphocytes activates suppressor cell activity. Wadee, A. A. and Rabson, A. R. ..... (A) 445
Biochemical properties of *Mycobacterium lepraemurium* cultivated in cell-free liquid medium. Nakamura, M. ..... (A) 654
Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., *et al.* ..... (A) 301
Characterization of a suppressor cell-activating factor (SCAF) released by adherent cells treated with *M. tuberculosis*. Wadee, A. A., *et al.* ..... (A) 444
Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of *Mycobacterium lepraemurium* TMC 1701. Katoch, V. M., *et al.* ..... (A) 290
Chemical composition of cell-wall polysaccharides from leprosy-derived corynebacteria. Abou-Zeid, C., *et al.* ..... (A) 139
ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. SASIAIN, M. DEL C., *et al.* ..... (O) 321
Defect in the generation of cytotoxic T cells in lepromatous leprosy. Stach, J.-L., *et al.* ..... (A) 444
Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in *Mycobacterium lepraemurium* infection. Hoffenbach, A., *et al.* ..... (A) 292
E-rosettes in leprosy patients. Manimakalai, *et al.* ..... (A) 285
Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. Nouri-Arai, K. T., *et al.* ..... (A) 156
Effects of vaccination with *Mycobacterium leprae* on local cell-mediated immunity. Ridel, P.-R., *et al.* ..... (A) 645
Enhanced growth of *Mycobacterium lepraemurium* in cell-free liquid medium with DL-aspartic acid. Nakamura, M. ..... (A) 290
Evidence for generation of suppressor T cells in *Mycobacterium lepraemurium*-infected CBA/J mice, a mouse strain highly susceptible to the infection. Saito, N. and Hiroka, Y. ..... (A) 450
Growth stimulation of *Mycobacterium lepraemurium* by liposome in cell-free liquid medium. Nakamura, M. ..... (A) 141
Identification of T-cell subpopulations in granuloma annulare. Buechner, S. A., *et al.* ..... (A) 298
In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T. ..... (A) 443
In vitro proliferative response to *M. leprae* and PPD of isolated T cell subsets from leprosy patients. Bach, M.-A., *et al.* ..... (A) 442
Increased helper-suppressor T cell ratio in psoriasis. Ligesti, D. J., *et al.* ..... (A) 155
Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae*. A comparison. Kulkarni, V. M. and Seydel, J. K. ..... (A) 274
Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. ..... (A) 621
Isolated epithelioid cells from disaggregated BCG granulomas—some functional studies. Williams, G. T. ..... (A) 622
Langerhans' cell and leprosy. Mathur, N. K., *et al.* ..... (A) 443
Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. ..... (A) 628

Leprosy XII. T-cell subsets in lepromatous leprosy. Lim, S. D., *et al.* ..... (A) 443
Mechanisms of T-cell unresponsiveness in leprosy. Bach, M.-A., *et al.* ..... (A) 616
Monoclonal antibody-defined T-cell subsets in lepromatous leprosy. Bach, M.-A., *et al.* ..... (A) 442
Rosette-forming cells in patients with treated leprosy. DANG DUC TRACH, *et al.* ..... (O) 174
Serum-mediated suppression of E-RFC levels in leprosy and reversal by fetal calf serum. Jaswaney, V. L., *et al.* ..... (A) 284
Stimulating effects of lecithin and cholesterol on the growth of *Mycobacterium lepraemurium* in cell-free liquid medium. Nakamura, M. ..... (A) 141
Studies in interleukin 1 production by peripheral blood mononuclear cells from leprosy patients. Watson, S. R., *et al.* ..... (A) 649
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., *et al.* ..... (A) 650
Suppressed natural killer cell activity during episodes of erythema nodosum leprosum in lepromatous leprosy. Humphres, R. C., *et al.* ..... (A) 134
Suppressor cells of mouse and man. What is the evidence that they contribute to the aetiology of the mycobacterioses? Rook, G. A. W. ..... (A) 137
T cell subsets in leprosy lesions: *in situ* characterization using monoclonal antibodies. Narayanan, R. B., *et al.* ..... (A) 287
T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Haregewoin, A., *et al.* ..... (A) 618
T-cell subsets in cutaneous sarcoidosis. Buechner, S. A., *et al.* ..... (A) 632
T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors. Fleming, B. and Rook, G. A. W. ..... (A) 283
The cutaneous infiltrates of leprosy. Cellular charcteristics and the predominant T cell phenotypes. Van Voorhis, W. C., *et al.* ..... (A) 288
The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S. ..... (O) 225
The resistance of C57BL/6 mice to subcutaneous infection with *Mycobacterium lepraemurium* is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., *et al.* ..... (A) 625
Use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. MATSUO, Y. ..... (O) 72
Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., *et al.* ..... (A) 301

CH50,

CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., *et al.* ..... (A) 618

Chemotherapy,

Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., *et al.* ..... (C) 592
Chemotherapy of non-lepromatous leprosy. ..... (A) 609
Leprosy and its chemotherapy. Beeching, N. J. and Ellis, C. J. ..... (A) 129
Nude mice as a model for chemotherapy of leprosy. Kohsaka, K., *et al.* ..... (A) 437
Polychemotherapy in leprosy. Terencio de las Aguas, J. ..... (A) 612
Report of the 11th and 12th meetings of the Steering Committee of the Scientific Working Group on the Chemotherapy of Leprosy. ..... (N) 429
The incidence of lagophthalmus and posterior synechiae of the iris during chemotherapy of leprosy (morbus Hansen). Brandt, F. and Kalthoff, P. C. ..... (A) 613
Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. Mshana, R. N., *et al.* ..... (A) 286

Child(ren),

Lepromatous leprosy in children. (An account of the last three observations.) Ravettini, B. A., *et al.* ..... (A) 614

Leprosy in 18-month-old children, Bichena District, Gojjam Administrative Region, Ethiopia. Fekete, E. and Tedla, T. ..... (A) 295
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. ..... (A) 296
Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., *et al.* ..... (A) 301

China, People's Republic of,
HLA and leprosy. I. Frequency incidence of HLA-A, B antigens among leprosy patients of Han nationality. Xu Keyu, *et al.* ..... (A) 150
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. Wu Qin-xue. ..... (N) 119
Second Plenary Session of the National Consultative Committee on Leprosy Control convened at Kunming. Ye Gan-yun. ..... (N) 266
Workshop on Epidemiology and Statistics in Leprosy held in Guangdong. Ye Gan-yun. ..... (N) 430

Chloramphenicol,
Treatment of erythema nodosum leprosum with chloramphenicol—a comparison with thalidomide. Saint-André, P., *et al.* ..... (A) 611

Cholesterol,
Cholesterol metabolism of macrophages in relation to the presence of *Mycobacterium leprae.* Kurup, I. G. and Mahadevan, P. R. ..... (A) 135
Stimulating effects of lecithin and cholesterol on the growth of *Mycobacterium lepraemurium* in cell-free liquid medium. Nakamura, M. ..... (A) 141

Chromatography,
Gas chromatography of constitutive fatty acids in *Mycobacterium leprae.* Kusaka, T. and Izumi, S. ..... (A) 624

Classification of leprosy,
Analysis of the inter- and intrapathological concordances and discordances in a comparative study of Madrid and Ridley-Jopling classifications of leprosy. Haddad, N., *et al.* ..... (A) 435
Comparative clinicohistopathological study of Madrid and Ridley-Jopling classifications of leprosy. Bechelli, L. M., *et al.* ..... (A) 435
Leprosy classification for use in control programs. Bernardi, C., *et al.* ..... (A) 275
Positioning of borderline and indetermined groups in the hanseniasis classification. Pereira, A. C., Jr. and Gurfinkel, A. C. M. ..... (A) 128
The Biology of Mycobacteria. Vol. 1. Physiology, Identification and Classification. Ratledge, C. and Stanford, J., eds. ..... (B) 127

Clinical,
A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. Duncan, M. E., *et al.* ..... (O) 7
Associations of circulating immune complexes, clinical activity, and bacterial index in Japanese patients with leprosy. Furukawa, F., *et al.* ..... (A) 617
Clinical and histopathological difficulties in the differential diagnosis of Hansen's disease. Gatti, J. C., *et al.* ..... (A) 278
Clinical, electrophysiological and teased fibre study of peripheral nerves in leprosy. Chopra, J. S., *et al.* ..... (A) 631
Clinical epidemiology of nonlepromatous leprosy among service personnel. (Armed Forces—India). Guha, P. K. ..... (A) 149
Clinical observation on iridocyclitis in leprosy patients. Acharya, B. P. ..... (A) 612
Comparative clinicohistopathological study of Madrid and Ridley-Jopling classifications of leprosy. Bechelli, L. M., *et al.* ..... (A) 435
Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., *et al.* ..... (A) 279
Effect of levamisole on clinical outcome and DNCB conversion in leprosy patients. A long term study. Yagnik, C. S., *et al.* ..... (A) 439
Management of clinical trials in developing countries. de Maar, E. W. J., *et al.* ..... (A) 277
Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., *et al.* ..... (A) 630

Relation between anti-*Mycobacterium leprae* antibody activity and clinical features in borderline tuberculoid (BT) leprosy. Touw Langendijk, E. J. M., *et al.* ..... (O) 305
Study of immunological parameters in patients with different clinical forms of leprosy; the influence of treatment. Bottasso, O. A., *et al.* ..... (A) 133
The development of clinical tuberculosis following infection with tubercule bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., *et al.* ..... (A) 302

Clofazimine,
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. Winsley, B. E., *et al.* ..... (C) 592
Exudative enteropathy due to clofazimine: about a case. Belaube, P., *et al.* ..... (A) 129
Reduced estrogen excretion due to clofazimine? Duncan, M. E. and Oakey, R. E. .... (C) 112
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene®) in the treatment of prurigo nodularis. Belaube, P., *et al.* ..... (O) 328

Cloning,
Construction and partial characterization of *Mycobacterium leprae* genomic libraries using an *in vivo* cosmid cloning system. Jacobs, W. R., *et al.* ..... (A) 667

Complement,
An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., *et al.* ..... (A) 138
Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., *et al.* ..... (A) 288
CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., *et al.* ..... (A) 618

Concanavalin A,
ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. Sasiain, M. del C., *et al.* ..... (O) 321

Control of leprosy,
A 20-year study of the leprosy control programme at the Government Leprosy Treatment and Study Centre at Tirukoilur in South India. Radhakrishna, S., *et al.* ..... (A) 149
Action plans for leprosy control meeting. (India). Sansarricq, H. ..... (N) 263
An appraisal of medical research in the treatment and control of leprosy. Rees, R. J. W. ..... (A) 271
Basic Epidemiological Indicators for Monitoring Leprosy Control. Lechat, M. F. and Vanderveken, M. ..... (B) 434
Considerations in a leprosy control program. Risso, H. I. and Gimenez, M. M. ..... (A) 150
HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. van Eden, W., *et al.* ..... (A) 150
III Meeting of the Standing Committee of Leprosy Control in the Caribbean (SLCC III). ..... (N) 120
Leprosy classification for use in control programs. Bernardi, C., *et al.* ..... (A) 275
Leprosy control project funded. (West Indies). ..... (N) 432
Leprosy under control in Togo with work done increasingly by Togolese. ..... (N) 595
Mouse foot pad technique for evaluation of drug resistance of *M. leprae* and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. ..... (A) 436
Policy and strategy for leprosy control programs. (Latin America). Romero, A. ..... (A) 628
Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7–11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. ..... (B) 608
Recent changes in leprosy control. Sansarricq, H. ..... (A) 628
Second Plenary Session of the National Consultative Committee on Leprosy Control convened at Kunming. (China). Ye Gan-yun. ..... (N) 266
Tuberculosis and leprosy control: WHO consultation. ..... (A) 451

Corticosteroid(s),
Corticosteroids and lepromin sensitivity. Kundu, S. K., *et al.* ..... (A) 131

Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. Nouri-Arai, K. T., *et al.* ..... (A) 156

Corynebacteria,
Biochemical studies of leprosy-derived corynebacteria. Cocito, C., *et al.* ..... (A) 140
Biological properties of diphtheroid bacteria (LDC) isolated from human leprosy lesions. Delville, J., *et al.* ..... (A) 140
Chemical composition of cell-wall polysaccharides from leprosy-derived corynebacteria. Abou-Zeid, C., *et al.* ..... (A) 139
Comparison of the cytoplasmic antigens of leprosy-derived corynebacteria and some mycobacteria. Gueur, M. C., *et al.* ..... (A) 623
Modification of the kinetics of growth of *Mycobacterium leprae* by a group of corynebacteria. Delville, J., *et al.* ..... (A) 290
Structure of the wall polysaccharide isolated from a group of corynebacteria. Abou-Zeid, C., *et al.* ..... (A) 622

Cultivation,
Pathogenicity of *in vitro* cultivated *Mycobacterium lepraemurium* in rats. Ishaque, M. ..... (A) 293
In vitro cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. ..... (O) 77
Use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. MATSUO, Y. ..... (O) 72
Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. ..... (A) 294
Biochemical properties of *Mycobacterium lepraemurium* cultivated in cell-free liquid medium. Nakamura, M. ..... (A) 654
Method of cultivation of *M. leprae.* Veeraraghavan, N. ..... (A) 291

Cutaneous,
Assessment of cutaneous autonomic nerve functions in leprosy. Boyle, A. and Ramu, G. ..... (A) 151
Cutaneous sarcoidosis. Treatment with thalidomide. Barriere, H. ..... (A) 632
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., *et al.* ..... (A) 650
T-cell subsets in cutaneous sarcoidosis. Buechner, S. A., *et al.* ..... (A) 632
The cutaneous infiltrates of leprosy. Cellular charcteristics and the predominant T cell phenotypes. Van Voorhis, W. C., *et al.* ..... (A) 288
Ulcerative cutaneous mycobacteriosis. Lavalle, P., *et al.* ..... (A) 633

Cycloheximide,
Use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. MATSUO, Y. ..... (O) 72

Damien-Dutton Society,
Damien-Dutton Society history. Crouch, H. E. ..... (N) 124
Dr. Ma Haide receives the 1982 Damien-Dutton Award. Lechat, M. F. ..... (N) 422

Dapsone (DDS),
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., *et al.* ..... (C) 592
Co-incident (simultaneous) dapsone sensitivity and dapsone-resistant leprosy. PETTIT, J. H. S. ..... (C) 258
Dapsone compliance in an urban field project. Revankar, C. R., *et al.* ..... (A) 438
Dapsone in allergic vasculitis: Its use in Henoch-Schonlein disease following vaccination. Ledermann, J. A. and Hoffbrand, B. I. ..... (A) 633
Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., *et al.* ..... (O) 191
Dapsone-resistant leprosy. Pearson, J. M. H. ..... (A) 611
DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk,

South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. ALMEIDA, J. G., *et al.* ..... (O) 366
Follow-up of lepromatous (LL and BL) patients on dapsone (DDS) monotherapy after attainment of smear negativity in Gudiyatham Taluk, South India. ALMEIDA, J. G., *et al.* ..... (O) 382
Further results on dapsone-resistant leprosy in Bamako (Mali). Baquillon, G., *et al.* ... (A) 273
Hemolytic anemia induced by dapsone transmitted through breast milk. Sanders, S. W., *et al.* ..... (A) 275
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., *et al.* ..... (O) 461
Monitoring the regularity of self administration of dapsone by leprosy patients. Kumar, A. and Balakrishnan, S. ..... (A) 274
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. (China) Wu Qin-xue. ..... (N) 119
Qualitative quick simplified methods in the determination of urinary DDS. Jin Liang-Jian. ..... (A) 273
Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* ..... (A) 610
Response to dapsone (DDS) monotherapy in leprosy patients of Gudiyatham Taluk, South India: Comparison between the 1960s and the 1970s. ALMEIDA, J. G., *et al.* ... (O) 378
Results of long-term domiciliary dapsone (DDS) monotherapy for lepromatous leprosy in Gudiyatham Taluk, South India. ALMEIDA, J. G., *et al.* ..... (O) 385
Sensitivity of mycobacteria to dapsone. Portaels, F., *et al.* ..... (A) 142
Sex differences in the absorption of dapsone after intramuscular injection. MODDERMAN, E. S. M., *et al.* ..... (O) 359
Social and personality factors in dapsone resistant patients. John, J. K., *et al.* ..... (A) 437
The significance of dapsone (DDS)-resistant *Mycobacterium leprae* in untreated patients. ALMEIDA, J. G., *et al.* ..... (O) 374

Davey, Thomas Frank,
Obituary. Seal, K. S. ..... (Ob) 405

Deformity(ies),
A study of leprosy patients with deformities and the implications of the treatment of all leprosy patients. Price, J. A. ..... (A) 631
Changes in epidemiology of deformity in leprosy in a rural area in South India. Srinivasan, H. ..... (A) 297
Rehabilitation of leprous deformity. Enna, C. D. ..... (A) 152

Deoxyfructose,
Deoxyfructo-serotonin: a new drug with anti-leprosy activity. Mester de Parajd, L., *et al.* ..... (A) 274

Dermatoglyphics,
A preliminary study of dermatoglyphics in patients with leprosy. Ruan Xi-Yuan, *et al.* ..... (A) 280
A study of palmar dermatoglyphics in leprosy. Nagar, K. S., *et al.* ..... (A) 279

Dermatology,
Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, R. and Grange, J. M. ..... (A) 300
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. (China). Wu, Qin-xue. ..... (N) 119
Registry of patients of the Service of Dermatoleprology of the Policlinico Intendente Carrasco de Rosario. (Argentina). Arpini, R. H., *et al.* ..... (A) 451
Sociedad Argentina de Dermatologia (Asociacion Medica Argentina). ..... (N) 596
V International Congress of Tropical Dermatology to meet in Mexico City. ..... (N) 266

Diabetes,
Diabetes and leprosy. Terencio de las Aguas, J. ..... (A) 133

Diacylphthiocerol,
Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from *Mycobacterium leprae.* Hunter, S. W. and Brennan, P. J. ..... (A) 623

Diaminodiphenylsulfone,
Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae.* A comparison. Kulkarni, V. M. and Seydel, J. K. ..... (A) 274

Dimorphous leprosy, *see* **Borderline leprosy**

DL-Aspartic acid,
Enhanced growth of *Mycobacterium lepraemurium* in cell-free liquid medium with DL-aspartic acid. Nakamura, M. ..... (A) 290

DNCB,
Effect of levamisole on clinical outcome and DNCB conversion in leprosy patients. A long term study. Yagnik, C. S., *et al.* ..... (A) 439

Drug(s),
Deoxyfructo-serotonin: a new drug with anti-leprosy activity. Mester de Parajd, L., *et al.* ..... (A) 274
In vitro activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* ..... (A) 157
In vitro sensitivity of *Mycobacterium lepraemurium* for antimycobacterial drugs. Portaels, F., *et al.* ..... (A) 142
Mouse foot pad technique for evaluation of drug resistance of *M. leprae* and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. ..... (A) 436
Mutagenic activity of antileprosy drugs and their derivatives. PETERS, J. H., *et al.* ..... (O) 45
Preliminary study on R761 treatment for leprosy. Li Wenzhong, *et al.* ..... (A) 130
Rapid, radiolabeled-microculture method that uses macrophages for *in vitro* evaluation of *Mycobacterium leprae* viability and drug susceptibilty. Mittal, A., *et al.* ..... (A) 446
Recent studies of antileprosy drugs. Shepard, C. C., *et al.* ..... (A) 612
Selecting drug combinations for treatment of drug-resistant mycobacterial diseases. Nash, D. R. and Steingrube, V. A. ..... (A) 155
Solid, fragmented and granular index as one of the parameters in drug trials. Sharma, V. D., *et al.* ..... (A) 132

Electron microscopy,
Electron microscopic observations of intracytoplasmic inclusions in human and murine leprosy bacilli. HIRATA, T. ..... (O) 84
Electron microscopic study of leprosy in a mangabey monkey (naturally acquired infection). Fukunishi, Y., *et al.* ..... (A) 666
Electron microscopic study of *Mycobacterium leprae* membrane. SILVA, M. T. and MACEDO, P. M. ..... (O) 219
The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S. ..... (O) 225

ELISA test(s) (enzyme-linked immunosorbent assay),
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae.* Young, D. B. and Buchanan, T. M. ..... (A) 660
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* ..... (A) 300
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. ..... (A) 157

Enteropathy,
Exudative enteropathy due to clofazimine: about a case. Belaube, P., *et al.* ..... (A) 129

Enzyme(s),
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae.* Young, D. B. and Buchanan, T. M. ..... (A) 660

Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* ..... (A) 443
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. ..... (A) 157

Eosinophilia,
Eosinophilia as a result of rifampicin therapy. Nigam, P., *et al.* ..... (A) 131

Epidemiology,
Basic Epidemiological Indicators for Monitoring Leprosy Control. Lechat, M. F. and Vanderveken, M. ..... (B) 434
Changes in epidemiology of deformity in leprosy in a rural area in South India. Srinivasan, H. ..... (A) 297
Clinical epidemiology of nonlepromatous leprosy among service personnel. (Armed Forces—India). Guha, P. K. ..... (A) 149
Epidemiologic patterns of leprosy in Vallegrande, Bolivia. De Muynck, A. ..... (A) 295
Epidemiological considerations in vaccine trials in leprosy. NOORDEEN, S. K. ..... (O) 556
Epidemiology of hanseniasis in the state of Rio Grande do Sul. (Brazil). Bernardi, C. and Ferreira, J. ..... (A) 146
Epidemiology of leprosy in rural population of Pondicherry. (India). Lal, S., *et al.* ..... (A) 296
Leprosy in wild armadillos (*Dasypus novemcinctus*) of the Texas Gulf Coast: Epidemiology and mycobacteriology. (U.S.A.). Smith, J. H., *et al.* ..... (A) 629
Leprosy: the epidemiology of a slow bacterium. Fine, P. E. M. ..... (A) 147
The epidemiology of leprosy in Chaco. (Brazil). Risso, H. I. ..... (A) 296
Workshop on Epidemiology and Statistics in Leprosy held in Guangdong (China). Ye Gan-yun. ..... (N) 430

Epstein-Barr,
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., *et al.* ..... (A) 138

Erythema nodosum leprosum (ENL),
A study of serum fibrinolytic activity in erythema nodosum leprosum (ENL). Jain, V. K., *et al.* ..... (A) 440
An appraisal of third complement component (C3) and breakdown product (C3d) in erythema nodosum leprosum (ENL). Saha, K., *et al.* ..... (A) 138
An unusual case of erythema nodosum leprosum. Petri, V. ..... (A) 132
ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. SASIAIN, M. DEL C., *et al.* ..... (O) 321
Suppressed natural killer cell activity during episodes of erythema nodosum leprosum in lepromatous leprosy. Humphres, R. C., *et al.* ..... (A) 134
The immunopathology of erythema nodosum leprosum: The role of extravascular complexes. Ridley, M. J. and Ridley, D. S. ..... (A) 620
Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* ..... (A) 647
Treatment of erythema nodosum leprosum with chloramphenicol—a comparison with thalidomide. Saint-André, P., *et al.* ..... (A) 611
Ultrastructure of skin in erythema nodosum leprosum. Anthony, J., *et al.* ..... (A) 442

Esterase,
Demonstration of T lymphocytes in leprous granuloma using the acid alpha naphthyl acetate esterase activity. An attempt of quantitative analysis. Gaulier, A., *et al.* ..... (A) 617

Estrogen,
Estrogen excretion in pregnant women with leprosy; evidence of diminished fetoplacental function. Duncan, M. E. and Oakey, R. E. ..... (A) 130
Reduced estrogen excretion due to clofazimine? DUNCAN, M. E. and OAKEY, R. E. ..... (C) 112

Ethambutol,
In vitro activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* ..... (A) 157

Ethionamide,
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., *et al.* ..... (C) 592
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., *et al.* ..... (O) 461

Ethiopia,
Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., *et al.* ..... (O) 191
Leprosy in 18-month-old children, Bichena District, Gojjam Administrative Region, Ethiopia. Fekete, E. and Tedla, T. ..... (A) 295
Skin diseases in Addis Ababa: A preliminary review. Manzur, J. ..... (A) 279
The age at onset of overt leprosy patients presenting at the Addis Ababa Leprosy Hospital. Alemayehu, A. and Naafs, B. ..... (A) 295

Experimental leprosy,
Immunological effects of experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* ..... (A) 665
Quantitative analysis of the sequence of nerve damage in experimental leprosy. Bhat, K. R. and Vaidya, M. C. ..... (A) 292
Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. ..... (A) 449

Eye(s),
Blindness from cataract formation in leprosy. Brandt, F., *et al.* ..... (A) 440
Ocular complications in leprosy. Das, R., *et al.* ..... (A) 276
The incidence of lagophthalmus and posterior synechiae of the iris during chemotherapy of leprosy (morbus Hansen). Brandt, F. and Kalthoff, P. C. ..... (A) 613

Eyebrow(s),
The distribution of *Mycobacterium leprae* in the hair follicle of the eyebrow. GUMMER, C. L., *et al.* ..... (O) 205

Face,
Lesions of the facial and trigeminal nerve in leprosy. An evaluation of 43 cases. Reichart, P. E., *et al.* ..... (A) 280

Factor B,
Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., *et al.* ..... (A) 288

Family(ies),
Familial clustering of leprosy patients in an Israeli village. Barreyo, D. A., *et al.* ..... (A) 146

Feline leprosy,
Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schiefer, H. B. and Middleton, D. M. ..... (A) 626

Fernandez reaction,
Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* ..... (O) 481

Fetus,
Estrogen excretion in pregnant women with leprosy; evidence of diminished fetoplacental function. Duncan, M. E. and Oakey, R. E. ..... (A) 130

Fieldsteel, A. Howard,
Obituary. Dawson, P. J. and Krahenbuhl, J. L. ..... (Ob) 105

Filariasis,
Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. Piessens, W. F., *et al.* ..... (A) 156

Foot,
"Dorsal incision"—the treatment of complicated forefoot plantar ulcers in the malignant degeneration in chronic ulceration of the leg and foot in leprosy patients; two case reports. Andersen, J. G. ..... (A) 130
Teaching foot care. Fritschi, E. P. ..... (A) 298
Ulceration in the neurotrophic foot of Hansen's disease. Jones, R. O. ..... (A) 453
Transposition of post-tibial muscles and fasciae for correcting leprosy patient's drop foot. Lin De-Pao, *et al.* ..... (A) 298

Foot pad(s),
DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. ALMEIDA, J. G., *et al.* ..... (O) 366
Mouse foot pad technique for evaluation of drug resistance of *M. leprae* and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. ..... (A) 436

Freezing,
Effect of freezing *Mycobacterium leprae* in tissues. Dhople, A. M. ..... (A) 140

Gamma-Interferon,
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., *et al.* ..... (A) 650

Gastric,
Radiotelemetric examination of gastric function in patients with leprosy. Kenzhebaev, A. Y., *et al.* ..... (A) 278

Genetic(s),
An approach to study *in vitro* the expression of HLA-encoded genetic factors predisposing to tuberculoid leprosy. van Eden, W., *et al.* ..... (A) 444
HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. van Eden, W., *et al.* ..... (A) 150

Genome,
Construction and partial characterization of *Mycobacterium leprae* genomic libraries using an *in vivo* cosmid cloning system. Jacobs, W. R., *et al.* ..... (A) 667
Deoxyribonucleic acid of *Mycobacterium lepraemurium*: Its genome size, base ratio, and homology with those of other bacteria. Imaeda, T., *et al.* ..... (A) 290

German Leprosy Relief Association,
German Leprosy Relief Association funds leprosy work. (Thailand). ..... (N) 605
German Leprosy Relief Association Rehabilitation Fund (GLRARF) services. (India). Gershon, W. and Srinivasan, G. R. ..... (N) 121
"Pro Merito Melitensi" awards go to three members of the Deutsches Aussatzigen-Hilfswerk. ..... (N) 597
Southern Sudan to receive DM1.8 million for leprosy work from the German Leprosy Relief Association (GLRA). ..... (N) 595

Germany, Federal Republic of,
Death of Dr. Lutz Hartdegen. ..... (N) 263
Hubert Count of Ballestrem awarded Federal Distinguished Service Cross. ..... (N) 596

Glucose,
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. ..... (A) 624
Erythrocyte glucose-6-phosphate dehydrogenase isoenzyme phenotypes in leprosy. SAOJI, A. M. and KELKAR, S. S. ..... (O) 41
Glucose-6-phosphate dehydrogenase in Hansen's disease patients receiving sulfones or sulfamethoxypyridazine. Takizawa, H., *et al.* ..... (A) 281

Glycerol,
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. ..... (A) 624

Metabolism of glycerolipids in *Mycobacterium lepraemurium*; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. ..... (A) 653

Granuloma,
Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., *et al.* ..... (A) 293
Demonstration of T lymphocytes in leprous granuloma using the acid alpha naphthyl acetate esterase activity. An attempt at quantitative analysis. Gaulier, A., *et al.* ..... (A) 617
Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., *et al.* ..... (A) 620
Identification of T-cell subpopulations in granuloma annulare. Buechner, S. A., *et al.* ..... (A) 298
In situ demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., *et al.* ..... (A) 285
Infectious granulomas: Exposit from the leprosy model. Skinsnes, O. K. ..... (A) 139
Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. ..... (A) 621
Isolated epithelioid cells from disaggregated BCG granulomas—some functional studies. Williams, G. T. ..... (A) 622
Leprosy (Hansen's disease). Symposium on granulomatous disorders of the head and neck. Brazin, S. A. ..... (A) 276
Role of the major histocompatibility complex in resistance and granuloma formation in response to *Mycobacterium lepraemurium* infection. Adu, H. O., *et al.* ..... (A) 441
The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* ..... (A) 621

Griseofulvin,
Leprosy downgrading reaction associated with griseofulvin. Shulman, D. G., *et al.* ..... (A) 132

Guadeloupe,
Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* ..... (A) 610

Guinto, Ricardo S.,
Obituary. Binford, C. H. and Reich, C. V. ..... (Ob) 587

Guyana,
An urban community's thoughts about leprosy: a survey of Guyana. Cook, A. ..... (A) 152

Hand(s),
A comparative study of EFMT and sublimis transfer operations in the claw hand. SUNDARARAJ, G. D., *et al.* ..... (O) 197
A study of palmar dermatoglyphics in leprosy. Nagar, K. S., *et al.* ..... (A) 279
Evaluation of "power grip and pinch test" in relation to claw hand disability. Kumar, R. P. ..... (A) 153
Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., *et al.* ..... (A) 630

Hansen's disease,
1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. (Argentina). Charosky, C. B. ..... (A) 151
A comparative study between the therapeutic activity of thalidomide and the therapeutic activity of triamcinolone in the treatment of reactions in Virchowian hanseniasis. Almeida Neto, E. ..... (A) 273
Again on "indeterminate leprosy" (alias immature hanseniasis). RABELLO, F. E., *et al.* ..... (C) 418
An inquiry into the adoption of the term *Mycobacterium hansenii*. Rotberg, A. ..... (A) 142
CH50 and C3 component of complement in Hansen's disease. Iliadi-Alexandrou, M. E., *et al.* ..... (A) 618
Clinical and histopathological difficulties in the differential diagnosis of Hansen's disease. Gatti, J. C., *et al.* ..... (A) 278
Creatinphosphokinase (CPK) activity in the sera of hanseniasis patients. Garcia, R. R., *et al.* ..... (A) 277

Epidemiology of hanseniasis in the state of Rio Grande do Sul. (Brazil). Bernardi, C. and Ferreira, J. ..... (A) 146
Glucose-6-phosphate dehydrogenase in Hansen's disease patients receiving sulfones or sulfamethoxypyridazine. Takizawa, H., *et al.* ..... (A) 281
Hansen's disease in the United States. Hudson, T. and Genessi, J. ..... (A) 295
II International Congress of the College of Hansenology of the Endemic Countries. ..... (N) 263
International seminar schedule for 1984 at the National Hansen's Disease Center. (U.S.A.). ..... (N) 266
IV Brazilian Congress of Hansenology. Bechelli, L. M. ..... (N) 118
Leprosy (Hansen's disease). Symposium on granulomatous disorders of the head and neck. Brazin, S. A. ..... (A) 276
Meningoencephalitis due to *Cryptococcus neoformans* complicated by arteriosclerotic vascular insufficiency in virchowian hanseniasis. Fleury, R. N., *et al.* ..... (A) 277
Neuropathies in Hansen's disease. CHAROSKY, C. B., *et al.* ..... (E) 576
Otolaryngologic manifestations of Hansen's disease. Stevens, M. H. and Nielsen, D. R. ..... (A) 615
Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* ..... (A) 283
Positioning of borderline and indetermined groups in the hanseniasis classification. Pereira, A. C., Jr. and Gurfinkel, A. C. M. ..... (A) 128
Prevalence of Australia antigen (HBsAg) in hanseniasis patients. Sarno, E. N., *et al.* ... (A) 281
Some aspects of hanseniasis in the region of Londrina, Parana, 1968–1978. (Brazil). Tornero, N., *et al.* ..... (A) 297
Some aspects of hanseniasis in the region of Londrina, Parana, 1968–1978. 1. General characteristics. (Brazil). Asseis, E. A., *et al.* ..... (A) 145
Study of the association between the antigens of the HLA system and Hansen's disease. de la Cruz, F., *et al.* ..... (A) 283
The "Hansen-anergic fringe" and renewed doubts about vaccination. ROTBERG, A. .... (C) 411
The incidence of lagophthalmus and posterior synechiae of the iris during chemotherapy of leprosy (morbus Hansen). Brandt, F. and Kalthoff, P. C. ..... (A) 613
Ulceration in the neurotrophic foot of Hansen's disease. Jones, R. O. ..... (A) 453
Waldemar F. Kirchheimer, M.D., Ph.D., retires from National Hansen's Disease Center (U.S.A.). Hastings, R. C. ..... (N) 124

Heiser Program, The,
The Heiser Program for Research in Leprosy; 1984 opportunities. ..... (N) 431

Hepatitis,
Effect of corticosteroids on suppressor-cell activity in "autoimmune" and viral chronic active hepatitis. Nouri-Arai, K. T., *et al.* ..... (A) 156
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., *et al.* ..... (O) 461
Hepatitis-B-surface antigen (HBsAg) in leprosy patients. Balakrishnan, S., *et al.* ..... (A) 439

Histoid leprosy,
Histoid lepromas. Ramos-Caro, F. A. ..... (A) 280
Preliminary observation on 20 cases of histoid leproma. Zhang Jun-Tan, *et al.* ..... (A) 133

Histology,
Mycobacterium leprae infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., *et al.* ..... (A) 293
Sequential histological study of lepromin reaction. DESIKAN, K. V., *et al.* ..... (O) 473

Histopathology,
A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, *et al.* ..... (A) 135
Clinical and histopathological difficulties in the differential diagnosis of Hansen's disease. Gatti, J. C., *et al.* ..... (A) 278
The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of *Mycobacterium lepraemurium.* Adu, H. O., *et al.* ..... (A) 449

HLA,
An approach to study *in vitro* the expression of HLA-encoded genetic factors predisposing to tuberculoid leprosy. van Eden, W., *et al.* ..... (A) 444
HLA and leprosy. I. Frequency incidence of HLA-A, B antigens among leprosy patients of Han nationality. (China). Xu Keyu, *et al.* ..... (A) 150
HLA and leprosy. II. The associate of HLA-DR2 with lepromatous leprosy. Xu Keyu, *et al.* ..... (A) 629
HLA and susceptibility to leprosy. Serjeantson, S. W. ..... (A) 451
HLA antigens in leprosy patients. Bale, U. M., *et al.* ..... (A) 146
HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. van Eden, W., *et al.* ..... (A) 150
In vitro lymphocyte stimulation in an approach to study the expression of HLA-encoded genes predisposing to tuberculoid leprosy. VAN EDEN, W. and ELFERINK, D. ..... (C) 110
Study of the association between the antigens of the HLA system and Hansen's disease. de la Cruz, F., *et al.* ..... (A) 283
Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. ..... (A) 137

Hydrocortisone,
Hydrocortisone production in lepromatous patients with insulin load. BALYBIN, E. S. and NAZAROV, K. I. ..... (O) 18

Hypersensitivity,
Delayed hypersensitivity eliciting lipoprotein antigen of *Mycobacterium tuberculosis* H37Rv. Deshpande, J. M., *et al.* ..... (A) 155
Induction of delayed type hypersensitivity against ultrasonicated *Mycobacterium lepraemurium* bacilli without simultaneous local reactivity against live bacilli. Lovik, M. and Closs, O. ..... (A) 625

ICRC bacilli,
Antileprosy potentials of ICRC vaccine. A study in patients and healthy volunteers. DEO, M. G., *et al.* ..... (O) 540
Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* ..... (O) 466

IgA,
IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* ..... (A) 136
Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. AHMED, H. A., *et al.* ..... (O) 22

IgE,
IgE in leprosy. LYNCH, N. R. and LOPEZ, R. I. ..... (C) 416
IgE in leprosy; effect of a *Mycobacterium leprae*-BCG vaccine. LYNCH, N. R., *et al.* ..... (O) 169
Reply to Drs. Lynch and Lopez's letter. NUTI, M., *et al.* ..... (C) 417

IgG,
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., *et al.* ..... (A) 138
IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* ..... (A) 136

IgM,
IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* ..... (A) 136

ILEP,
Guidelines for the Campaign Against Leprosy. ..... (B) 433
ILEP members aid 1.23 million leprosy patients. ..... (N) 597

IMMLEP,
IMMLEP and THELEP seek trial sites. ..... (N) 604
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific

Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. ..... (O) 500

Immune complexes,

Associations of circulating immune complexes, clinical activity, and bacterial index in Japanese patients with leprosy. Furukawa, F., *et al.* ..... (A) 617

Circulating immune complexes in patients with nodular lepromatous leprosy. Vazquez-Escobosa, C., *et al.* ..... (A) 289

Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., *et al.* ..... (A) 620

Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., *et al.* ..... (A) 442

Immune responses,

Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., *et al.* ..... (A) 301

Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. Mshana, R. N., *et al.* ..... (O) 33

Immune status of subsided cases of tuberculoid (TT) and borderline tuberculoid (BT) leprosy. Mackay, I. G., *et al.* ..... (A) 285

Immune-response gene-associated antigens (Ia/DR). Structure and function in immunologically related diseases. Gorzynski, T. J. and David, C. S. ..... (A) 632

Waning of cell mediated immune response in preschool children given BCG at birth. Seth, V., *et al.* ..... (A) 301

Immunodiffusion,

Immunodiffusion analyses of some diphtheroid organisms isolated from patients with leprosy. Ridell, M. ..... (O) 179

Immunoglobulin(s),

Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. Ahmed, H. A., *et al.* ..... (O) 22

Immunoglobulin deposits in leprosy skin. Higashi, G. I., *et al.* ..... (A) 440

Immunoglobulins in the urine of leprosy patients. Sengupta, U., *et al.* ..... (C) 409

Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., *et al.* ..... (A) 132

Salivary immunoglobulin and antibody activities in leprosy. Abe, M., *et al.* ..... (A) 657

Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Harikrishnan, S., *et al.* ..... (A) 134

Immunology,

A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. Duncan, M. E., *et al.* ..... (O) 7

A single subcutaneous inoculation of 10^7 armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* ..... (A) 450

Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* ..... (A) 300

Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, T. and Grange, J. M. ..... (A) 300

Immune-response gene-associated antigens (Ia-DR). Structure and function in immunologically related diseases. Gorzynski, T. J. and David, C. S. ..... (A) 632

Immunologic profile in patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* ..... (A) 137

Immunological aspects of leprosy. Harboe, M. and Closs, O. ..... (A) 618

Immunological effects of experimental leprosy in the mangabey (*Cercocebus atys*). Martin, L. N., *et al.* ..... (A) 665

Immunological profile in lepromatous leprosy patients; our experience. Gimenez, M. M., *et al.* ..... (A) 284

Immunological research in tuberculosis: Memorandum from a WHO meeting. ..... (A) 299
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., *et al.* ..... (A) 132
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., *et al.* ..... (A) 650
Study of immunological parameters in patients with different clinical forms of leprosy; the influence of treatment. Bottasso, O. A., *et al.* ..... (A) 133

Immunopharmacology,
The immunopharmacology of antileprosy agents. Anderson, R. ..... (A) 609

Immunosuppression,
Mechanism of immunosuppression in leprosy: Presence of suppressor factor(s) from macrophages of lepromatous patients. Salgame, P. R., *et al.* ..... (A) 620
Probable mechanisms of immunosuppression in leprosy. Bottasso, O. A., *et al.* ..... (A) 282

Indeterminate leprosy,
Again on "indeterminate leprosy" (alias immature hanseniasis). RABELLO, F. E., *et al.* ..... (C) 418
Indeterminate leprosy. KLOKKE, A. H. ..... (C) 256
Reply to Dr. Klokke's letter. BROWNE, S. G. ..... (C) 256
Reply to Dr. Rabello, *et al.*'s letter. JOPLING, W. H. ..... (C) 420
Reply to Dr. Rabello, *et al.*'s letter. PETTIT, J. H. S. ..... (C) 420

India,
A review of five years leprosy work in an urban area Rayadurg. Krishnamoorthy, K. V., *et al.* ..... (A) 296
A 20-year study of the leprosy control programme at the Government Leprosy Treatment and Study Centre at Tirukoilur in South India. Radhakrishna, S., *et al.* ..... (A) 149
Absenteeism during treatment of leprosy: An analysis of its causes as evidenced by a survey in South India. Vellut, C., *et al.* ..... (A) 438
Action plans for leprosy control meeting. Sansarricq, H. ..... (N) 263
Changes in epidemiology of deformity in leprosy in a rural area in South India. Srinivasan, H. ..... (A) 297
Clinical epidemiology of nonlepromatous leprosy among service personnel. Guha, P. K. ..... (A) 149
Comparison of slum survey, school survey and health education as methods of detection of leprosy cases in an urban area. Soni, S. and Ingle, P. ..... (A) 297
DDS-resistant infection among leprosy patients in the population of Gudiyatham Taluk, South India. Part 3. Prevalence, incidence, risk factors, and interpretation of mouse foot pad test results. ALMEIDA, J. G., *et al.* ..... (O) 366
Dr. Nilakanta Rao awarded Damien-de-Veuster Medal. Christian, M. ..... (N) 264
Endemicity of leprosy in the Union Territory of Chandigarh and surrounding states. Kaur, S., *et al.* ..... (A) 149
Epidemiology of leprosy in rural population of Pondicherry. Lal, S., *et al.* ..... (A) 296
Follow-up of lepromatous (LL and BL) patients on dapsone (DDS) monotherapy after attainment of smear negativity in Gudiyatham Taluk, South India. ALMEIDA, J. G., *et al.* ..... (O) 382
Gandhi Memorial Leprosy Foundation Report 1981–82. ..... (N) 267
Geo-ecology of leprosy with special reference to West Bengal. Banerjee, B. and Hazra, J. ..... (A) 627
German Leprosy Relief Association Rehabilitation Fund (GLRARF) services. Gershon, W. and Srinivasan, G. R. ..... (N) 121
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., *et al.* ..... (A) 138
Indian railways launch antileprosy campaign in collaboration with Bombay Leprosy Project. Revankar, C. R. ..... (N) 430
JALMA 1981 annual report. ..... (N) 264
"Jal Neti" a yoga technique for nasal comfort and hygiene in leprosy patients. Appa Rao, A. V. N., *et al.* ..... (A) 275

Leprosy workshop held in Bombay. Naik, S. S. ..... (N) 431
Multidrug regimen project initiated. Christian, M. ..... (N) 265
Nalgonda Leprosy Center treating 7600 leprosy patients. ..... (N) 597
Observance of Antileprosy Week by Bombay Leprosy Project. Revankar, C. R. ..... (N) 431
Padma Shri awarded to Dr. Ganapati. Christian, M. ..... (N) 265
Proceedings of 1983 Eastern Regional Leprosy Workers' Conference. Chaudhury, D. S. ..... (N) 267
Prospects for a *Mycobacterium leprae* vaccine against leprosy after Madras. Stoner, G. L. ..... (A) 645
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. ..... (O) 500
Response to dapsone (DDS) monotherapy in leprosy patients of Gudiyatham Taluk, South India: Comparison between the 1960s and the 1970s. ALMEIDA, J. G., *et al.* ..... (O) 378
Results of long-term domiciliary dapsone (DDS) monotherapy for lepromatous leprosy in Gudiyatham Taluk, South India. ALMEIDA, J. G., *et al.* ..... (O) 385
Tuberculosis in India—the prospect. Sivaraman, S. ..... (A) 635
XII International Leprosy Congress. ..... (N) 114
..... (N) 424
..... (N) 598
XII International Leprosy Congress abstract deadline extended. ..... (N) 265
XIII Biennial Conference of Indian Association of Leprologists. ..... (N) 269

INFOLEP,
INFOLEP 1982 Annual Report. ..... (N) 603

Injection(s),
Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., *et al.* ..... (O) 191
Sensitization or tolerance to *Mycobacterium leprae* antigen by route of injection. Shepard, C. C., *et al.* ..... (A) 138
Sex differences in the absorption of dapsone after intramuscular injection. MODDERMAN, E. S. M., *et al.* ..... (O) 359

Inoculation,
A single subcutaneous inoculation of 10^7 armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* ..... (A) 450
Mycobacterium leprae infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., *et al.* ..... (A) 293

Insulin,
Hydrocortisone production in lepromatous patients with insulin load. BALYBIN, E. S. and NAZAROV, K. I. ..... (O) 18

Interleukin,
Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in *Mycobacterium lepraemurium* infection. Hoffenbach, A., *et al.* ..... (A) 292
Studies in interleukin 1 production by peripheral blood mononuclear cells from leprosy patients. Watson, S. R., *et al.* ..... (A) 649
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., *et al.* ..... (A) 650

International Congress for Tropical Medicine and Malaria (ICTMM),
Meeting announcement. ..... (N) 263

INTERNATIONAL JOURNAL OF LEPROSY (IJL),
On the Journal's 50th anniversary. TRAN HUU-NGOAN. ..... (C) 262
Reviewers. ..... (—) 673
Statement of financial condition. ..... (—) 455

Statement of ownership, management and circulation. ..... (—) 460
The 1982 Journal—a continuing perspective. HASTINGS, R. C. ..... (E) 89

International Leprosy Association (ILA),
Organization and membership. ..... (—) 674

International Leprosy Congress, XII,
Abstract deadline extended. ..... (N) 265
Announcement and preliminary program. ..... (N) 114
Program. ..... (N) 424
..... (N) 598

Iridocyclitis,
Clinical observation on iridocyclitis in leprosy patients. Acharya, B. P. ..... (A) 612

Isoniazid (INH),
In vitro activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* ..... (A) 157

Isoprinosine,
Utilization of an immunomodulant (isoprinosine) in multibacillary leprosy. Preliminary study. Saint-André, P., *et al.* ..... (A) 611

Israel,
Familial clustering of leprosy patients in an Israeli village. Barreyo, D. A., *et al.* ..... (A) 146

Italy,
Leprosy in Italy. GRECO, D. and GALANTI, M. R. ..... (O) 495
Raoul Follereau grant for leprosy research. ..... (N) 429

Japan,
Associations of circulating immune complexes, clinical activity, and bacterial index in Japanese patients with leprosy. Furukawa, F., *et al.* ..... (A) 617
Immunogenetical studies of leprosy in Japan. Ozawa, T., *et al.* ..... (A) 655
Sasakawa Memorial Health Foundation publications available in English. ..... (N) 603

Kellersberger Memorial Lecture,
The Kellersberger Memorial Lecture 1981: The general situation of leprosy in the world. Sansarricq, H. ..... (A) 272

Kinetics,
Modification of the kinetics of growth of *Mycobacterium leprae* by a group of coryne-bacteria. Delville, J., *et al.* ..... (A) 290

Lamprene®,
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene®) in the treatment of prurigo nodularis. BELAUBE, P., *et al.* ..... (O) 328

Latin America,
Policy and strategy for leprosy control programs. Romero, A. ..... (A) 628

Lecithin,
Stimulating effects of lecithin and cholesterol on the growth of *Mycobacterium lepraemurium* in cell-free liquid medium. Nakamura, M. ..... (A) 141

Leg(s),
Malignant degeneration in chronic ulceration of the leg and foot in leprosy patients; two case reports. Andersen, J. G. ..... (A) 130

Leishmaniasis,
Diffuse anergic leishmaniasis (lepromatous leishmaniasis). Gatti, C. F. and Sampaio, A. P. ..... (A) 632

Leonard Wood Memorial,
Leonard Wood Memorial research grant for early diagnosis of leprosy. ..... (A) 605

Leproma,
An unusual location of leproma of bone; a case report. ANDERSEN, J. G. and WARNDORFF, J. ..... (O) 203

Diffuse lepromatasis of Lucio-Alvarado-Latapi with Lucio phenomenon. First case in the Near East. Sheskin, J. ..... (A) 281
Histoid lepromas. Ramos-Caro, F. A. ..... (A) 280
Preliminary observation on 20 cases of histoid leproma. Zhang Jun-Tan, *et al.* ..... (A) 133

Lepromatous leprosy,
A case report of lepromatous leprosy. Mishner, H. S. and McTighe, A. H. ..... (A) 279
A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. DUNCAN, M. E., *et al.* ..... (O) 7
A comparative study between the therapeutic activity of thalidomide and the therapeutic activity of triamcinolone in the treatment of reactions in Virchowian hanseniasis. Almeida Neto, E. ..... (A) 273
A comparison of the incidence of type 2 reactions in lepromatous leprosy with two regimens of treatment. Manungo, J. and Thomas, J. E. P. ..... (A) 130
A study of continuous bacillaemia in borderline and lepromatous type of leprosy. Raval, S. N., *et al.* ..... (A) 280
A study of type 2 reactions in lepromatous leprosy. Manungo, J. and Thomas, J. E. P. ..... (A) 131
An unusual presentation of lepromatous leprosy. Selliah, K. and Ayasamy, A. ..... (A) 614
Analysis of pathological changes of peripheral nerve trunks in 70 autopsies of lepromatous leprosy. Liu Zijun, *et al.* ..... (A) 135
Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L. and Sanchez Caballero, H. ..... (A) 131
Breakdown product of factor B as an index of complement activation in lepromatous leprosy and its relation with bacillary load. Saha, K., *et al.* ..... (A) 288
Chemotherapy of non-lepromatous leprosy. ..... (A) 609
Circulating immune complexes in patients with nodular lepromatous leprosy. Vazquez-Escobosa, C., *et al.* ..... (A) 289
ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum. SASIAIN, M. DEL C., *et al.* ..... (O) 321
Defect in the generation of cytotoxic T cells in lepromatous leprosy. Stach, J.-L., *et al.* ..... (A) 444
Follow-up of lepromatous (LL and BL) patients on dapsone (DDS) monotherapy after attainment of smear negativity in Gudiyatham Taluk, South India. ALMEIDA, J. G., *et al.* ..... (O) 382
Gonadotropin, prolactin, and thyrotropin secretion in lepromatous leprosy. Shilo, S., *et al.* ..... (A) 132
High incidence of IgG class of Epstein-Barr virus capsid antibody in Indian patients of lepromatous leprosy. Saha, K., *et al.* ..... (A) 138
HLA and leprosy. II. The associate of HLA-DR2 with lepromatous leprosy. Xu Keyu, *et al.* ..... (A) 629
Hydrocortisone production in lepromatous patients with insulin load. BALYBIN, E. S. and NAZAROV, K. I. ..... (O) 18
Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., *et al.* ..... (A) 442
Immunohistological studies of skin biopsies from patients with lepromatous leprosy. Mshana, R. N., *et al.* ..... (A) 286
Immunologic profile in patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* ..... (A) 137
Immunological profile in lepromatous leprosy patients; our experience. Gimenez, M. M., *et al.* ..... (A) 284
Impairment in the number of circulating T lymphocytes in lepromatous leprosy. Preliminary study. Kodjovi, M., *et al.* ..... (A) 135
Involvement of subcutaneous veins in lepromatous leprosy. MUKHERJEE, A., *et al.* ..... (O) 1
Lepromatous leprosy in children. (An account of the last three observations.) Ravettini, B. A., *et al.* ..... (A) 614
Lepromatous leprosy in man; depth of the cellular infiltrate and bacillary mass in relation to the possibility of transmission of leprosy by biting arthropods. McDougall, A. C. and Cologlu, A. S. ..... (A) 628

Leprosy XII. T-cell subsets in lepromatous leprosy. Lim, S. D., *et al.* ..... (A) 443
Leprosy, borderline-lepromatous, and cytomegalovirus infection. Kruyt, J. A., *et al.* ... (A) 278
Meningoencephalitis due to *Cryptococcus neoformans* complicated by arteriosclerotic vascular insufficiency in virchowian hanseniasis. Fleury, R. N., *et al.* ..... (A) 277
Monoclonal antibody-defined T-cell subsets in lepromatous leprosy. Bach, M.-A., *et al.* ..... (A) 442
Monocyte suppressor factor(s) and release of *in vitro* suppression in lepromatous leprosy. Nath, I., *et al.* ..... (A) 669
Phagocytosis of *Candida albicans* by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* ..... (A) 287
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. ..... (A) 438
Protease inhibitors activity in lepromatous leprosy and lepra reactions. Yemul, V. L., *et al.* ..... (A) 441
Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., *et al.* ..... (A) 443
Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* ..... (A) 610
Results of long-term domiciliary dapsone (DDS) monotherapy for lepromatous leprosy in Gudiyatham Taluk, South India. ALMEIDA, J. G., *et al.* ..... (O) 385
Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* ..... (O) 466
Rifampicin (RFP) trial in lepromatous leprosy. Koticha, K. K., *et al.* ..... (A) 129
SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* ..... (A) 134
Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Harikrishnan, S., *et al.* ..... (A) 134
Serum lipoproteins in lepromatous leprosy. Kher, J. R., *et al.* ..... (A) 441
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., *et al.* ..... (A) 650
Suppressed natural killer cell activity during episodes of erythema nodosum leprosum in lepromatous leprosy. Humphres, R. C., *et al.* ..... (A) 134
T-cell conditioned media reverse T-cell unresponsiveness in lepromatous leprosy. Haregewoin, A., *et al.* ..... (A) 618
Ultrastructural alterations of *Mycobacterium leprae* in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., *et al.* ..... (A) 291

Lepromin,
Corticosteroids and lepromin sensitivity. Kundu, S. K., *et al.* ..... (A) 131
Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved *Mycobacterium w.* CHAUDHURI, S., *et al.* ..... (O) 159
Sequential histological study of lepromin reaction. DESIKAN, K. V., *et al.* ..... (O) 473
Variable lepromin response to *Mycobacterium leprae* in resistant armadillos. JOB, C. K., *et al.* ..... (O) 347

Leprosy,
Actualizaciones Leprologica. Gatti, J. C., *et al.* ..... (B) 606
An Atlas of Leprosy. Guinto, R. S., *et al.* ..... (B) 606
Articular manifestations in leprosy. Bonvoisin, B., *et al.* ..... (A) 613
Attitude of doctors to working in leprosy. Ramanthan, U. and Ramu, G. ..... (A) 271
Biblical leprosy as compared to present-day leprosy. Baillie, R. A. and Baillie, E. E. ... (A) 271
Grid system and body diagram for leprosy. Boerrigter, G. ..... (A) 613
Integration of leprosy into general health services in an urban area—a feasibility study. Revankar, C. R., *et al.* ..... (A) 128
Leprosy. Hendrick, S. S. and Wilkin, J. K. ..... (A) 436
Leprosy. Stingl, P. ..... (A) 436
Leprosy as a correlate of anxiety on the self-erosion dimension. Chauhan, N. S., *et al.* ..... (A) 152

Leprosy today. Shepard, C. C. ..... (A) 272
Leprosy, an overview. Goihman-Yahr, M. ..... (A) 437
Leprosy; the epidemiology of a slow bacterium. Fine, P. E. M. ..... (A) 147
Pattern of leprosy in a city hospital. SEHGAL, V. N., *et al.* ..... (O) 354
Risks of treating leprosy in a general hospital. NELSON, K. E. and SCHAUF, V. ..... (C) 413
The complexities of health education in leprosy. Dharmalingam, R. and Shanmugan, P. ..... (A) 627
The method of retrieval of data for statistical registration of leprosy patients. Aguero, H., *et al.* ..... (A) 451
Tzaraat—"biblical leprosy." Freilich, A. R. ..... (A) 609

Lesions,
A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, *et al.* ..... (A) 135
Atrophic lesions of the tongue in leprosy patients. Prabhu, S. R. and Daftary, D. K. ... (A) 280
Biological properties of diphtheroid bacteria (LDC) isolated from human leprosy lesions. Delville, J., *et al.* ..... (A) 140
Lesions of the facial and trigeminal nerve in leprosy. An evaluation of 43 cases. Reichart, P. E., *et al.* ..... (A) 280
Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., *et al.* ..... (A) 613
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patients with IL-2. Kaplan, G., *et al.* ..... (A) 650
T cell subsets in leprosy lesions: *in situ* characterization using monoclonal antibodies. Narayanan, R. B., *et al.* ..... (A) 287
T lymphocyte subsets in the skin lesions of patients with leprosy. Modlin, R. L., *et al.* ..... (A) 274
Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. ..... (A) 137

Leukocytes,
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and *Mycobacterium lepraemurium*. Stach, J.-L., *et al.* ..... (A) 294
Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* ..... (A) 283
Phagocytosis of *Candida albicans* by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* ..... (A) 287

Levamisole,
Effect of levamisole on clinical outcome and DNCB conversion in leprosy patients. A long term study. Yagnik, C. S., *et al.* ..... (A) 439
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. ..... (A) 438

Lipid(s),
Fatty acid and polar lipid analysis as tools in the identification of *Mycobacterium leprae* and some related slow-growing mycobacterial species. Anderson, O., *et al.* ..... (A) 445
Mycobacterial lipids in infected tissue samples. Young, D. B. ..... (A) 292
The phthiocerol-containing surface lipids of *Mycobacterium leprae*—a perspective of past and present work. BRENNAN, P. J. ..... (E) 387

Lipoprotein,
Delayed hypersensitivity eliciting lipoprotein antigen of *Mycobacterium tuberculosis* H37Rv. Deshpande, J. M., *et al.* ..... (A) 155
Serum lipoproteins in lepromatous leprosy. Kher, J. R., *et al.* ..... (A) 441

Liposome,
Growth stimulation of *Mycobacterium lepraemurium* by liposome in cell-free liquid medium. Nakamura, M. ..... (A) 141

Liver(s),
Bacteriological studies of armadillo livers infected with *Mycobacterium leprae*. Portaels, F., *et al.* ..... (A) 141

Lucio leprosy,
Diffuse lepromatasis of Lucio-Alvarado-Latapi with Lucio phenomenon. First case in the Near East. Sheskin, J. ..... (A) 281
Lucio leprosy. Gilbert, E., *et al.* ..... (A) 284

Lymphocyte(s),
Active and total E-rosette forming T-lymphocytes in pulmonary tuberculosis. Prabhu, R. and Reddy, M. V. ..... (A) 634
Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. Piessens, W. F., *et al.* ..... (A) 156
Binding of phosphatidylethanolamine and phosphatidylinositol to OKT8+ lymphocytes activates suppressor cell activity. Wadee, A. A. and Rabson, A. R. ..... (A) 445
Demonstration of T lymphocytes in leprous granuloma using the acid alpha naphthyl acetate esterase activity. An attempt at quantitative analysis. Gaulier, A., *et al.* ..... (A) 617
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., *et al.* ..... (A) 132
Impairment in the number of circulating T lymphocytes in lepromatous leprosy. Preliminary study. Kodjovi, M., *et al.* ..... (A) 135
In situ characterization of T lymphocyte subsets in the reactional states of leprosy. Modlin, R. L., *et al.* ..... (A) 619
In situ demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., *et al.* ..... (A) 285
In vitro lymphocyte stimulation in an approach to study the expression of HLA-encoded genes predisposing to tuberculoid leprosy. VAN EDEN, W. and ELFERINK, D. ..... (C) 110
Lymphocyte subpopulations in mice infected with *Mycobacterium leprae.* Ganguly, N. K., *et al.* ..... (A) 450
Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., *et al.* ..... (A) 443
Subpopulations of T and B lymphocytes in leprosy patients. Finiasz, M. R., *et al.* ..... (A) 283
T lymphocyte subsets in the skin lesions of patients with leprosy. Modlin, R. L., *et al.* ..... (A) 274
The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* ..... (A) 133
Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. Mshana, R. N., *et al.* ..... (A) 286
Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* ..... (A) 647

Lysis,
Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* ..... (A) 283
The microcolonial texture and demonstration of a phage-like lysis in the "Douglas" strain of *Mycobacterium lepraemurium.* Sula, L. ..... (A) 448

Macrophage(s),
Adherence of *Mycobacterium leprae* to macrophage as an indicator of pathogen induced membrane changes. Lad, S. J. and Mahadevan, P. R. ..... (A) 284
Alterations in the membrane of macrophages from leprosy patients. Birdi, T. J., *et al.* (A) 616
Cholesterol metabolism of macrophages in relation to the presence of *Mycobacterium leprae.* Kurup, I. G. and Mahadevan, P. R. ..... (A) 135
Foam—the result of an interaction between unactivated macrophages and dead *Mycobacterium leprae*? JOB, C. K., *et al.* ..... (C) 256
Increased H_2O_2 production by splenic murine macrophages asociated with susceptibility of *Mycobacterium lepraemurium* infection. Sankaran, K., *et al.* ..... (A) 652
Lack of correlation between morphological index and viability as assessed by the uptake of ^{3}H-thymidine by macrophage resident *M. leprae.* Sathish, M., *et al.* ..... (A) 142
Macrophage function in *Mycobacterium lepraemurium* infection: Morphological and functional changes of peritoneal and splenic macrophages *in vitro.* Ha, D. K. K., *et al.* ..... (A) 292

Mechanism of immunosuppression in leprosy: Presence of suppressor factor(s) from macrophages of lepromatous patients. Salgame, P. R., *et al.* ..... (A) 620
Radiolabelled *M. leprae* resident in human macrophage cultures as an *in vitro* indicator of effective immunity in human leprosy. Prasad, H. K., *et al.* ..... (A) 137
Rapid, radiolabeled-microculture method that uses macrophages for *in vitro* evaluation of *Mycobacterium leprae* viability and drug susceptibility. Mittal, A., *et al.* ..... (A) 446
Serum macrophage migration inhibition activity in patients with leprosy. Rea, T. H. and Yoshida, T. ..... (A) 288

Macular leprosy,
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., *et al.* ..... (A) 132

Madrid classification,
Analysis of the inter- and intrapathological concordances and discordances in a comparative study of Madrid and Ridley-Jopling classifications of leprosy. Haddad, N., *et al.* ..... (A) 435
Comparative clinicohistopathological study of Madrid and Ridley-Jopling classifications of leprosy. Bechelli, L. M., *et al.* ..... (A) 435

Malaysia,
Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7–11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. ..... (B) 608

Mali,
Further results on dapsone-resistant leprosy in Bamako (Mali). Baquillon, G., *et al.* ..... (A) 273

Mallorca,
Assistance to patients on Mallorca in ancient times. Mas, A. C. and Vaquer, R. R. ..... (A) 271

Martinique,
Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* ..... (A) 610

Metabolism,
Cholesterol metabolism of macrophages in relation to the presence of *Mycobacterium leprae.* Kurup, I. G. and Mahadevan, P. R. ..... (A) 135
Infection by *Mycobacterium haemorphilum,* a metabolically fastidious acid-fast bacillus. Moulsdale, M. T., *et al.* ..... (A) 301
Metabolism of carbon sources of *Mycobacterium leprae*: a preliminary report. Wheeler, P. R. ..... (A) 143
Metabolism of glycerolipids in *Mycobacterium lepraemurium*; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. ..... (A) 653

Mexico,
V International Congress of Tropical Dermatology to meet in Mexico City. ..... (N) 266

Mice,
A single subcutaneous inoculation of 10^7 armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* ..... (A) 450
Comparative immunogenicity of BCG and *Mycobacterium leprae* in normal and in *M. leprae*-tolerant mice. Shepard, C. C. ..... (A) 646
Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae,* and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* ..... (A) 626
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and *Mycobacterium lepraemurium.* Stach, J.-L., *et al.* ..... (A) 294

Evidence for generation of suppressor T cells in *Mycobacterium lepraemurium*-infected CBA/J mice, a mouse strain highly susceptible to the infection. Saito, N. and Hiroka, Y. ..... (A) 450
Inbred mouse strain resistance to *Mycobacterium lepraemurium* follows the *Ity/Lsh* pattern. Brown, I. N., *et al.* ..... (A) 143
Lymphocyte subpopulations in mice infected with *Mycobacterium leprae*. Ganguly, N. K., *et al.* ..... (A) 450
Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. ..... (A) 294
Peripheral neuropathy in mice infected with *Mycobacterium lepraemurium*. Lefford, M. J., *et al.* ..... (A) 651
Suppressor cells of mouse and man. What is the evidence that they contribute to the aetiology of the mycobacterioses? Rook, G. A. W. ..... (A) 137
Survival of *Mycobacterium leprae* in mice administered several antibiotics *per os*. LEVY, L., *et al.* ..... (C) 254
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. II. On the cases with subcutaneous infection. Tanemura, M. ..... (A) 145
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. III. On the cases intraperitoneally infected with small dose. Tanemura, M., *et al.* ..... (A) 145
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. IV. Comparative observations on virulence of four strains of *M. avium*. Kawaguchi, Y., *et al.* ... (A) 144
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. V. Host resistance of *M. avium* of hybrids of C3H origin. Kawaguchi, Y., *et al.* ..... (A) 144
Susceptibility to *M. lepraemurium* of CBA, DBA and C3H mice. Kawaguchi, Y., *et al.* ..... (A) 625
The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of *Mycobacterium lepraemurium*. Adu, H. O., *et al.* ..... (A) 449
The resistance of C57BL/6 mice to subcutaneous infection with *Mycobacterium lepraemurium* is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., *et al.* ..... (A) 625

Mice, nude,
Mycobacterium leprae infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., *et al.* ..... (A) 293
Nude mice as a model for chemotherapy of leprosy. Kohsaka, K., *et al.* ..... (A) 437
Reversal reactions in *Mycobacterium leprae*-infected nude mice. Chehl, S. K., *et al.* ... (A) 649

Microscopy,
Technical Guide for Smear Examination for Leprosy by Direct Microscopy. Leiker, D. L. and McDougall, A. C. ..... (B) 606

Mitsuda reaction,
Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* ..... (O) 481

Monkeys,
Experimental transmission of leprosy in African green monkeys (*Cercopithecus aethiops*) and the rhesus monkey (*Macaca mulatta*). Wolf, R. H., *et al.* ..... (A) 664

Monocytes,
Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* ..... (A) 285

Morphology,
Isolation and study of the morphological properties and immunogenicity of *Mycobacterium tuberculosis*. Khomenko, A. G., *et al.* ..... (A) 633
Lack of correlation between morphological index and viability as assessed by the uptake of ^{3}H-thymidine by macrophage resident *M. leprae*. Sathish, M., *et al.* ..... (A) 142
Macrophage function in *Mycobacterium lepraemurium* infection: Morphological and

functional changes of peritoneal and splenic macrophages *in vitro*. Ha, D. K. K., *et al.* ..... (A) 292
Morphology of bacteriophages from *Mycobacterium lepraemurium*. Rastogi, N. and David, H. L. ..... (A) 142
Mouse foot-pad growth patterns of *M. leprae* in relation to Morphological Index. Venkataramaniah, H. N., *et al.* ..... (A) 295

Muscle(s),
Reproducibility of sensory testing and voluntary muscle testing in evaluating the treatment of acute neuritis in leprosy patients. Lewis, S. ..... (A) 279
Transposition of post-tibial muscles and fasciae for correcting leprosy patient's drop foot. Lin De-Pao, *et al.* ..... (A) 298

Mycobacteria,
Activity of amikacin against mycobacteria *in vitro* and in murine tuberculosis. Sanders, W. E., Jr., *et al.* ..... (A) 156
Comparison of the cytoplasmic antigens of leprosy-derived corynebacteria and some mycobacteria. Gueur, M. C., *et al.* ..... (A) 623
Dissociation between allergy and immunity in mycobacterial infections. Turk, J. L. ..... (A) 288
Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., *et al.* ..... (A) 620
Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schiefer, H. B. and Middleton, D. M. ..... (A) 626
Fatty acid and polar lipid analysis as tools in the identification of *Mycobacterium leprae* and some related slow-growing mycobacterial species. Anderson, O., *et al.* ..... (A) 445
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *Mycobacterium leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 655
Growth of mycobacteria in relation to the pH of the medium. Portaels, F. and Pattyn, S. R. ..... (A) 446
In vitro induction of human suppressor T cells by mycobacterial antigens. BCG activated OKT4+ cells mediate suppression of antigen induced T cell proliferation. Mustafa, A. S. and Godal, T. ..... (A) 443
Mycobacterial lipids in infected tissue samples. Young, D. B. ..... (A) 292
Selecting drug combinations for treatment of drug-resistant mycobacterial diseases. Nash, D. R. and Steingrube, V. A. ..... (A) 155
Sensitivity of mycobacteria to dapsone. Portaels, F., *et al.* ..... (A) 142
Sensitization and immunization of mycobacteria. FREERKSEN, E. ..... (C) 261
Serological approaches for the characterization of catalase in tissue-derived mycobacteria. Katoch, V. M., *et al.* ..... (A) 624
T-cell-dependent polyclonal activation by soluble mycobacterial extracts of B cells in peripheral blood mononuclear cell populations from leprosy patients and normal donors. Fleming, B. and Rook, G. A. W. ..... (A) 283
The Biology of Mycobacteria. Vol. 1. Physiology, Identification and Classification. Ratledge, C. and Stanford, J., eds. ..... (B) 127
The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures. Nye, P. M., *et al.* ..... (A) 287
The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S. ..... (O) 225

Mycobacteriosis,
A new communication on natural mycobacteriosis in armadillos (*Dasypus novemcinctus* Linn.). Martinez, A. R., *et al.* ..... (A) 144
Ulcerative cutaneous mycobacteriosis. Lavalle, P., *et al.* ..... (A) 633

***Mycobacterium avium*,**
Comparative ultrastructure of *Mycobacterium leprae* and *M. avium* grown in experimental hosts. Rastogi, N., *et al.* ..... (A) 447
In vitro activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* ..... (A) 157
Infection with *Mycobacterium avium-intracellulare* and the protective effects of bacille Calmette-Guérin. Edwards, M. L., *et al.* ..... (A) 453

Susceptibility to *Mycobacterium avium* of various inbred strains of mice. II. On the cases with subcutaneous infection. Tanemura, M. ....(A) 145
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. III. On the cases intraperitoneally infected with small dose. Tanemura, M., *et al.* ....(A) 145
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. IV. Comparative observations on virulence of four strains of *M. avium.* Kawaguchi, Y., *et al.* ...(A) 144
Susceptibility to *Mycobacterium avium* of various inbred strains of mice. V. Host resistance of *M. avium* of hybrids of C3H origin. Kawaguchi, Y., *et al.* ....(A) 144

Mycobacterium avium-intracellulare,
In vitro activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* ....(A) 157
Infection with *Mycobacterium avium-intracellulare* and the protective effects of bacille Calmette-Guérin. Edwards, M. L., *et al.* ....(A) 453

Mycobacterium bovis,
Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. ....(A) 299
Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae,* and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* ....(A) 626
Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* ....(A) 285

Mycobacterium haemorphilum,
Infection by *Mycobacterium haemorphilum,* a metabolically fastidious acid-fast bacillus. Moulsdale, M. T., *et al.* ....(A) 301

Mycobacterium hansenii,
An inquiry into the adoption of the term *Mycobacterium hansenii.* Rotberg, A. ....(A) 142

Mycobacterium leprae,
A serological test for leprosy with a glycolipid specific for *Mycobacterium leprae.* Young, D. B. and Buchanan, T. M. ....(A) 622
A single subcutaneous inoculation of 10^7 armadillo-derived irradiated *Mycobacterium leprae* evokes different immunological behavior in C57BL/6 and C3H mice. Lagrange, P. H., *et al.* ....(A) 450
Adherence of *Mycobacterium leprae* to macrophage as an indicator of pathogen induced membrane changes. Lad, S. J. and Mahadevan, P. R. ....(A) 284
Adsorption of mycobacteriophages on *Mycobacterium leprae*: taxonomic significance. David, H. L., *et al.* ....(A) 140
Bacteriological studies of armadillo livers infected with *Mycobacterium leprae.* Portaels, F., *et al.* ....(A) 141
Bacteriology of *Mycobacterium leprae.* Pattyn, S. R. ....(A) 624
Biochemical investigation of the peribacillary substance of *Mycobacterium leprae.* Fukunishi, Y., *et al.* ....(A) 668
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. ....(A) 624
Cholesterol metabolism of macrophages in relation to the presence of *Mycobacterium leprae.* Kurup, I. G. and Mahadevan, P. R. ....(A) 135
Comparative immunogenicity of BCG and *Mycobacterium leprae* in normal and in *M. leprae*-tolerant mice. Shepard, C. C. ....(A) 646
Comparative ultrastructure of *Mycobacterium leprae* and *M. avium* grown in experimental hosts. Rastogi, N., *et al.* ....(A) 447
Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae,* and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* ....(A) 626
Construction and partial characterization of *Mycobacterium leprae* genomic libraries using an *in vivo* cosmid cloning system. Jacobs, W. R., *et al.* ....(A) 667
Crossreactivity between *Mycobacterium leprae* and various actinomycetes and related organisms. RIDELL, M. ....(O) 185

Definition of species-specific and cross-reactive antigenic determinants of *Mycobacterium leprae* using monoclonal antibodies. Ivanyi, J., *et al.* ..... (A) 619
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae*. Young, D. B. and Buchanan, T. M. ..... (A) 660
Effect of freezing *Mycobacterium leprae* in tissues. Dhople, A. M. ..... (A) 140
Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* ..... (A) 285
Effect of treatment on antibody activity against *Mycobacterium leprae* antigen 7 in tuberculoid leprosy. DAHLE, J. S., *et al.* ..... (O) 312
Effects of vaccination with *Mycobacterium leprae* on local cell-mediated immunity. Ridel, P.-R., *et al.* ..... (A) 645
Electron microscopic study of *Mycobacterium leprae* membrane. SILVA, M. T. and MACEDO, P. M. ..... (O) 219
Evaluation of the significance of antibodies to phenolic glycolipid of *Mycobacterium leprae* in leprosy patients and their contacts. Buchanan, T. M., *et al.* ..... (A) 658
Exochelin-mediated iron uptake into *Mycobacterium leprae*. HALL, R. M., *et al.* ..... (O) 490
Fatty acid and polar lipid analysis as tools in the identification of *Mycobacterium leprae* and some related slow-growing mycobacterial species. Anderson, O., *et al.* ..... (A) 445
Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* ..... (O) 481
Foam—the result of an interaction between unactivated macrophages and dead *Mycobacterium leprae*? JOB, C. K., *et al.* ..... (C) 256
Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from *Mycobacterium leprae*. Hunter, S. W. and Brennan, P. J. ..... (A) 623
Further studies of monoclonal antibodies directed against defined mycobacterial antigens present in *Mycobacterium leprae* and other mycobacteria. Miller, R. A., *et al.* ..... (A) 655
Gas chromatography of constitutive fatty acids in *Mycobacterium leprae*. Kusaka, T. and Izumi, S. ..... (A) 624
Generation and characterization of monoclonal antibodies to the *Mycobacterium leprae* phenolic glycolipid. Khanolkar, S. R., *et al.* ..... (A) 662
IgA, IgM and IgG anti-*M. leprae* antibodies in babies of leprosy mothers during the first 2 years of life. Melsom, R., *et al.* ..... (A) 136
IgE in leprosy; effect of a *Mycobacterium leprae*-BCG vaccine. LYNCH, N. R., *et al.* ..... (O) 169
In vitro cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. ..... (O) 77
In vitro proliferative response to *M. leprae* and PPD of isolated T cell subsets from leprosy patients. Bach, M.-A., *et al.* ..... (A) 442
Infection of the congenitally athymic rat with *Mycobacterium leprae*. DAWSON, P. J., *et al.* ..... (O) 336
Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae*. A comparison. Kulkarni, V. M. and Seydel, J. K. ..... (A) 274
Isolation of a characteristic phthiocerol dimycocerosate from *Mycobacterium leprae*. Draper, P., *et al.* ..... (A) 446
Lack of correlation between morphological index and viability as assessed by the uptake of ^{3}H-thymidine by macrophage resident *M. leprae*. Sathish, M., *et al.* ..... (A) 142
Leprosy review: The bacteriology of *Mycobacterium leprae*. DRAPER, P. ..... (O) 563
Lymphocyte subpopulations in mice infected with *Mycobacterium leprae*. Ganguly, N. K., *et al.* ..... (A) 450
Metabolism of carbon sources of *Mycobacterium leprae*: a preliminary report. Wheeler, P. R. ..... (A) 143
Method of cultivation of *M. leprae*. Veeraraghavan, N. ..... (A) 291
Modification of the kinetics of growth of *Mycobacterium leprae* by a group of corynebacteria. Delville, J., *et al.* ..... (A) 290
Mouse foot pad technique for evaluation of drug resistance of *M. leprae* and other laboratory techniques to be used in leprosy control programmes. Pattyn, S. R. ..... (A) 436

Mouse foot-pad growth patterns of *M. leprae* in relation to Morphological Index. Venkataramaniah, H. N., *et al.* ..... (A) 295
Mycobacterium leprae infection in nude mice: Bacteriological and histological responses to primary infection and large inocula. Lancaster, R. D., *et al.* ..... (A) 293
N-Acetyl-β-glucosaminidase, β-glucuronidase and acid phosphatase in *Mycobacterium leprae.* Wheeler, P. R., *et al.* ..... (A) 291
Persistence of *Mycobacterium leprae* in the peripheral nerve. Antia, M. H. and Nedugayil, K. ..... (A) 615
Progress in the preparation of an antileprosy vaccine from armadillo-derived *Mycobacterium leprae.* Rees, R. J. W. ..... (O) 515
Prospects for a *Mycobacterium leprae* vaccine against leprosy after Madras. Stoner, G. L. ..... (A) 645
Pyrolysis mass spectrometry: its applicability to mycobacteriology, including *Mycobacterium leprae.* Wieten, G., *et al.* ..... (A) 448
Radiolabelled *M. leprae* resident in human macrophage cultures as an *in vitro* indicator of effective immunity in human leprosy. Prasad, H. K., *et al.* ..... (A) 137
Rapid, radiolabeled-microculture method that uses macrophages for *in vitro* evaluation of *Mycobacterium leprae* viability and drug susceptibility. Mittal, A., *et al.* ..... (A) 446
Reduction of potassium tellurite and ATP content in *Mycobacterium leprae.* David, H. L., *et al.* ..... (A) 445
Relation between anti-*Mycobacterium leprae* antibody activity and clinical features in borderline tuberculoid (BT) leprosy. Touw Langendijk, E. J. M., *et al.* ..... (O) 305
Replication of *Mycobacterium leprae* in hibernating ground squirrels (*Citellus tridecemlineatus*). Galletti, G., *et al.* ..... (A) 143
Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* ..... (A) 610
Reversal reactions in *Mycobacterium leprae*-infected nude mice. Chehl, S. K., *et al.* ..... (A) 649
Ribosomal antigens of *Mycobacterium leprae.* Ridell, M. ..... (A) 291
SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* ..... (A) 134
Sensitization or tolerance to *Mycobacterium leprae* antigen by route of injection. Shepard, C. C., *et al.* ..... (A) 138
Serodiagnosis of infection with *Mycobacterium leprae.* Buchanan, T. M., *et al.* ..... (O) 524
Serological specificity of phenolic glycolipid I from *Mycobacterium leprae* and use in serodiagnosis of leprosy. Cho, S.-N., *et al.* ..... (A) 616
Serological specificity of phenolic glycolipid-I from *Mycobacterium leprae* and use of serodiagnosis in leprosy. Cho, S.-N., *et al.* ..... (A) 659
Studies on sulphone resistant strains of *M. leprae* in field and institutionalized cases of leprosy. Balakrishnan, S., *et al.* ..... (A) 436
Survival of *Mycobacterium leprae* in mice administered several antibiotics *per os.* Levy, L., *et al.* ..... (C) 254
Taxonomic studies on *Mycobacterium leprae.* Dhople, A. M. ..... (A) 446
Taxonomy of *Mycobacterium leprae* and *M. lepraemurium.* Portaels, F. and Pattyn, S. R. ..... (A) 447
The degradation of *Mycobacterium leprae* by a comparison of its staining properties. Ridley, M. J. ..... (O) 211
The distribution of *Mycobacterium leprae* in the hair follicle of the eyebrow. Gummer, C. L., *et al.* ..... (O) 205
The mycolic acids of *Mycobacterium leprae* harvested from experimentally infected nine-banded armadillos. Draper, P., *et al.* ..... (A) 446
The phthiocerol-containing surface lipids of *Mycobacterium leprae*—a perspective of past and present work. Brennan, P. J. ..... (E) 387
The production of human monoclonal antibodies against *Mycobacterium leprae.* Atlaw, T. and Roder, J. C. ..... (A) 656
The significance of dapsone (DDS)-resistant *Mycobacterium leprae* in untreated patients. Almeida, J. G., *et al.* ..... (O) 374

Ultrastructural alterations of *Mycobacterium leprae* in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., *et al.* ..... (A) 291
Ultrastructure of *Mycobacterium leprae* and other acid-fast bacteria as influenced by fixation conditions. Silva, M. T. and Macedo, P. M. ..... (A) 448
Use of a unit gravity sedimentation chamber for the purification of *Mycobacterium leprae.* Das, P. K. and Tulp, A. ..... (A) 289
Variable lepromin response to *Mycobacterium leprae* in resistant armadillos. Job, C. K., *et al.* ..... (O) 347

Mycobacterium lepraemurium,
Biochemical properties of *Mycobacterium lepraemurium* cultivated in cell-free liquid medium. Nakamura, M. ..... (A) 654
Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of *Mycobacterium lepraemurium* TMC 1701. Katoch, V. M., *et al.* ..... (A) 290
Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., *et al.* ..... (A) 293
Deficit of interleukin 2 production associated with impaired T-cell proliferative responses in *Mycobacterium lepraemurium* infection. Hoffenbach, A., *et al.* ..... (A) 292
Deoxyribonucleic acid of *Mycobacterium lepraemurium*: Its genome size, base ratio, and homology with those of other bacteria. Imaeda, T., *et al.* ..... (A) 290
Effect of phorbol myristate acetate, a tumor-promoting agent, on the growth of *Mycobacterium lepraemurium* in the mouse footpad. Tomioka, H. and Saito, H. ..... (A) 626
Electron microscopic observations of intracytoplasmic inclusions in human and murine leprosy bacilli. Hirata, T. ..... (O) 84
Enhanced growth of *Mycobacterium lepraemurium* in cell-free liquid medium with DL-aspartic acid. Nakamura, M. ..... (A) 290
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and *Mycobacterium lepraemurium.* Stach, J.-L., *et al.* ..... (A) 294
Evidence for generation of suppressor T cells in *Mycobacterium lepraemurium*-infected CBA/J mice, a mouse strain highly susceptible to the infection. Saito, N. and Hirooka, Y. ..... (A) 450
Growth stimulation of *Mycobacterium lepraemurium* by liposome in cell-free liquid medium. Nakamura, M. ..... (A) 141
H-2 linkage control of resistance to subcutaneous infection with *Mycobacterium lepraemurium.* Curtis, J., *et al.* ..... (A) 143
In vitro sensitivity of *Mycobacterium lepraemurium* for antimycobacterial drugs. Portaels, F., *et al.* ..... (A) 142
Inbred mouse strain resistance to *Mycobacterium lepraemurium* follows the *Ity/Lsh* pattern. Brown, I. N., *et al.* ..... (A) 143
Increased H_2O_2 production by splenic murine macrophages associated with susceptibility of *Mycobacterium lepraemurium* infection. Sankaran, K., *et al.* ..... (A) 652
Induction of delayed type hypersensitivity against ultrasonicated *Mycobacterium lepraemurium* bacilli without simultaneous local reactivity against live bacilli. Lovik, M. and Closs, O. ..... (A) 625
Macrophage function in *Mycobacterium lepraemurium* infection: Morphological and functional changes of peritoneal and splenic macrophages *in vitro.* Ha, D. K. K., *et al.* ..... (A) 292
Metabolism of glycerolipids in *Mycobacterium lepraemurium*; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. ..... (A) 653
Morphology of bacteriophages from *Mycobacterium lepraemurium.* Rastogi, N. and David, H. L. ..... (A) 142
Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. ..... (A) 294
Pathogenicity of *in vitro* cultivated *Mycobacterium lepraemurium* in rats. Ishaque, M. ..... (A) 293
Peripheral neuropathy in mice infected with *Mycobacterium lepraemurium.* Lefford, M. J., *et al.* ..... (A) 651

Respiratory activities of *in vitro* grown *Mycobacterium lepraemurium*. ISHAQUE, M. ...(O) 64
Role of the major histocompatibility complex in resistance and granuloma formation in response to *Mycobacterium lepraemurium* infection. Adu, H. O., *et al.* ...(A) 441
Stimulating effects of lecithin and cholesterol on the growth of *Mycobacterium lepraemurium* in cell-free liquid medium. Nakamura, M. ...(A) 141
Stimulation effect of dextran on *in vitro* growth of *Mycobacterium lepraemurium*. Nakamura, M. ...(A) 290
Study of growth factor for *Mycobacterium lepraemurium* grown in the Ogawa yolk medium. II. Egg yolk protein fraction and effect of reducing reagents. Mori, T. and Nyein, M.-M. ...(A) 141
Susceptibility to *M. lepraemurium* of CBA, DBA and C3H mice. Kawaguchi, Y., *et al.* ...(A) 625
Taxonomy of *Mycobacterium leprae* and *M. lepraemurium*. Portaels, F. and Pattyn, S. R. ...(A) 447
The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of *Mycobacterium lepraemurium*. Adu, H. O., *et al.* ...(A) 449
The microcolonial texture and demonstration of a phage-like lysis in the "Douglas" strain of *Mycobacterium lepraemurium*. Sula, L. ...(A) 448
The resistance of C57BL/6 mice to subcutaneous infection with *Mycobacterium lepraemurium* is dependent on both T cells and other cells of bone marrow origin. Adu, H. O., *et al.* ...(A) 625
Use of cycloheximide for cultivating *Mycobacterium lepraemurium* in cell culture. MATSUO, Y. ...(O) 72

Mycobacterium lufu,
Inhibitory activity and mode of action of diaminodiphenylsulfone in cell-free folate-synthesizing systems prepared from *Mycobacterium lufu* and *Mycobacterium leprae*. A comparison. Kulkarni, V. M. and Seydel, J. K. ...(A) 274

Mycobacterium smegmatis,
Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* ...(A) 443

Mycobacterium tuberculosis,
Bacteriophage typing of strains of *Mycobacterium tuberculosis* from Nepal. Goode, D. ...(A) 299
Characterization of a suppressor cell-activating factor (SCAF) released by adherent cells treated with *M. tuberculosis*. Wadee, A. A., *et al.* ...(A) 444
Delayed hypersensitivity eliciting lipoprotein antigen of *Mycobacterium tuberculosis* H37Rv. Deshpande, J. M., *et al.* ...(A) 155
Isolation and study of the morphological properties and immunogenicity of *Mycobacterium tuberculosis*. Khomenko, A. G., *et al.* ...(A) 633

Mycobacterium w,
Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved *Mycobacterium w*. CHAUDHURI, S., *et al.* ...(O) 159

Mycobacterium X,
In vitro cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. ...(O) 77

Near East,
Diffuse lepromatasis of Lucio-Alvarado-Latapi with Lucio phenomenon. First case in the Near East. Sheskin, J. ...(A) 281

Neck,
Leprosy (Hansen's disease). Symposium on granulomatous disorders of the head and neck. Brazin, S. A. ...(A) 276

Necrolysis,
Toxic epidermal necrolysis (Lyell syndrome). Katoch, K., *et al.* ...(A) 437

Nepal,
Bacteriophage typing of strains of *Mycobacterium tuberculosis* from Nepal. Goode, D. (A) 299
Tuberculosis case-finding in eastern Nepal. Cassels, A., *et al.* (A) 154

Nerve(s),
A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, *et al.* (A) 135
Analysis of pathological changes of peripheral nerve trunks in 70 autopsies of lepromatous leprosy. Liu Zijun, *et al.* (A) 135
Assessment of cutaneous autonomic nerve functions in leprosy. Boyle, A. and Ramu, G. (A) 151
Calcification in ulnar nerve abscess in a patient with leprosy—a case report. Prasad, S. B. (A) 280
Clinical, electrophysiological and teased fibre study of peripheral nerves in leprosy. Chopra, J. S., *et al.* (A) 631
Functional changes of the ulnar nerve in leprosy patients following neurolysis. Brandsma, J. W., *et al.* (A) 298
Lesions of the facial and trigeminal nerve in leprosy. An evaluation of 43 cases. Reichart, P. E., *et al.* (A) 280
Nerve conduction in leprosy: *in vivo* and *in vitro* study. Donde, S. V., *et al.* (A) 440
Persistence of *Mycobacterium leprae* in the peripheral nerve. Antia, M. H. and Nedugayil, K. (A) 615
Pure neural tuberculoid leprosy simulating a peripheral nerve tumor. Finkelstein, S., *et al.* (A) 277
Quantitative analysis of the sequence of nerve damage in experimental leprosy. Bhat, K. R. and Vaidya, M. C. (A) 292
Steroid therapy in recent "quiet nerve paralysis" in leprosy. Srinivasan, H., *et al.* (A) 153
Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. (A) 449

Netherlands, The,
INFOLEP 1982 Annual Report. (N) 603
The development of clinical tuberculosis following infection with tubercule bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., *et al.* (A) 302

Neurology,
1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. Charosky, C. B. (A) 151
Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. MSHANA, R. N., *et al.* (O) 33
Pure neural tuberculoid leprosy simulating a peripheral nerve tumor. Finkelstein, S., *et al.* (A) 277

Neuritis,
Reproducibility of sensory testing and voluntary muscle testing in evaluating the treatment of acute neuritis in leprosy patients. Lewis, S. (A) 279

Neuropathy,
Autonomic neuropathy in leprosy. KYRIAKIDIS, M. K., *et al.* (O) 301
Neuropathies in Hansen's disease. CHAROSKY, C. B., *et al.* (E) 576
Peripheral neuropathy in mice infected with *Mycobacterium lepraemurium*. Lefford, M. J., *et al.* (A) 651

Nose,
Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. AHMED, H. A., *et al.* (O) 22
"Jal Neti" a yoga technique for nasal comfort and hygiene in leprosy patients. Appa Rao, A. V. N., *et al.* (A) 275

Obituaries (*see also* under surnames),
Belehu, Ayele. Haregewoin, A. and Olcen, P. (Ob) 404
Davey, Thomas Frank. Seal. K. S. (Ob) 405

Fieldsteel, A. Howard. Dawson, P. J. and Krahenbuhl, J. L. ..... (Ob) 105
Guinto, Ricardo S. Binford, C. H. and Reich, C. V. ..... (Ob) 587
Ross, Sister Hilary. ..... (Ob) 253

Okinawa,
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. ..... (A) 296

OMSLEP,
Proceedings of the 4th International Workshop on Leprosy Control in Asia, Kuala Lumpur, Malaysia, 7–11 June 1982. Evaluation of Leprosy Control Programme and OMSLEP Information System. ..... (B) 608

Orchiepididymitis,
Orchiepididymitis in dimorphous leprosy. Gimenez, M. F. and Tonelli, H. B. ..... (A) 278

Osteosclerosis,
Osteosclerosis in leprosy. Simone, C. and Racanelli, A. ..... (A) 615

Otolaryngology,
Otolaryngologic manifestations of Hansen's disease. Stevens, M. H. and Nielsen, D. R. ..... (A) 615

Papua New Guinea,
Hepatic structure and function in Papua New Guineans with leprosy. Cook, G. C. and Corachan, M. ..... (A) 276
The treatment of leprosy in Papua New Guinea. Ree, G. H. ..... (A) 438

Paramedics,
Teaching Guide for Paramedical Workers in Leprosy. Vol. 2. Chaudhury, D. S. ..... (B) 126

Pathology,
Analysis of pathological changes of peripheral nerve trunks in 70 autopsies of lepromatous leprosy. Liu Zijun, *et al.* ..... (A) 135
Adherence of *Mycobacterium leprae* to macrophage as an indicator of pathogen induced membrane changes. Lad, S. J. and Mahadevan, P. R. ..... (A) 284
Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. ..... (A) 139
Pathogenicity of *in vitro* cultivated *Mycobacterium lepraemurium* in rats. Ishaque, M. ..... (A) 293
"Pro-eu-karyote" graft acceptance: A mechanism for intracellular parasitism—a new hypothesis for pathogenesis of leprosy. Deo, M. G. ..... (A) 617

Pediatrics,
Leprosy—a major community health problem in pediatric age group. Das, M. L., *et al.* ..... (A) 295

Phagocytosis,
Phagocytosis and lysis of *Candida albicans* and *Candida pseudotropicalis* by polymorphonuclear leukocytes of hanseniasis patients. Fliess, E. L., *et al.* ..... (A) 283
Phagocytosis of *Candida albicans* by polymorphonuclear leukocytes from patients with nodular lepromatous leprosy. Ramos-Zepeda, R., *et al.* ..... (A) 287

Phenolic glycolipid(s),
Development of an enzyme-linked immunosorbent assay (ELISA) to measure antibodies to the phenolic glycolipid of *Mycobacterium leprae.* Young, D. B. and Buchanan, T. M. ..... (A) 660
Evaluation of the significance of antibodies to phenolic glycolipid of *Mycobacterium leprae* in leprosy patients and their contacts. Buchanan, T. M., *et al.* ..... (A) 658
Further specific extracellular phenolic glycolipid antigens and a related diacylphthiocerol from *Mycobacterium leprae.* Hunter, S. W. and Brennan, P. J. ..... (A) 623
Generation and characterization of monoclonal antibodies to the *Mycobacterium leprae* phenolic glycolipid. Khanolkar, S. R., *et al.* ..... (A) 662
Serological specificity of phenolic glycolipid I from *Mycobacterium leprae* and use in serodiagnosis of leprosy. Cho, S.-N., *et al.* ..... (A) 616

Serological specificity of phenolic glycolipid-I from *Mycobacterium leprae* and use of serodiagnosis in leprosy. Cho, S.-N., *et al.* ..... (A) 659

Phenotypes,
Erythrocyte glucose-6-phosphate dehydrogenase isoenzyme phenotypes in leprosy. Saoji, A. M. and Kelkar, S. S. ..... (O) 41
The cutaneous infiltrates of leprosy. Cellular charcteristics and the predominant T cell phenotypes. Van Voorhis, W. C., *et al.* ..... (A) 288

Philippines, The,
Dr. Jose Tolentino succumbs. Binford, C. H. ..... (N) 429

Phorbol myristate acetate,
Effect of phorbol myristate acetate, a tumor-promoting agent, on the growth of *Mycobacterium lepraemurium* in the mouse footpad. Tomioka, H. and Saito, H. ..... (A) 626

6-Phosphogluconate,
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. ..... (A) 624

Phospholipid(s),
Metabolism of glycerolipids in *Mycobacterium lepraemurium*; biosynthesis of phospholipids. Nakagawa, H. and Kashiwabara, Y. ..... (A) 653

Phthiocerol,
Isolation of a characteristic phthiocerol dimycocerosate from *Mycobacterium leprae.* Draper, P., *et al.* ..... (A) 446
The phthiocerol-containing surface lipids of *Mycobacterium leprae*—a perspective of past and present work. Brennan, P. J. ..... (E) 387

Physiotherapy,
Physiotherapy in leprosy. Furness, M. A. ..... (A) 271

Polysaccharide(s),
Chemical composition of cell-wall polysaccharides from leprosy-derived corynebacteria. Abou-Zeid, C., *et al.* ..... (A) 139
Structure of the wall polysaccharide isolated from a group of corynebacteria. Abou-Zeid, C., *et al.* ..... (A) 622

Protease,
Protease inhibitors activity in lepromatous leprosy and lepra reactions. Yemul, V. L., *et al.* ..... (A) 441

Protein(s),
Immune responses to bovine neural antigens in leprosy patients. 1. Absence of antibodies to an insolated myelin protein. Mshana, R. N., *et al.* ..... (O) 33
SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* ..... (A) 134
Serological study of presence of C-reactive protein, rheumatoid factor, anti-streptolysis O in leprosy cases. Bhatia, V. N., *et al.* ..... (A) 439
Study of growth factor for *Mycobacterium lepraemurium* grown in the Ogawa yolk medium. II. Egg yolk protein fraction and effect of reducing reagents. Mori, T. and Nyein, M.-M. ..... (A) 141

Prothionamide,
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. Winsley, B. E., *et al.* ..... (C) 592
Disposition of prothionamide in rats and armadillos. Peters, J. H., *et al.* ..... (O) 54
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. Cartel, J.-L., *et al.* ..... (O) 461

Prurigo nodularis,
Small bowel deposition of crystals associated with the use of clofazimine (Lamprene®) in the treatment of prurigo nodularis. Belaube, P., *et al.* ..... (O) 328

Psoriasis,
Increased helper-suppressor T cell ratio in psoriasis. Ligesti, D. J., *et al.* ..... (A) 155

Purified protein derivative (PPD),
Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. ..... (A) 299
Effect of purified protein derivative and sonicates of *Mycobacterium leprae* and *Mycobacterium bovis* BCG on thromboplastin response in human monocytes. Lyberg, T., *et al.* ..... (A) 285
In vitro proliferative response to *M. leprae* and PPD of isolated T cell subsets from leprosy patients. Bach, M.-A., *et al.* ..... (A) 442

Radiology,
Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., *et al.* ..... (A) 279
Radiological bone and joint findings in clinically normal hands and feet of leprosy patients. Preliminary report. Angulo, M. H., *et al.* ..... (A) 630

Rat(s),
Disposition of prothionamide in rats and armadillos. PETERS, J. H., *et al.* ..... (O) 54
Experimental granulomas induced by mycobacterial immune complexes in rats. Ridley, M. J., *et al.* ..... (A) 620
Infection of the congenitally athymic rat with *Mycobacterium leprae*. DAWSON, P. J., *et al.* ..... (O) 336
Pathogenicity of *in vitro* cultivated *Mycobacterium lepraemurium* in rats. Ishaque, M. ..... (A) 293
The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* ..... (A) 621

Reaction(s),
A comparative study between the therapeutic activity of thalidomide and the therapeutic activity of triamcinolone in the treatment of reactions in Virchowian hanseniasis. Almeida Neto, E. ..... (A) 273
A comparison of the incidence of type 2 reactions in lepromatous leprosy with two regimens of treatment. Manungo, J. and Thomas, J. E. P. ..... (A) 130
A study of type 2 reactions in lepromatous leprosy. Manungo, J. and Thomas, J. E. P. ..... (A) 131
Alpha-1-antitrypsin in lepra reaction. Chawhan, R. N., *et al.* ..... (A) 614
Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., *et al.* ..... (A) 293
Evolutionary aspects of the Rubino reaction. Opromolla, D. V. A., *et al.* ..... (A) 287
In situ characterization of T lymphocyte subsets in the reactional states of leprosy. Modlin, R. L., *et al.* ..... (A) 619
Leprosy downgrading reaction associated with griseofulvin. Shulman, D. G., *et al.* ..... (A) 132
Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. ..... (A) 294
Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., *et al.* ..... (A) 613
Protease inhibitors activity in lepromatous leprosy and lepra reactions. Yemul, V. L., *et al.* ..... (A) 441
Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* ..... (O) 466
Reversal reactions in *Mycobacterium leprae*-infected nude mice. Chehl, S. K., *et al.* ..... (A) 649
Sequential histological study of lepromin reaction. DESIKAN, K. V., *et al.* ..... (O) 473
Simultaneous type I and type II reactions. CLEZY, J. K. A. ..... (C) 413
The reversal or inversal reaction—present point. Carayon, A. ..... (A) 130
Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* ..... (A) 647

Refugees,
Leprosy in Vietnamese refugees: a case report. Christiansen, J. V., *et al.* ..... (A) 276
Leprosy; our Southeast Asian refugee experience. Younger, B., *et al.* ..... (A) 150

Rehabilitation,
Contribution of surgery to the treatment and rehabilitation of patients with leprosy. Bourrel, P. ..... (A) 630
Rehabilitation of leprous deformity. Enna, C. D. ..... (A) 152

Rheumatoid factor,
Serological study of presence of C-reactive protein, rheumatoid factor, anti-streptolysis O in leprosy cases. Bhatia, V. N., *et al.* ..... (A) 439

Rhinoscleroma,
In situ demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., *et al.* ..... (A) 285

Rifampin,
Chemotherapy of leprosy; "bubble" or "calendar" packs for the administration of rifampin, dapsone, clofazimine, or prothionamide/ethionamide. WINSLEY, B. E., *et al.* ..... (C) 592
Eosinophilia as a result of rifampicin therapy. Nigam, P., *et al.* ..... (A) 131
Hepatitis in leprosy patients treated by a daily combination of dapsone, rifampin, and a thioamide. CARTEL, J.-L., *et al.* ..... (O) 461
In vitro activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* ..... (A) 157
Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* ..... (A) 610
Rifampicin (RFP) trial in lepromatous leprosy. Koticha, K. K., *et al.* ..... (A) 129
Therapeutic study in leprosy. VI. Observation of the therapeutic effect of isobutylpiperazinylrifamycin. Shanghai Zhunyi Hospital, *et al.* ..... (A) 611
Unique and high does of rifampin in leprosy treatment. A warning. Pattyn, S. R., *et al.* ..... (A) 610

Ross, Sister Hilary,
Obituary ..... (Ob) 253

Rubino reaction,
Evolutionary aspects of the Rubino reaction. Opromolla, D. V. A., *et al.* ..... (A) 287

Saliva,
Immunoglobulin A (IgA) in nasal washings and saliva of leprosy patients. AHMED, H. A., *et al.* ..... (O) 22
Salivary immunoglobulin and antibody activities in leprosy. Abe, M., *et al.* ..... (A) 657

Sarcoidosis,
Cutaneous sarcoidosis. Treatment with thalidomide. Barriere, H. ..... (A) 632
In situ demonstration of T lymphocyte subsets in granulomatous inflammation: leprosy, rhinoscleroma and sarcoidosis. Modlin, R. L., *et al.* ..... (A) 285
T-cell subsets in cutaneous sarcoidosis. Buechner, S. A., *et al.* ..... (A) 632

Screening for leprosy,
Development of an enzyme-linked immunosorbent assay using arabinomannan from *Mycobacterium smegmatis*: A potentially useful screening test for the diagnosis of incubating leprosy. Miller, R. A., *et al.* ..... (A) 443
Rapid screening for leprosy. Caver, C. V. ..... (A) 613
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. ..... (A) 157

SEARO,
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. ..... (O) 500

Sensation(s),
Congenital absence of sensation. Krishnamoorthy, K. V. ..... (A) 131
Plantar trophic ulcers in patients with leprosy. A correlative study of sensation, pressure and mobility. Sabato, S., *et al.* ..... (A) 631

Sensitivity,
Co-incident (simultaneous) dapsone sensitivity and dapsone-resistant leprosy. PETTIT, J. H. S. ..... (C) 258
Corticosteroids and lepromin sensitivity. Kundu, S. K., *et al.* ..... (A) 131
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and *Mycobacterium lepraemurium.* Stach, J.-L., *et al.* ..... (A) 294
In vitro sensitivity of *Mycobacterium lepraemurium* for antimycobacterial drugs. Portaels, F., *et al.* ..... (A) 142
Sensitivity of mycobacteria to dapsone. Portaels, F., *et al.* ..... (A) 142

Sera, of leprosy patients,
Creatinphosphokinase (CPK) activity in the sera of hanseniasis patients. Garcia, R. R., *et al.* ..... (A) 277
Identification of components of IC purified from human sera. II. Demonstration of mycobacterial antigens in immune complexes isolated from sera of lepromatous patients. Chakrabarty, A. K., *et al.* ..... (A) 442
SDS-PAGE analysis of *M. leprae* protein antigens reacting with antibodies from sera from lepromatous patients and infected armadillos. Chakrabarty, A. K., *et al.* ..... (A) 134

Serodiagnosis,
Serodiagnosis of infection with *Mycobacterium leprae.* BUCHANAN, T. M., *et al.* ..... (O) 524
Serodiagnosis of leprosy: the past, the present, and some prospects for the future. MELSOM, R. ..... (E) 235
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. ..... (A) 157
Serological specificity of phenolic glycolipid I from *Mycobacterium leprae* and use in serodiagnosis of leprosy. Cho, S.-N., *et al.* ..... (A) 616
Serological specificity of phenolic glycolipid-I from *Mycobacterium leprae* and use of serodiagnosis in leprosy. Cho, S.-N., *et al.* ..... (A) 659
Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shriniwas. ..... (A) 154

Serum,
A study of serum fibrinolytic activity in erythema nodosum leprosum (ENL). Jain, V. K., *et al.* ..... (A) 440
Concentration of serum calcium in leprosy. Pal, R., *et al.* ..... (A) 441
Immunological status of maculo-anaesthetic leprosy: T and B lymphocytes and serum immunoglobulins. Rao, S. S. L., *et al.* ..... (A) 132
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. Wu Qin-xue. ..... (N) 119
Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., *et al.* ..... (A) 443
Serum immunoglobulin profile and C3 levels in lepromatous leprosy patients. Harikrishnan, S., *et al.* ..... (A) 134
Serum levels of C3-activator (antifactor B) in leprosy. WEMAMBU, S. N. C. ..... (C) 259
Serum lipoproteins in lepromatous leprosy. Kher, J. R., *et al.* ..... (A) 441
Serum macrophage migration inhibition activity in patients with leprosy. Rea, T. H. and Yoshida, T. ..... (A) 288
Serum-mediated suppression of E-RFC levels in leprosy and reversal by fetal calf serum. Jaswaney, V. L., *et al.* ..... (A) 284

Shoe(s),
Simple plantar ulcers treated by below-knee plaster and moulded double-rocker plaster shoe—a comparative study. Pring, D. J. and Casabianca, N. ..... (A) 153
The moulded double-rocker plaster shoe in the field treatment of plantar ulcer. Joseph, B., *et al.* ..... (A) 298

Skin,
Composite skin contact smears in multibacillary leprosy patients. Hameedullah, A., *et al.* ..... (A) 278
Experimental transmission of a feline mycobacterial skin disease (feline leprosy). Schiefer, H. B. and Middleton, D. M. ..... (A) 626
Fernandez and Mitsuda reactivity in guinea pigs sensitized with heat-killed *Mycobacterium leprae*: Persistence and specificity of skin reactivity to soluble and particulate antigens. COLLINS, F. M., *et al.* ..... (O) 481
Immunoglobulin deposits in leprosy skin. Higashi, G. I., *et al.* ..... (A) 440
Immunohistological studies of skin biopsies from patients with lepromatous leprosy. Mshana, R. N., *et al.* ..... (A) 286
Skin diseases in Addis Ababa: A preliminary review. Manzur, J. ..... (A) 279
T lymphocyte subsets in the skin lesions of patients with leprosy. Modlin, R. L., *et al.* ..... (A) 274
The role of antibody in primary and reinfection BCG granulomas of rat skin. Spector, W. G., *et al.* ..... (A) 621
Ultrastructural alterations of *Mycobacterium leprae* in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., *et al.* ..... (A) 291
Ultrastructure of skin in erythema nodosum leprosum. Anthony, J., *et al.* ..... (A) 442

Skin tests,
The demonstration of two types of suppressor mechanism in leprosy patients and their contacts by quadruple skin-testing with mycobacterial reagent mixtures. Nye, P. M., *et al.* ..... (A) 287

Somalia,
Remarks on the orofacial symptoms of leprosy observed in Somalia. Goracci, G. and Clangelo, G. ..... (A) 614

Southeast Asia,
Leprosy; our Southeast Asian refugee experience. Younger, B., *et al.* ..... (A) 150

Spain,
Fontilles announces courses in leprosy. ..... (N) 266

Spectrometry,
Pyrolysis mass spectrometry: its applicability to mycobacteriology, including *Mycobacterium leprae*. Wieten, G., *et al.* ..... (A) 448

Spleen,
Enhancement of dismutase activity in the splenic leukocytes of mice sensitive to BCG and *Mycobacterium lepraemurium*. Stach, J.-L., *et al.* ..... (A) 294
Increased H_2O_2 production by splenic murine macrophages asociated with susceptibility of *Mycobacterium lepraemurium* infection. Sankaran, K., *et al.* ..... (A) 652
Macrophage function in *Mycobacterium lepraemurium* infection: Morphological and functional changes of peritoneal and splenic macrophages *in vitro*. Ha, D. K. K., *et al.* ..... (A) 292

Squirrel(s),
Replication of *Mycobacterium leprae* in hibernating ground squirrels (*Citellus tridecemlineatus*). Galletti, G., *et al.* ..... (A) 143

Stain(s),
The degradation of *Mycobacterium leprae* by a comparison of its staining properties. RIDLEY, M. J. ..... (O) 211

Steroid(s),
Steroid therapy in recent "quiet nerve paralysis" in leprosy. Srinivasan, H., *et al.* ..... (A) 153

Streptomycin,
In vitro activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against *Mycobacterium avium-intracellulare* complex. Zimmer, B. L., *et al.* ..... (A) 157

Sulfone(s),
A simple urine test for sulfonamides. de Almeida-Filho, J. and de Souza, J. M. ..... (A) 273
Bacteriologic involution in dimorphous Virchowian patients treated with sulfones—comparison of Virchowian patients treated with the same doses. Jonguieres, E. D. L. and Sanchez Caballero, H. ..... (A) 131
Glucose-6-phosphate dehydrogenase in Hansen's disease patients receiving sulfones or sulfamethoxypyridazine. Takizawa, H., *et al.* ..... (A) 281
Resistance of *Mycobacterium leprae* to sulfone (DDS) and rifampin during recurrences of lepromatous leprosy in Martinique and Guadeloupe since February 1980. Guelpa-Lauras, C.-C., *et al.* ..... (A) 610
Studies on sulphone resistant strains of *M. leprae* in field and institutionalized cases of leprosy. Balakrishnan, S., *et al.* ..... (A) 436
Treatment of sulphone resistant leprosy—a review of sixty one cases. Seshadri, P. S. and Ravi, N. T. ..... (A) 275

Surgery,
1981 Guillermo Basombrio Prize—Neural surgery in Hansen's disease. Charosky, C. B. ..... (A) 151
A comparative study of EFMT and sublimis transfer operations in the claw hand. SUNDARARAJ, G. D., *et al.* ..... (O) 197
Contribution of surgery to the treatment and rehabilitation of patients with leprosy. Bourrel, P. ..... (A) 630
Correction of cubital contractures in leprous patient employing Zancolli's lasso technique. Boucher, P. ..... (A) 630
Correction of the paralytic claw-thumb by two-tailed transfer of the superficialis tendon through a window in the flexor retinaculum. Srinivasan, H. ..... (A) 153
Timing of tendon-transfer surgery. Brandsma, J. W. and Liftogt, T. ..... (A) 630
Transposition of post-tibial muscles and fasciae for correcting leprosy patient's drop foot. Lin De-Pao, *et al.* ..... (A) 298

Surinam,
HLA-DR-associated genetic control of the type of leprosy in a population from Surinam. van Eden, W., *et al.* ..... (A) 150

Switzerland,
IMMLEP and THELEP seek trial sites. ..... (N) 604
Report of the 11th and 12th meetings of the Steering Committee of the Scientific Working Group on the Chemotherapy of Leprosy. ..... (N) 429
Sixth report of the WHO Special Progamme for Research and Training in Tropical Diseases. ..... (N) 604

Synovitis,
Leprous synovitis. A study of fifty cases. HOLLA, V. V., *et al.* ..... (O) 29

Syphilis,
Studies on the Paul-Bunnell antigen-antibody system. III. Detection of a Paul-Bunnell-related antigen in syphilis and leprosy. Morito, T., *et al.* ..... (A) 619

Tape,
Treatment of leprosy wounds with adhesive zinc tape. Soderberg, T., *et al.* ..... (A) 153

Thailand,
German Leprosy Relief Association funds leprosy work. ..... (N) 605
Proceedings of the 3rd International Workshop in Training of Leprosy Workers in Asia, Bangkok, Thailand, 18–28 January 1982. ..... (B) 607

Thalidomide,
A comparative study between the therapeutic activity of thalidomide and the therapeutic activity of triamcinolone in the treatment of reactions in Virchowian hanseniasis. Almeida Neto, E. ..... (A) 273
Cutaneous sarcoidosis. Treatment with thalidomide. Barriere, H. ..... (A) 632
Thalidomide: a review of the literature. Santos, M. F. G., Jr., *et al.* ..... (A) 275
Treatment of erythema nodosum leprosum with chloramphenicol—a comparison with thalidomide. Saint-André, P., *et al.* ..... (A) 611

THELEP,
IMMLEP and THELEP seek trial sites. ....(N) 604
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. ....(O) 500

Therapy,
Dapsone levels after oral therapy and weekly oily injections in Ethiopian leprosy patients. MODDERMAN, E. S. M., *et al.* ....(O) 191
Eosinophilia as a result of rifampicin therapy. Nigam, P., *et al.* ....(A) 131
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. ....(A) 438
Steroid therapy in recent "quiet nerve paralysis" in leprosy. Srinivasan, H., *et al.* ....(A) 153
Treatment of leprosy using combination therapy—but how? FREERKSEN, E. ....(C) 407

Thymidine,
Lack of correlation between morphological index and viability as assessed by the uptake of ^{3}H-thymidine by macrophage resident *M. leprae.* Sathish, M., *et al.* ....(A) 142

Thymus,
Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations. Mshana, R. N., *et al.* ....(A) 286

Tissue(s),
Catabolic pathways for glucose, glycerol and 6-phosphogluconate in *Mycobacterium leprae* grown in armadillo tissues. Wheeler, P. R. ....(A) 624
Characterization of catalase by micro-immunoprecipitation in tissue-derived cells of *Mycobacterium lepraemurium* TMC 1701. Katoch, V. M., *et al.* ....(A) 290
Comparative study with two polar types of murine leprosy: An involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction. Izaki, S., *et al.* ....(A) 293
Effect of freezing *Mycobacterium leprae* in tissues. Dhople, A. M. ....(A) 140
In vitro cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected tissues in acetone-dimethylsulfoxide-tetradecane medium. KATO, L. ....(O) 77
Mycobacterial lipids in infected tissue samples. Young, D. B. ....(A) 292
Observations on the host reaction to the cultivated *Mycobacterium lepraemurium* in the spread subcutaneous tissue preparations of mice. Matsuoka, M. and Kawaguchi, Y. ....(A) 294
Serodiagnosis of tissue dwelling parasites: Application of a multi-antigen enzyme-linked immunosorbent assay (ELISA) for screening. Speiser, F. ....(A) 157
Serological approaches for the characterization of catalase in tissue-derived mycobacteria. Katoch, V. M., *et al.* ....(A) 624
The histopathology of tissues in "resistant" and "susceptible" strains of mice infected with a moderate dose of *Mycobacterium lepraemurium.* Adu, H. O., *et al.* ....(A) 449
Tissue and blood T lymphocyte subsets in erythema nodosum leprosum and reversal reactions. Rea, T. H., *et al.* ....(A) 647

Tongue,
Atrophic lesions of the tongue in leprosy patients. Prabhu, S. R. and Daftary, D. K. ....(A) 280

Toxicity,
Toxic epidermal necrolysis (Lyell syndrome). Katoch, K., *et al.* ....(A) 437

Training,
Proceedings of the 3rd International Workshop in Training of Leprosy Workers in Asia, Bangkok, Thailand, 18–28 January 1982. ....(B) 607
Sixth report of the WHO Special Progamme for Research and Training in Tropical Diseases. ....(N) 604
The Social Dimension of Leprosy. Training Manual for Health Workers. Kaufmann, A., *et al.* ....(B) 270

Trial(s),
Epidemiological considerations in vaccine trials in leprosy. NOORDEEN, S. K. ....(O) 556

IMMLEP and THELEP seek trial sites. ....(N) 604
Management of clinical trials in developing countries. de Maar, E. W. J., *et al.* ....(A) 277
Methodology of therapeutic trials in leprosy. Ji Bao-Hong. ....(A) 273
Operational problems in vaccine trials. GULD, J. ....(O) 559
Preliminary trial of intervention levamisole therapy in persistently bacteriologically positive lepromatous leprosy. Ramu, G. and Sengupta, U. ....(A) 438
Rifampicin (RFP) trial in lepromatous leprosy. Koticha, K. K., *et al.* ....(A) 129
Solid, fragmented and granular index as one of the parameters in drug trials. Sharma, V. D., *et al.* ....(A) 132
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. ....(A) 296

Tuberculin,
An investigation of a range of new tuberculins. I. The effects of ageing, place of domicile, BCG immunisation and tuberculosis. Stanford, J. L., *et al.* ....(A) 302
Antigens of PPD, old tuberculin, and autoclaved *Mycobacterium bovis* BCG studied by crossed immunoelectrophoresis. Harboe, M. ....(A) 299
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* ....(A) 300
Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, T. and Grange, J. M. ....(A) 300

Tuberculoid leprosy,
A study of histopathologic lesions in peripheral nerve trunks in tuberculoid leprosy. Liu Zijun, *et al.* ....(A) 135
An approach to study *in vitro* the expression of HLA-encoded genetic factors predisposing to tuberculoid leprosy. van Eden, W., *et al.* ....(A) 444
Effect of treatment on antibody activity against *Mycobacterium leprae* antigen 7 in tuberculoid leprosy. DAHLE, J. S., *et al.* ....(O) 312
Immune status of subsided cases of tuberculoid (TT) and borderline tuberculoid (BT) leprosy. Mackay, I. G., *et al.* ....(A) 285
In vitro lymphocyte stimulation in an approach to study the expression of HLA-encoded genes predisposing to tuberculoid leprosy. VAN EDEN, W. and ELFERINK, D. ....(C) 110
Oral lesions in borderline and reactional tuberculoid leprosy. Alfieri, N., *et al.* ....(A) 613
Pure neural tuberculoid leprosy simulating a peripheral nerve tumor. Finkelstein, S., *et al.* ....(A) 277
Relation between anti-*Mycobacterium leprae* antibody activity and clinical features in borderline tuberculoid (BT) leprosy. TOUW LANGENDIJK, E. J. M., *et al.* ....(O) 305
Studies on leprosy: A. Structural: The nature of infiltrating cells in the cutaneous lesions of leprosy. B. Immunological: Gamma-IFN production in lepromatous and tuberculoid leprosy: restoration of production in lepromatous patient with IL-2. Kaplan, G., *et al.* ....(A) 650
Unique expression of HLA-DR (Ia-like) antigen in the lesions of polar tuberculoid leprosy. Ridley, M. J. and Ridley, D. S. ....(A) 137

Tuberculosis,
Active and total E-rosette forming T-lymphocytes in pulmonary tuberculosis. Prabhu, R. and Reddy, M. V. ....(A) 634
Activity of amikacin against mycobacteria *in vitro* and in murine tuberculosis. Sanders, W. E., Jr., *et al.* ....(A) 156
Amikacin in the treatment of pulmonary tuberculosis. Allen, B. W., *et al.* ....(A) 631
An investigation of a range of new tuberculins. I. The effects of ageing, place of domicile, BCG immunisation and tuberculosis. Stanford, J. L., *et al.* ....(A) 302
Concomitant occurrence of leprosy and tuberculosis—a clinical, bacteriological and radiological evaluation. Kumar, B., *et al.* ....(A) 279
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* ....(A) 300
Diagnosis of active tuberculosis by immunological methods. 2. Qualitative differences

in the dermal response to tuberculin in patients with active pulmonary disease and healthy tuberculin-positive individuals. Kardjito, T. and Grange, J. M. ..... (A) 300
Immunity in tuberculosis. Chaparas, S. D. ..... (A) 154
Immunological research in tuberculosis: Memorandum from a WHO meeting. ..... (A) 299
Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. ..... (A) 139
Soluble antigen fluorescent antibody test in the serodiagnosis of tuberculosis: selection of antigenic preparation. Bhardwaj, O. P. and Shriniwas. ..... (A) 154
The development of clinical tuberculosis following infection with tubercule bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data in the risk of tuberculous infection and the incidence of clinical tuberculosis in The Netherlands. Sutherland, I., *et al.* ..... (A) 302
The effect of delayed addition of antigen and "E" rosetting on the proliferative response to mycobacterial antigens of peripheral blood lymphocytes from normal individuals or from patients with tuberculosis or leprosy. Bahr, G. M., *et al.* ..... (A) 133
Tuberculosis and leprosy control: WHO consultation. ..... (A) 451
Tuberculosis case-finding in eastern Nepal. Cassels, A., *et al.* ..... (A) 154
Tuberculosis in India—the prospect. Sivaraman, S. ..... (A) 635

Ultrastructural characteristics,
Isolated epithelioid cells from disaggregated BCG granulomas—an ultrastructural study. Williams, G. T. ..... (A) 621
The interpretation of the ultrastructure of mycobacterial cells in transmission electron microscopy of ultrathin sections. SILVA, M. T. and MACEDO, P. S. ..... (O) 225
Ultrastructural alterations of *Mycobacterium leprae* in skin biopsies of untreated and treated lepromatous patients. Silva, M. T., *et al.* ..... (A) 291
Ultrastructure of *Mycobacterium leprae* and other acid-fast bacteria as influenced by fixation conditions. Silva, M. T. and Macedo, P. M. ..... (A) 448
Ultrastructure of skin in erythema nodosum leprosum. Anthony, J., *et al.* ..... (A) 442
Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. ..... (A) 449

Uremia,
Quantitation of the soluble receptor of human T lymphocytes for sheep erythrocytes by electroimmunodiffusion in the serum of patients with cancer, uremia and lepromatous leprosy. Moura, N. C., *et al.* ..... (A) 443

Urine,
A simple urine test for sulfonamides. de Almeida-Filho, J. and de Souza, J. M. ..... (A) 273
Immunoglobulins in the urine of leprosy patients. SENGUPTA, U., *et al.* ..... (C) 409
National Workshop on Detection of Dapsone (DDS) in Serum and Urine held by Institute of Dermatology, CAMS. (China). Wu Qin-xue. ..... (N) 119

U.S.A.,
Carville Director appointed Acting Division Director. ..... (N) 123
Damien-Dutton Society history. Crouch, H. E. ..... (N) 124
Dr. Roy F. Pfaltzgraff joins American Leprosy Missions. ..... (N) 124
Eighteenth Joint Leprosy Conference, Bethesda, Maryland, U.S.A., 3–4 August 1983. (U.S.–Japan Cooperative Medical Science Program) ..... (—) 636
Hansen's disease in the United States. Hudson, T. and Genessi, J. ..... (A) 295
Leonard Wood Memorial research grant for early diagnosis of leprosy. ..... (N) 605
Leprosy cases reported in the United States in 1982. ..... (N) 124
Leprosy in wild armadillos (*Dasypus novemcinctus*) of the Texas Gulf Coast: Epidemiology and mycobacteriology. Smith, J. H., *et al.* ..... (A) 629
President Ronald Reagan joins in observing World Leprosy Day. ..... (N) 124
Sylvatic leprosy in wild armadillos of the Texas Gulf Coast. Smith, J. H., *et al.* ..... (A) 663
Waldemar F. Kirchheimer, M.D., Ph.D., retires from National Hansen's Disease Center. Hastings, R. C. ..... (N) 124

U.S.–Japan Cooperative Medical Science Program,
Eighteenth Joint Leprosy Conference, Bethesda, Maryland, U.S.A., 3–4 August 1983. (U.S.–Japan Cooperative Medical Science Program) ..... (—) 636

Vaccination,
A model of vaccination with two microorganisms in infectious disease. Convit, J., *et al.* ..... (A) 670
Animal vaccination studies with *Mycobacterim leprae.* SHEPARD, C. C. ..... (O) 519
Cell mediated immune response after BCG as a determinant of optimum age of vaccination. Kathipari, K., *et al.* ..... (A) 301
Dapsone in allergic vasculitis: Its use in Henoch-Schonlein disease following vaccination. Ledermann, J. A. and Hoffbrand, B. I. ..... (A) 633
Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA. Kardjito, T., *et al.* ..... (A) 300
Effects of vaccination with *Mycobacterium leprae* on local cell-mediated immunity. Ridel, P.-R., *et al.* ..... (A) 645
Intradermal BCG vaccination complications—analysis of 51 cases. Murzy de Souza, G. R., *et al.* ..... (A) 301
Pathogenesis of tuberculosis and effectiveness of BCG vaccination. ten Dam, H. G. and Pio, A. ..... (A) 139
Study on prevention of leprosy. I. BCG vaccination trial for leprosy contact children in Okinawa. Saikawa, K. ..... (A) 296
The "Hansen-anergic fringe" and renewed doubts about vaccination. ROTBERG, A. .... (C) 411

Vaccine(s),
Analyzing the cost-effectiveness and cost-benefit of vaccines. Sisk, J. E. and Sanders, C. R. ..... (A) 634
Antileprosy potentials of ICRC vaccine. A study in patients and healthy volunteers. DEO, M. G., *et al.* ..... (O) 540
Comparison of the immunogenicity of vaccines prepared from viable *Mycobacterium bovis* BCG, heat-killed *Mycobacterium leprae,* and a mixture of the two for normal and *M. leprae*-tolerant mice. Shepard, C. C., *et al.* ..... (A) 626
Epidemiological considerations in vaccine trials in leprosy. NOORDEEN, S. K. ..... (O) 556
IgE in leprosy; effect of a *Mycobacterium leprae*-BCG vaccine. LYNCH, N. R., *et al.* .... (O) 169
Investigations related to the development of a leprosy vaccine. CONVIT, J., *et al.* ..... (O) 531
Leprosy vaccines. BARKSDALE, L. ..... (C) 107
Natural history of leprosy—Aspects relevant to a leprosy vaccine. FINE, P. E. M. ..... (O) 553
Operational problems in vaccine trials. GULD, J. ..... (O) 559
Progress in the preparation of an antileprosy vaccine from armadillo-derived *Mycobacterium leprae.* REES, R. J. W. ..... (O) 515
Prospects for a *Mycobacterium leprae* vaccine against leprosy after Madras. Stoner, G. L. ..... (A) 645
Rationales for vaccines against leprosy. BLOOM, B. R. ..... (O) 505
Reversal reaction in lepromatous patients induced by a vaccine containing killed ICRC bacilli—A report of five cases. BHATKI, W. S., *et al.* ..... (O) 466
Two candidate antileprosy vaccines—Current status of their development. TALWAR, G. P. and FOTEDAR, A. ..... (O) 550

Vascular,
Meningoencephalitis due to *Cryptococcus neoformans* complicated by arteriosclerotic vascular insufficiency in virchowian hanseniasis. Fleury, R. N., *et al.* ..... (A) 277
Vascular changes in nerves in experimental leprosy—an ultrastructural study. Bhat, K. R. and Vaidya, M. C. ..... (A) 449

Vasculitis,
Dapsone in allergic vasculitis: Its use in Henoch-Schonlein disease following vaccination. Ledermann, J. A. and Hoffbrand, B. I. ..... (A) 633

Veins,
Involvement of subcutaneous veins in lepromatous leprosy. MUKHERJEE, A., *et al.* ..... (O) 1

Vietnam,
Leprosy in Vietnamese refugees: a case report. Christiansen, J. V., *et al.* ..... (A) 276

West Indies,
Leprosy control project funded. ..... (N) 432

World Health Organization (WHO),
Immunological research in tuberculosis: Memorandum from a WHO meeting. ....(A) 299
Sixth report of the WHO Special Programme for Research and Training in Tropical Diseases. ....(N) 604
The WHO leprosy programme. Sansarricq, H. ....(A) 128
Tuberculosis and leprosy control: WHO consultation. ....(A) 451

WPRO,
Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. ....(O) 500

Zambia,
National seminar on leprosy disability prevention. de Soldenhoff, R. ....(N) 125

Zimbabwe,
Leprosy in Zimbabwe. Lyons, N. F. and Ellis, B. P. B. ....(A) 296
Zimbabwe Leprosy Symposium. Browne, S. G. ....(N) 596

Zinc,
Oral zinc in the trophic ulcers of leprosy. MATHUR, N. K. and BUMB, R. A. ....(C) 410
Treatment of leprosy wounds with adhesive zinc tape. Soderberg, T., *et al.* ....(A) 153

VOLUME 51 1983

INTERNATIONAL JOURNAL OF LEPROSY

And Other Mycobacterial Diseases

Official Organ of the
INTERNATIONAL LEPROSY ASSOCIATION
(Société Internationale de la Lèpre)
(Asociación Internacional contra la Lepra)

Contents

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

Official Organ of the International Leprosy Association

President: Prof. M. F. Lechat, Ecole de Santé Publique, Epid.-UCL 30.34, Clos Chapelle aux Champs 30, 1200 Bruxelles, Belgium

Secretary: Dr. S. G. Browne, 16 Bridgefield Road, Sutton, Surrey, SM1 2DG, England

Treasurer: Dr. W. F. Ross, 1262 Broad Street, Bloomfield, New Jersey 07003, U.S.A.

EDITORIAL AND PUBLICATION OFFICE

National Hansen's Disease Center
Carville, Louisiana 70721, U.S.A.
Cable Address: IJL CAR

Editor, ROBERT C. HASTINGS, Carville, Louisiana

Assistant Editor, DEE D. GOODMAN, Carville, Louisiana

BUSINESS AND CIRCULATION OFFICE

Executive Officer, W. FELTON ROSS
1262 Broad Street
Bloomfield, New Jersey 07003, U.S.A.

BOARD OF DIRECTORS

Dr. Michel F. Lechat (President, ILA), Chairman
Dr. Stanley G. Browne (Secretary, ILA)
Dr. Wayne M. Meyers
Dr. W. Felton Ross (Treasurer, ILA)
Dr. Charles C. Shepard

CONTRIBUTING EDITORS

Argentina: Dr. J. E. Cardama (Buenos Aires)
Australia: Dr. J. C. Hargrave (Darwin)
Brazil: Dr. L. M. Bechelli (São Paulo)
France & Fr. Terr.: Dr. D. Wallach (Paris)
India (North): Dr. S. Ghosh (Calcutta)
India (South): Dr. M. Christian (Karigiri)
Israel: Dr. L. Levy (Jerusalem)
Japan: Dr. M. Nishiura (Kyoto)
Malaysia & SE Asia: Dr. J. H. S. Pettit (Kuala Lumpur)
Mali: Dr. J. Languillon (Bamako)
Mexico: Dr. A. Saúl (Mexico, D.F.)
Netherlands: Dr. D. L. Leiker (Amsterdam)
People's Republic of China: Dr. Ye Gan-yun (Taizhou)
Philippines: Dr. R. M. Abalos (Cebu City)
Spain: Dr. J. Terencio de las Aguas (Fontilles)
United Kingdom: Dr. S. G. Browne (London)
United Kingdom: Dr. R. J. W. Rees (London)
U.S.A.: Dr. H. L. Arnold, Jr. (Honolulu)
U.S.A.: Dr. P. W. Brand (Carville)
U.S.S.R.: Dr. A. A. Juscenko (Astrakhan)
Venezuela: Dr. J. Convit (Caracas)

This JOURNAL is indexed in CURRENT CONTENTS/LIFE SCIENCES, BIOLOGICAL ABSTRACTS, and CHEMICAL ABSTRACTS. Microform available from University Microfilms International, Ann Arbor, Michigan 48106, U.S.A. or London WC1R 4EJ, U.K.

The INTERNATIONAL JOURNAL OF LEPROSY (ISSN 0148-916X) is published quarterly for $40.00 per year for members and $60.00 per year for subscribers by Allen Press, Inc., 1041 New Hampshire St., Lawrence, Kansas 66044, U.S.A. Second-class postage paid at Bloomfield, New Jersey and additional mailing office. POSTMASTER: Send address changes to INTERNATIONAL JOURNAL OF LEPROSY, Business and Circulation Office, 1262 Broad Street, Bloomfield, New Jersey 07003, U.S.A.

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 51, Number 1, March 1983

Original Articles — Page

Mukherjee, Ashok, Girdhar, Bhaneshwar K., Malviya, Govind N., Ramu, Gopal, and Desikan, Kottapalli, V. Involvement of Subcutaneous Veins in Lepromatous Leprosy. 1

Duncan, M. Elizabeth, Melsom, Reidar, Pearson, John M. H., Menzel, S., and Barnetson, R. St.C. A Clinical and Immunological Study of Four Babies of Mothers with Lepromatous Leprosy, Two of Whom Developed Leprosy in Infancy. 7

Balybin, Eugene S. and Nazarov, Konstantin I. Hydrocortisone Production in Lepromatous Patients with Insulin Load. 18

Ahmed, Haidar A., Touw, Jacob, Stoner, Gerald L., and Belehu, Ayele. Immunoglobulin A (IgA) in Nasal Washings and Saliva of Leprosy Patients. 22

Holla, Vasudeva V., Kenetkar, Maneesha V., Kolhatkar, Madhav K., and Kulkarin, Chandrashekhar N. Leprous Synovitis. A Study of Fifty Cases. 29

Mshana, Robert N., Harboe, Morten, Stoner, Gerald L., Hughes, R. A. C., Kadlubowski, M., and Belehu, Ayele. Immune Responses to Bovine Neural Antigens in Leprosy Patients. I. Absence of Antibodies to an Isolated Myelin Protein. 33

Saoji, Arun M. and Kelkar, Subhash S. Erythrocyte Glucose-6-phosphate Dehydrogenase Isoenzyme Phenotypes in Leprosy. 41

Peters, John H., Gordon, G. Ross, Murray, John F., Jr., and Simmon, Vincent F. Mutagenic Activity of Antileprosy Drugs and Their Derivatives. 45

Peters, John H., Gordon, G. Ross, and Murray, John F., Jr. Disposition of Prothionamide in Rats and Armadillos. 54

Ishaque, Muhammad. Respiratory Activities of *In Vitro* Grown *Mycobacterium lepraemurium*. 64

Matsuo, Yoshiyasu. Use of Cycloheximide for Cultivating *Mycobacterium lepraemurium* in Cell Culture. 72

Kato, Laszlo. *In Vitro* Cultivation of *Mycobacterium X* from *Mycobacterium leprae*-infected Tissues in Acetone-dimethylsulfoxide-tetradecane Medium. 77

Hirata, Tsunehiko. Electron Microscopic Observations of Intracytoplasmic Inclusions in Human and Murine Leprosy Bacilli. 84

Editorial

The 1982 JOURNAL—a Continuing Perspective. (Robert C. Hastings). 89

Obituary

Fieldsteel, A. Howard. 105

Correspondence

Leprosy Vaccines. (Lane Barksdale). 107

***In Vitro* Lymphocyte Stimulation in an Approach to Study the Expression of HLA-encoded Genes Predisposing to Tuberculoid Leprosy.** (Willem van Eden and Dienne Elferink). 110

Reduced Estrogen Excretion Due to Clofazimine? (M. Elizabeth Duncan and R. E. Oakey). 112

News and Notes 114

Book Reviews 126

Current Literature 128

Special Grantors and Sustaining Members 158

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 51, Number 2, June 1983

Original Articles — **Page**

Chaudhuri, Sachin, Fotedar, Arun, and Talwar, Gursaran P. Lepromin Conversion in Repeatedly Lepromin Negative BL/LL Patients After Immunization with Autoclaved *Mycobacterium w.* ... 159

Lynch, Neil R., Lopez, Reina I., Ulrich, Marian, Aranzazu, Nacarid, and Convit, Jacinto. IgE in Leprosy; Effect of a *Mycobacterium leprae*-BCG Vaccine. ... 169

Dang Duc Trach, Pham Man Hung, Hoang Thuy Long, Lai Van Gioi, and Nguyen Huu Huan. Rosette-forming Cells in Patients with Treated Leprosy. ... 174

Ridell, Malin. Immunodiffusion Analyses of Some Diphtheroid Organisms Isolated from Patients with Leprosy. ... 179

Ridell, Malin. Crossreactivity Between *Mycobacterium leprae* and Various Actinomycetes and Related Organisms. ... 185

Modderman, Ellen S. M., Merkus, Frans W. H. M., Zuidema, Jan, Hilbers, Hans W., and Warndorff, Titia. Dapsone Levels After Oral Therapy and Weekly Oily Injections in Ethiopian Leprosy Patients. ... 191

Sundararaj, Gabriel D., Selvapandian, Ambrose J., and Mani, Kandasamy. A Comparative Study of EFMT and Sublimis Transfer Operations in the Claw Hand. ... 197

Andersen, J. G. and Warndorff, J. An Unusual Location of Leproma of Bone; A Case Report. ... 203

Gummer, Christopher L., Starley, John N. A., Dawber, Rodney P. R., and Pearson, John M. H. The Distribution of *Mycobacterium leprae* in the Hair Follicle of the Eyebrow. ... 205

Ridley, Marian J. The Degradation of *Mycobacterium leprae* by a Comparison of Its Staining Properties. ... 211

Silva, M. T. and Macedo, Paula M. Electron Microscopic Study of *Mycobacterium leprae* Membrane. ... 219

Silva, M. T. and Macedo, Paula M. The Interpretation of the Ultrastructure of Mycobacterial Cells in Transmission Electron Microscopy of Ultrathin Sections. ... 225

Editorial

Serodiagnosis of Leprosy: The Past, the Present, and Some Prospects for the Future. (Reidar Melsom) ... 235

Obituary

Ross, Sister Hilary ... 253

Correspondence

Survival of *Mycobacterium leprae* in Mice Administered Several Antibiotics *per Os*. (Louis Levy, Fanny Aizer, Irving Lutsky) ... 254

Indeterminate Leprosy. (A. H. Klokke) ... 256

Reply to Dr. Klokke's Letter. (Stanley G. Browne) ... 256

Foam—the Result of an Interaction Between Unactivated Macrophages and Dead *Mycobacterium leprae*? (Charles K. Job, Sumir K. Chehl, Robert C. Hastings, J. R. Ruby) ... 256

Co-incident (Simultaneous) Dapsone Sensitivity and Dapsone-resistant Leprosy. (John H. S. Pettit) ... 258

Serum Levels of C3-activator (Antifactor B) in Leprosy. (S. N. C. Wemambu) ... 259

Sensitization and Immunization by Mycobacteria. (Enno Freerksen) ... 261

On the JOURNAL's 50th Anniversary. (Tran Huu-Ngoan) ... 262

News and Notes ... 263

Book Reviews ... 270

Current Literature ... 271

Special Grantors and Sustaining Members ... 304

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 51, Number 3, September 1983

Original Articles — **Page**

Touw Langendijk, Els J. M., van Diepen, Titia Warndorff, Harboe, Morten, and Belehu, Ayele. Relation Between Anti-*Mycobacterium leprae* Antibody Activity and Clinical Features in Borderline Tuberculoid (BT) Leprosy. 305

Dahle, John Sverre, van Diepen, Titia Warndorff, Touw Langendijk, Els J. M., Harboe, Morten, and Belehu, Ayele. Effect of Treatment on Antibody Activity Against *Mycobacterium leprae* Antigen 7 in Tuberculoid Leprosy. 312

Sasiain, María del C., Rubial Ares, Beatriz, Baliña, Luis M., Valdez, Raúl, and Bachmann, Alois E. ConA-induced Suppressor Cells in Lepromatous Leprosy Patients During and After Erythema Nodosum Leprosum. 321

Belaube, Pierre, Devaux, Jean, Pizzi, Marthe, Boutboul, Richard, and Privat, Yvan. Small Bowel Deposition of Crystals Associated with the Use of Clofazimine (Lamprene®) in the Treatment of Prurigo Nodularis. 328

Kyriakidis, Michael K., Noutsis, Costas G., Robinson-Kyriakidis, Christine A., Venetsianos, Panayiotis J., Vyssoulis, Gregory P., Toutouzas, Pavlos C., Parissis, Nicolas G., and Avgoustakis, Dimitris G. Autonomic Neuropathy in Leprosy. 331

Dawson, Peter J., Colston, M. Joseph, and Fieldsteel, A. Howard. Infection of the Congenitally Athymic Rat with *Mycobacterium leprae*. 336

Job, Charles K., Kirchheimer, Waldemar F., and Sanchez, Rita M. Variable Lepromin Response to *Mycobacterium leprae* in Resistant Armadillos. 347

Sehgal, Virender N., Ghorpade, Ashok, Ramesh, V., and Gupta, Sunil. Pattern of Leprosy in a City Hospital. 354

Modderman, Ellen S. M., Merkus, Frans W. H. M., Zuidema, Jan, Hilbers, Hans W., and Warndorff, Titia. Sex Differences in the Absorption of Dapsone After Intramuscular Injection. 359

Almeida, Joel G., Chacko, Chinoy J. G., Christian, Melville, Taylor, Phyllis M., and Fritschi, Ernest P. DDS-resistant Infection Among Leprosy Patients in the Population of Gudiyatham Taluk, South India. Part 3. Prevalence, Incidence, Risk Factors, and Interpretation of Mouse Foot Pad Test Results. 366

Almeida, Joel G., Chacko, Chinoy J. G., and Christian, Melville. The Significance of Dapsone (DDS)-resistant *Mycobacterium leprae* in Untreated Patients. 374

Almeida, Joel G., Christian, Melville, and Chacko, Chinoy J. G. Response to Dapsone (DDS) Monotherapy in Leprosy Patients of Gudiyatham Taluk, South India: Comparison Between the 1960s and the 1970s. 378

Almeida, Joel G., Christian, Melville, and Chacko, Chinoy J. G. Follow-up of Lepromatous (LL and BL) Patients on Dapsone (DDS) Monotherapy After Attainment of Smear Negativity in Gudiyatham Taluk, South India. 382

Almeida, Joel G., Christian, Melville, and Chacko, Chinoy J. G. Results of Long-term Domiciliary Dapsone (DDS) Monotherapy for Lepromatous Leprosy in Gudiyatham Taluk, South India. 385

Editorials

The Phthiocerol-containing Surface Lipids of *Mycobacterium leprae*—a Perspective of Past and Present Work. (Patrick J. Brennan). 387

The *In Vitro* Culture of the Leprosy Bacillus. (Caroline J. Baker). 397

Obituaries

Belehu, Ayele. 404

Davey, Thomas Frank. 405

Correspondence

Treatment of Leprosy Using Combination Therapy—But How? (Enno Freerksen). 407

Immunoglobulins in the Urine of Leprosy Patients. (U. Sengupta, G. Ramu, Sudhir Sinha, V. D. Ramanathan, and K. V. Desikan). 409

Oral Zinc in the Trophic Ulcers of Leprosy. (N. K. Mathur and R. A. Bumb). 410

The "Hansen-anergic Fringe" and Renewed Doubts About Vaccination. (Abrahão Rotberg). 411

Simultaneous Type I and Type II Reactions. (J. K. A. Clezy). 413

Risks of Treating Leprosy in a General Hospital. (Kenrad E. Nelson and Victoria Schauf). 413

Reply to Drs. Nelson and Schauf's Letter to the Editor. (Rachel Mathai and P. S. S. Sundar Rao). 416

IgE in Leprosy. (Neil R. Lynch and Reina I. Lopez). 416

Reply to Drs. Lynch and Lopez's Letter to the Editor. (Mario Nuti, Sergio Bonini, Guido Rasi, and Carla Rosa). 417

Again on "Indeterminate Leprosy" (Alias Immature Hanseniasis). (F. E. Rabello, R. D. Azulay, W. Belda, R. Garrido Neves, and A. C. Pereira, Jr.). 418

Reply to Dr. Rabello, *et al.*'s Letter to the Editor. (William H. Jopling). 420

Reply to Dr. Rabello, *et al.*'s Letter to the Editor. (John H. S. Pettit). 420

News and Notes 422

Book Reviews 433

Current Literature 435

Statement of Financial Condition 455

Special Grantors and Sustaining Members 458

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 51, Number 4, December 1983

Original Articles **Page**

Cartel, Jean-Louis, Millan, Jacques, Guelpa-Lauras, Claire-Cécile, and Grosset, Jacques H. Hepatitis in Leprosy Patients Treated by a Daily Combination of Dapsone, Rifampin, and a Thioamide. 461

Bhatki, Waman S., Chulawala, Ramesh G., Bapat, Chandrashekar V., and Deo, Madhav G. Reversal Reaction in Lepromatous Patients Induced by a Vaccine Containing Killed ICRC Bacilli—A Report of Five Cases. 466

Desikan, K. V., Mukherjee, Ashok, Ramu, Gopal, and Tiwari, Vishnu D. Sequential Histological Study of Lepromin Reaction. 473

Collins, Frank M., Morrison, Norman E., and Watson, Susan R. Fernandez and Mitsuda Reactivity in Guinea Pigs Sensitized with Heat-killed *Mycobacterium leprae*: Persistence and Specificity of Skin Reactivity to Soluble and Particulate Antigens. 481

Hall, Richard Malcolm, Wheeler, Paul Robert, and Ratledge, Colin. Exochelin-mediated Iron Uptake into *Mycobacterium leprae*. 490

Greco, Donato and Galanti, Maria Rosaria. Leprosy in Italy. 495

Report of the SEARO/WPRO/IMMLEP/THELEP Joint Scientific Meeting on Leprosy, Rangoon, Burma, 18–19 November 1981 and the Joint Indian and IMMLEP Scientific Meeting on Immunoepidemiology of Leprosy, New Delhi, India, 14–16 February 1983. 500

Reprinted Article

Draper, Philip. Leprosy Review: The Bacteriology of *Mycobacterium leprae.* 563

Editorial

Neuropathies in Hansen's Disease. (Claudio B. Charosky, Juan Carlos Gatti, and Jose E. Cardama). 576

Obituary

Guinto, Ricardo S. 587

Correspondence

Chemotherapy of Leprosy; "Bubble" or "Calendar" Packs for the Administration of Rifampin, Dapsone, Clofazimine, or Prothionamide/ethionamide. (Bryan E. Winsley, A. Colin McDougall, and Kenneth E. Brown). 592

News and Notes 595

Book Reviews 606

Current Literature 609

U.S.–Japan Cooperative Medical Science Program, Eighteenth Joint Leprosy Research Conference, Bethesda, Maryland, U.S.A., 1983. 636

Reviewers 673

International Leprosy Association Organization and Membership, 1983. 674

Special Grantors and Sustaining Members. 686

Index, Volume 51. 687